

Eculizumab and Efgartigimod for the Treatment of Myasthenia Gravis: Effectiveness and Value

Final Report

October 20, 2021

Prepared for



April 14, 2023 Update: Per ICER's guidelines on the acceptance and use of "In-Confidence" data from manufacturers of pharmaceutical products, academic-in-confidence data that was redacted in the report has been unmasked 18 months following the ICER Public Meeting date.

New evidence regarding treatments and therapies gets published on an ongoing basis. ICER reached out to key stakeholders included in this review 12 months after the publication of this report giving them an opportunity to submit public comments regarding new relevant evidence or information on coverage that they wish to highlight. No stakeholders submitted public comments. ICER has launched ICER Analytics to provide stakeholders an opportunity to work directly with ICER models and examine how changes in parameters would affect results. You can learn more about ICER Analytics <u>here</u>.

ICER Staff and Consultants	University of Illinois at Chicago (UIC) College of Pharmacy's Center for Pharmacoepidemiology and Pharmacoeconomic Research Modeling Group
Jeffrey A. Tice, MD	Daniel R. Touchette, PharmD, MA
Professor of Medicine	Professor
University of California, San Francisco	University of Illinois at Chicago College of Pharmacy
Dmitriv Nikitin. MSPH	Pei-Wen Lien. BPharm. MSc
Research Lead, Evidence Synthesis	PhD Student
ICER	University of Illinois at Chicago College of Pharmacy
Jon Campbell, PhD, MS	Mrinmavee Joshi, BPharm
Senior Vice President for Health Economics	PhD Student
ICER	University of Illinois at Chicago College of Pharmacy
Ashton Moradi. PharmD. MS	Zaid Yousif. PharmD. MAS
Health Economist	Post-Doctoral Fellow
ICER	Department of Biomedical Informatics, UCSD School
	of Medicine
David M. Rind, MD, MSc	
Chief Medical Officer	Shani Patel, BS
ICER	PharmD Student
	University of Illinois at Chicago College of Pharmacy
Steven D. Pearson, MD, MSc	
President	The role of the Chicago College of Pharmacy's Center
ICER	for Pharmacoepidemiology and Pharmacoeconomic
	Research is limited to the development of the cost-
Foluso Agboola, MBBS, MPH	effectiveness model, and the resulting ICER reports do
Vice President of Research	not necessarily represent the views of UIC.
ICER	

DATE OF PUBLICATION: October 20, 2021

How to cite this document: Tice JA, Touchette DR, Nikitin D, Campbell JD, Lien P-W, Moradi A, Rind DM, Pearson SD, Agboola F. Eculizumab and Efgartigimod for the Treatment of Myasthenia Gravis: Effectiveness and Value; Final Report. Institute for Clinical and Economic Review, September 10, 2021. <u>https://icer.org/assessment/myasthenia-gravis/#timeline</u>

Jeffrey A. Tice served as the lead author for the Report. Dmitriy Nikitin led the systematic review in collaboration with Avery McKenna. Daniel R. Touchette was responsible for the development of the cost-effectiveness model in collaboration with Pei-Wei Lien. Jon Campbell provided oversight of the cost-effectiveness analyses and developed the budget impact model in collaboration with Ashton Moradi. Foluso Agboola, David M. Rind, and Steven D. Pearson provided methodologic guidance on the clinical and economic evaluations. We would like to thank Maggie O'Grady and Monica Frederick for their contributions to this Report.

About ICER

The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. Through all its work, ICER seeks to help create a future in which collaborative efforts to move evidence into action provide the foundation for a more effective, efficient, and just health care system. More information about ICER is available at https://icer.org/.

The funding for this Report comes from government grants and non-profit foundations, with the largest single funder being the Arnold Ventures. No funding for this work comes from health insurers, pharmacy benefit managers, or life science companies. ICER receives approximately 19% of its overall revenue from these health industry organizations to run a separate Policy Summit program, with funding approximately equally split between insurers/PBMs and life science companies. There are no life science companies relevant to this review who participate in this program. For a complete list of funders and for more information on ICER's support, please visit https://icer.org/who-we-are/independent-funding/.

For drug topics, in addition to receiving recommendations <u>from the public</u>, ICER scans publicly available information and also benefits from a collaboration with <u>IPD Analytics</u>, an independent organization that performs analyses of the emerging drug pipeline for a diverse group of industry stakeholders, including payers, pharmaceutical manufacturers, providers, and wholesalers. IPD provides a tailored report on the drug pipeline on a courtesy basis to ICER but does not prioritize topics for specific ICER assessments.

About the New England CEPAC

The New England Comparative Effectiveness Public Advisory Council (New England CEPAC) – a core program of ICER – provides a public venue in which the evidence on the effectiveness and value of health care services can be discussed with the input of all stakeholders. The New England CEPAC seeks to help patients, clinicians, insurers, and policymakers interpret and use evidence to improve the quality and value of health care.

The New England CEPAC Panel is an independent committee of medical evidence experts from across New England, with a mix of practicing clinicians, methodologists, and leaders in patient engagement and advocacy. All Panel members meet strict conflict of interest guidelines and are convened to discuss the evidence summarized in ICER reports and vote on the comparative clinical effectiveness and value of medical interventions. More information about the New England CEPAC is available at https://icer.org/who-we-are/people/independent-appraisal-committees/new-england-cepac/.

The findings contained within this Report are current as of the date of publication. Readers should be aware that new evidence may emerge following the publication of this Report that could potentially influence the results. ICER may revisit its analyses in a formal update to this Report in the future.

The economic models used in ICER reports are intended to compare the clinical outcomes, expected costs, and cost-effectiveness of different care pathways for broad groups of patients. Model results therefore represent average findings across patients and should not be presumed to represent the clinical or cost outcomes for any specific patient. In addition, data inputs to ICER models often come from clinical trials; patients in these trials may differ in real-world practice settings.

In the development of this Report, ICER's researchers consulted with several clinical experts, patients, manufacturers, and other stakeholders. The following experts provided input that helped guide the ICER team as we shaped our scope and Report. It is possible that expert reviewers may not have had the opportunity to review all portions of this Report. None of these individuals is responsible for the final contents of this Report, nor should it be assumed that they support any part of it. The Report should be viewed as attributable solely to the ICER team and its affiliated researchers.

For a complete list of stakeholders from whom we requested input, please visit: <u>https://icer.org/wp-content/uploads/2021/04/ICER_Myasthenia-Gravis_Stakeholder_List_041221.pdf</u>

Expert Reviewers

Aaron Lewis, MD

San Francisco Kaiser Neurology

Neuromuscular Medical Director, NCAL

No relevant conflicts of interest to disclose, defined as more than \$10,000 in healthcare company stock or more than \$5,000 in honoraria or consultancies during the previous year from health care manufacturers or insurers.

Wendi Huff

Vice President of Programs and Clinical Care, Myasthenia Gravis Foundation of America *The MGFA receives >25% of its funding from health care companies, including Alexion and argenx.*

Pushpa Narayanaswami, MD, FAAN

Vice-Chair, Clinical Operations, Department of Neurology, Beth Israel Deaconess Medical Center Associate Professor of Neurology, Harvard Medical School

Dr. Narayanaswami has received funding in excess of \$5,000 from argenx and UCB, and has received research support from Momenta/Janssen, Alexion, and UCB.

A. Gordon Smith, MD, FAAN

Professor and Chair of Neurology and Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research (Neurology), VCU Department of Neurology

Dr. Smith has received funding in excess of \$5,000 from Alexion, argenx, Eidos, and Lexicon.

Table of Contents

Executive Summary	ES1
1. Background	1
2. Patient and Caregiver Perspectives	3
3. Comparative Clinical Effectiveness	5
3.1. Methods Overview	5
Scope of Review	5
Evidence Base	5
3.2. Results	7
Clinical Benefits	7
Harms	
Subgroup Analyses and Heterogeneity	11
Uncertainties and Controversies	
3.3. Summary and Comment	
Adults with gMG Positive for Anti-AChR Antibodies	12
Adults with gMG Negative for Anti-AChR Antibodies	13
New England CEPAC Votes	15
4. Long-Term Cost Effectiveness	16
4.1. Methods Overview	16
4.2. Key Model Assumptions and Inputs	20
4.3. Results	23
Base-Case Results	23
Sensitivity Analyses	24
Scenario Analyses	26
Threshold Analyses	27
Model Validation	
Uncertainties and Controversies	28
4.4 Summary and Comment	29
5. Contextual Considerations and Potential Other Benefits	
New England CEPAC Votes	

6. Health Benefit Price Benchmarks	
New England CEPAC Votes	
7. Potential Budget Impact	
7.1. Overview of Key Assumptions	
7.2. Results	
8. Policy Recommendations	
References	47
Supplemental Materials	
A. Background: Supplemental Information	A1
A1. Definitions	A1
A2. Potential Cost-Saving Measures in Myasthenia Gravis	A4
B. Patient Perspectives: Supplemental Information	B1
B1. Methods	B1
C. Clinical Guidelines	C1
D. Comparative Clinical Effectiveness: Supplemental Information	D1
D1. Detailed Methods	D1
D2. Evidence Tables	D10
D3. Ongoing Studies	D49
D4. Previous Systematic Reviews and Technology Assessments	D51
E. Long-Term Cost-Effectiveness: Supplemental Information	E1
E1. Detailed Methods	E1
E2. Model Assumptions and Inputs	E5
E3. Results	E13
E4. Sensitivity Analyses	E16
E5. Scenario Analyses	E18
E6. Heterogeneity and Subgroups	E18
E7. Model Validation	E19
F. Potential Budget Impact: Supplemental Information	F1
F1. Methods	F1
F2. Results	F2

G. Public Comments	G1
H. Conflict of Interest Disclosures	H1

List of Acronyms and Abbreviations Used in this Report

AChR	Acetylcholine receptor
AE	Adverse event
AHRQ	Agency for Healthcare Research and Quality
CADTH	Canadian Agency for Drugs and Technologies in Health
CSR	Complete stable remission
gMG	Generalized myasthenia gravis
IVIG	Intravenous immunoglobulin
MG	Myasthenia gravis
MG-ADL	Myasthenia gravis activities of daily living
MGC	Myasthenia gravis composite
MGFA	Myasthenia Gravis Foundation of America
MGFA-PIS	MGFA Post-Intervention Status
MG-QOL	Myasthenia gravis quality of life
MM	Minimal manifestation
MMF	Mycophenolate mofetil
MuSK	Muscle specific kinase
NMA	Network meta-analysis
PLEX	Plasma exchange
PML	Progressive multifocal leukoencephalopathy
PR	Pharmacologic remission
QMG	Quantitative myasthenia gravis score
RCT	Randomized controlled trial
RTX	Rituximab
SAE	Serious adverse event
USPSTF	US Preventative Services Task Force

Executive Summary

Myasthenia Gravis (MG) is an autoimmune disease that affects the neuromuscular junction. The prevalence in the United States is estimated to be between 14 and 20 per 100,000 people^{1,2} and the annual incidence is approximately 2.2 per 100,000.³ The characteristic finding of MG is muscle weakness that worsens with repeated use ("fatigable weakness").⁴

With progressive disease, treatment typically includes high-dose corticosteroids combined with or followed by "steroid-sparing" immunosuppressive drugs (most commonly azathioprine and mycophenolate mofetil [MMF]). The goal of therapy is to maintain the patient with minimal manifestations (MM) of disease (no symptoms or functional limitations from MG despite minimal weakness on examination) or better.⁵ Currently, about 20,000 patients with generalized MG are intolerant or have an inadequate response to conventional treatment options.⁶

In this Report, ICER reviews eculizumab, a monoclonal antibody, and efgartigimod, an immunoglobulin fragment that targets the neonatal Fc receptor. Eculizumab received US Food and Drug Administration (FDA) approval in October 2017 for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-AChR antibody positive,⁷ and an FDA decision on efgartigimod is expected on December 17, 2021.⁸

We identified one Phase III trial each for eculizumab (REGAIN) and efgartigimod (ADAPT) but found insufficient data to compare these drugs to maintenance intravenous immunoglobulin IVIG and rituximab (RTX). In the Phase III REGAIN trial, patients with anti-AChR antibody positive, treatment-resistant gMG who received eculizumab had significantly better improvement in the myasthenia gravis activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) scores than those on placebo at four weeks and eight weeks (Table ES1), and the improvements were sustained at 26 weeks. In addition, at week 26, the proportion of patients with minimal symptom expression (MG-ADL score of 0 or 1) was much greater in the eculizumab group (21.4% vs. 1.7%, p=0.0007).⁹ In the open label extension through 130 weeks of follow up, the benefits were maintained, and may have increased compared with 26 weeks.¹⁰ There were no excess adverse events (AEs) in the trials, although more patients in the eculizumab group stopped treatment due to AEs, and it carries a black box warning for meningococcal infections.

The Phase III ADAPT trial was conducted in gMG patients with or without anti-AChR-antibody; however, the primary outcome was in the subgroup of anti-AChR antibody positive patients. The proportion of patients with clinically meaningful improvement (≥2-point MG-ADL improvement sustained for ≥4 weeks) was much greater in the efgartigimod group compared to the placebo group. Anti-AChR antibody positive gMG patients who received efgartigimod did significantly better on MG-ADL and QMG than those who received placebo (Table ES1). However, the improvements were greater at four weeks than at eight weeks, reflecting the unusual dosing schedule in the trial. Patients received their second treatment cycle only when they no longer had a clinically meaningful improvement on the MG-ADL. Thus, many patients were back near baseline at eight weeks. The anti-AChR antibody negative patients randomized to efgartigimod were only slightly more likely to respond based on the MG-ADL (68% vs. 63% in placebo group, p=NR). AEs did not appear to be more common with efgartigimod, but there are long-term concerns about infections with lowering of IgG levels.

Intervention	Arms	Δ MG-ADL		ΔQMG	
(Trial)		4 weeks	8 weeks	4 weeks	8 weeks
REGAIN	Eculizumab	-3.5	-3.7	-3.3	-4.0
	Placebo	-1.5	-1.8	-1.5	-1.4
ADAPT	Efgartigimod	-4.6	-2.2	-6.2	-2.9
	Placebo	-1.8	-1.7	-1.0	-1.2

Table ES1. Pivotal Trial Results

MG-ADL: Myasthenia Gravis Activities of Daily Living score, QMG: Quantitative Myasthenia Gravis score Note: Numbers are digitized estimates. Efgartigimod ADAPT trial results for AChR-positive patients only

One important area of uncertainty is that it is not clear if or when to stop either of the drugs in patients who are responding to them. For efgartigimod, the primary uncertainty is the appropriate dosing regimen. In the ADAPT trial, subsequent cycles were started once patients lost clinical benefits. It seems likely that in routine practice, patients and clinicians will not want to wait until the benefits have receded before starting another round of therapy. Also, despite their use in clinical practice, there is a lack of comparative efficacy data for both rituximab and IVIG used as maintenance therapy for gMG.

Taking into consideration the above information on the benefits and AEs of eculizumab, we believe *there is moderate certainty of a small or substantial net health benefit with high certainty of at least a small benefit for eculizumab added to conventional therapy* (B+) in adults with gMG positive for anti-AChR antibodies "refractory" to conventional therapy. For efgartigimod, given the above information on short-term benefits, but uncertainties about dosing, long-term benefits, and long-term safety, we concluded *that there is moderate certainty of a comparable, small, or substantial net health benefit of efgartigimod added to conventional therapy with high certainty of at least comparable net health benefit (C++) in adults with gMG positive for anti-AChR antibodies. While there is evidence for efgartigimod in adults with gMG negative for anti-AChR antibodies, it is sparse and of uncertain clinical and statistical significance. Thus, we concluded that the evidence was <i>insufficient* (I) to distinguish the net health benefit of efgartigimod added to conventional therapy for anti-AChR antibodies. In addition, the evidence is *insufficient* (I) to distinguish the net health benefit of rituximab and IVIG from placebo, eculizumab, and efgartigimod.

In economic modeling, we evaluated the cost effectiveness of (1) eculizumab plus conventional therapy versus conventional therapy alone in patients with refractory anti-AChR antibody positive gMG as defined in the REGAIN trial and (2) efgartigimod plus conventional therapy versus conventional therapy alone in the patients with gMG including those with or without anti-AChR-antibodies. The analyses were conducted over a two-year time horizon, taking a health system perspective. Based on an annual cost of \$653,100, the incremental cost per QALY and incremental cost per evLYG for eculizumab were estimated to be \$5,210,000. For efgartigimod, using a placeholder price of \$418,400, the incremental cost per QALY and incremental cost per evLYG were estimated to be \$2,076,000. From the cost-effectiveness base case, we estimated the health benefit price benchmark (HBPB) for each intervention. The HBPB range for eculizumab was estimated to be \$13,200 to \$19,400 (97%-98% discount from the Federal Supply Schedule [FSS] price). For efgartigimod, the HBPB range was estimated to be \$18,300 to \$28,400 (discounts not presented due to placeholder price) (Table ES2).

	Annual FSS	Annual Price atAnnual Price at\$100,000\$150,000ThresholdThreshold		Discount from FSS to Reach Threshold Prices	
Eculizumab					
QALYs Gained	\$653,100	\$13,200	\$19,400	97.0-98.0%	
evLYG*	\$653,100	\$13,200	\$19,400	97.0-98.0%	
Efgartigimod**					
QALYs Gained	NA	\$18,300	\$28,400	NA	
evLYG*	NA	\$18,300	\$28,400	NA	

Table ES2. Annual Health Benefit Price Benchmarks for Eculizumab and Efgartigimod

evLYG: equal value life year gained, QALY: quality-adjusted life year, FSS: Federal Supply Schedule, NA: not applicable

*There were no differences in survival. Cost per evLYG is equal to the cost per QALY gained.

**Efgartigimod evaluated using an annual placeholder price of \$418,400

The model was sensitive to several inputs, including the QMG improvement assigned to improved and unimproved MG and the proportion of patients achieving at least a 3-point reduction in the QMG for efgartigimod or its comparator, or eculizumab and its comparator. However, despite the large impact of changing these inputs on the results, the incremental cost-effectiveness ratio was never less than \$3.8 million per QALY gained for eculizumab and \$1.7 million per QALY gained for efgartigimod. In addition, the results of the probabilistic sensitivity analysis and scenario analyses had similar cost/QALY estimates.

There are other potential benefits and important contextual considerations not fully captured in the economic model. For example, MG is a serious, lifelong disease with life-threatening manifestations, and most patients do not achieve treatment goals with conventional therapy. Additionally, there is potential to improve childbearing and career opportunities for women who

are often diagnosed early in their lives. This is particularly relevant for Black women who typically present at younger ages and may have a more severe disease course than other patient groups.

In conclusion, both eculizumab and efgartigimod significantly improve function and quality of life for patients with gMG. However, at the current price for eculizumab, the estimated cost effectiveness is well above typical willingness-to-pay thresholds. If the price of efgartigimod falls in the range reported by the company, it will also have an incremental cost-effectiveness ratio well above typical willingness-to-pay thresholds. The final estimate will depend on its actual price.

Themes and recommendations from the public meeting include:

- All stakeholders have a responsibility and an important role to play in ensuring that effective new treatment options for patients with gMG are introduced in a way that will help reduce health inequities.
- Payers should use the FDA label as the guide to coverage policy and engage clinical experts and diverse patient representatives in considering how to address coverage issues for which there is limited or no evidence at the current time.
- Payers should use step therapy based on clinical trial eligibility and/or authoritative evidence-based clinical specialty guidelines as they become available. Given the limited current evidence base for efgartigimod, payers should not require therapy with efgartigimod prior to coverage of eculizumab. However, as additional clinical evidence accumulates, it may be reasonable to require step therapy based on price.
- Manufacturers should set prices that will foster affordability and good access for all patients by aligning prices with the patient-centered therapeutic value of their treatments. In the setting of these new interventions for gMG, there remains substantial uncertainty regarding their longer-term safety and effectiveness. Manufacturer pricing should reflect these considerations in more moderate launch pricing.
- Clinical specialty societies should continue to bear witness to the impact of high prices for novel therapies on patients.
- Patient organizations have a vital role to play by complementing existing clinical research with patient-focused surveys collecting data on the impact of gMG on the diversity of patient experiences and the impact on caregivers.
- Researchers should collect data on the larger societal impact of novel therapeutics used to treat patients with gMG, not just the immediate impacts on patients.

Appraisal committee votes on questions of comparative effectiveness and value, along with key policy recommendations regarding pricing, access, and future research are included in the main report.

1. Background

Myasthenia Gravis (MG) is an autoimmune disease that affects the neuromuscular junction. The prevalence in the United States is estimated to be between 14 and 20 per 100,000 people^{1,2} and the annual incidence is approximately 2.2 per 100,000.³

The characteristic finding of MG is muscle weakness that worsens with repeated use ("fatigable weakness").⁴ MG symptoms often begin with ptosis (drooping eyelids) and diplopia (double vision) that worsens with activity and by the end of the day.¹¹ Ocular weakness may progress to affect the muscles controlling speech, swallowing, or body function ("generalized MG").¹¹ Weakness of respiratory muscles can result in life-threatening respiratory failure requiring intubation.¹¹ The majority of patients (~80%) progress to some form of generalized disease, typically within the first two years of symptom onset.^{3,11}

The majority of patients with MG have autoantibodies that bind to the acetylcholine receptor (AChR).⁴ First-line symptomatic treatment is pyridostigmine, which inhibits the breakdown of acetylcholine by acetylcholinesterase.¹² With progressive disease, disease-modifying therapy typically includes high-dose corticosteroids, frequently in combination with or followed by "steroid-sparing" immunosuppressive drugs (most commonly azathioprine and mycophenolate mofetil [MMF]) in order to reduce the corticosteroid dose while maximizing patients' quality of life. The goal of therapy is to maintain the patient with minimal manifestations (MM) of disease (no symptoms or functional limitations from MG despite minimal weakness on examination) or better (sustained remission of symptoms and full functional capacity) with minimal side effects.⁵ Currently, about 20,000 patients with generalized MG are intolerant or have inadequate response to conventional treatment options.⁶ The average annual cost per patient for MG-specific care paid by a private health plan was \$15,675 in 2009.¹³ The largest costs were home health services and intravenous immunoglobulin (IVIG) infusions.

New therapies are becoming available for patients with MG (Table 1.1). Eculizumab is a monoclonal antibody that inhibits the cleavage of C5, thus reducing the formation and deposition of terminal complement complex C5b-9 at the neuromuscular junction.¹⁴ It received US Food and Drug Administration (FDA) approval in October 2017 for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-AChR antibody positive.⁷ Efgartigimod is an immunoglobulin fragment that targets the neonatal Fc receptor and reduces IgG antibody levels by about 50% after a single infusion and 75% after repeated infusions.¹⁵ An FDA decision on efgartigimod is expected on December 17, 2021.⁸

Table 1.1. Interventions of Interest

Intervention Generic Name (Brand Name)	Mechanism of Action	Delivery Route	Recommended Dose
	Monoclonal antibody inhibiting		900 mg weekly x 4
Eculizumab	C5 cleavage reducing	Intravenous	weeks, then 1200 mg
(Soliris [®])	complement deposition at the	infusion	week 5, then 1200 mg
	neuromuscular junction		every two weeks
	Immunoglobulin G1 Fc		10 mg/kg weekly for 4
Efgortigimod	fragment antibody to the	Intravenous	weeks, followed by
Eigartiginiou	neonatal Fc receptor leading to	infusion	dosing based on
	decreased IgG levels		patient symptoms*

*Dosage at which investigational agent was evaluated in clinical trials

2. Patient and Caregiver Perspectives

This report was developed with input from diverse stakeholders, including individual patients, patient advocacy organizations, clinicians, researchers, and manufacturers of the agents of focus in this review. To obtain more detailed information about patient and caregiver perspectives, we also conducted a focus group with four patients, where we heard about their lived experiences in depth.

Patients with MG often experience a long and frustrating path to diagnosis and appropriate treatment. This reflects the paucity of experience physicians have in caring for patients with MG because the disease is rare. The disease is often referred to as a "snowflake disease" because of its heterogeneity, making the diagnosis even more difficult. As a result, patients are misdiagnosed and see many specialists before they receive the diagnosis of MG. The multiple medical appointments needed to reach a diagnosis and manage their disease necessitates missed work, family responsibilities, and social activities.

Living with a known diagnosis is no easier. As one patient put it, "A diagnosis with myasthenia gravis is like a full-time job." Patients highlighted the difficulty in finding a treatment plan that works, convincing insurers to cover their treatment plan, managing the unexpected flares, and the chronic fatigue associated with MG. These issues have significant impacts on school, work, and personal relationships. Patients also highlighted the importance of the caregiver role and the impact of MG on the lives of caregivers.

Many patients experience significant side effects from current therapies, such as corticosteroids and non-steroidal immunosuppressive agents. The side effects can contribute as much to patient disability as the disease itself. Some patient advocates feel that the manufacturers of drugs for MG downplay the impact of these side effects on patients' lives. In addition, patients experience significant barriers accessing some therapies. They particularly highlighted the challenges in accessing IVIG as maintenance therapy, and when approved, there were challenges getting coverage for home infusion rather than having to travel to an infusion center. For some patients, the requirement to travel to an infusion center impacted their ability to keep their job. Based on public comments that both IVIG and rituximab are widely used to treat patients with MG for whom other conventional immunosuppressive therapies have failed or not been tolerated, we have summarized the evidence base for both drugs as maintenance therapy.

Stakeholders also highlighted that eculizumab is very expensive. Some stakeholders noted that this has created a barrier to access for patients who might benefit from this treatment. Other stakeholders noted that while the pivotal trial of eculizumab studied patients with refractory disease, the drug is sometimes used in patients who have not received an adequate trial of less expensive conventional immunosuppressive therapy.

Additionally, patients and patient groups report concern about financial burden to both patients and caregivers. Specifically, they noted that the out-of-pocket costs for visits, medication, and hospitalizations can be substantial.

Patient groups emphasized the impact of the COVID-19 pandemic on patients with gMG. Many patients are treated chronically with immunosuppressive therapy. This puts them at risk for severe COVID-19 disease if they are infected. In addition, infection with COVID-19 can be a trigger for an MG exacerbation. Finally, when patients on immunosuppressive medications are vaccinated, they may not develop an antibody response, or their response may be weaker than that of an otherwise healthy person. This has recently been acknowledged with the emergency use authorization of a COVID-19 booster vaccine for patients who are immunosuppressed.

Stakeholders highlighted some important race/ethnicity differences in MG. We heard how important it was to consider the impact of MG on delayed childbearing potential particularly in Black women since they are diagnosed at significantly younger ages on average than white women. In response, we added lost or delayed childbearing to the list of outcomes that matter to patients.

3. Comparative Clinical Effectiveness

3.1. Methods Overview

Please see <u>Supplement Section D</u> for details of the literature search, quality assessment, and quantitative summary methods.

Scope of Review

This review compares the outcomes of adding eculizumab or efgartigimod to standard therapy with the outcomes of standard therapy alone in adults with gMG for whom conventional immunosuppressive therapies have not been effective or have not been tolerated. We also sought to compare the interventions to each other and to two off label interventions: rituximab and maintenance IVIG. We searched for evidence on patient-important outcomes, including symptom improvement (using Myasthenia Gravis Activities of Daily Living [MG-ADL], Quantitative Myasthenia Gravis score [QMG]), remission, minimal symptom expression, and quality of life. We also looked for data on subpopulations of interest, including those who are positive for anti-muscle-specific kinase (MuSK) antibodies and those who test negative for all known MG-associated antibodies ("seronegative MG"). The full scope of the review, including the complete outcomes list, can be found in <u>Supplement Section D</u>.

Evidence Base

A total of 11 references on eculizumab and efgartigimod met our inclusion criteria. Of these, we identified one Phase III randomized controlled trial (RCT) of eculizumab (REGAIN, Table 3.1)¹⁶ with many additional reports^{9,10,17-21} and one small (n=14) Phase II RCT of eculizumab.²² For efgartigimod, we identified one Phase III RCT (ADAPT, Table 3.1²³ and one small (n=24) Phase II RCT.²⁴ A summary of the pivotal trials of eculizumab (REGAIN) and efgartigimod (ADAPT) is presented below. Additional details are available in <u>Supplement Section D</u>.

In the pivotal trial of eculizumab (REGAIN), 125 patients with gMG that is anti-AChR antibodypositive and "refractory" to conventional therapy were randomized 1:1 to intravenous eculizumab or intravenous placebo for 26 weeks. There are a number of different definitions of "refractory." In the REGAIN study, "refractory" was defined as having failed two or more immunosuppressive therapies or at least one immunosuppressive therapy with either IVIG or PLEX given at least four times annually for at least one year without symptom control.

In the pivotal trial of efgartigimod (ADAPT), 167 patients with gMG were randomized 1:1 to intravenous efgartigimod or intravenous placebo for 26 weeks. The ADAPT trial enrolled patients with or without anti-AChR antibody; however, the primary outcome was in the subgroup of patients

who are antibody positive (n=129). We also obtained academic-in-confidence data from the manufacturer on the subgroup of patients in the ADAPT trial who were anti-AChR antibody-positive and "refractory" to conventional therapy, using the same definition of "refractory" that was used in the REGAIN trial.

In both the ADAPT and REGAIN trials, patients continued background conventional therapy throughout the trial periods. The outcomes assessed in each trial are presented in Table 3.1.

The clinical evidence is summarized separately below for each drug because the pivotal trials for the two drugs differed in the populations studied. However, despite differences in inclusion and exclusion criteria (<u>Supplement Table D2.2</u>), the baseline characteristics of the anti-AChR antibody-positive patients in the pivotal trials of eculizumab and efgartigimod were similar (Table 3.2), and even more similar for the patients "refractory" to conventional treatment using the definition of refractory used in the REGAIN trial.

We did not identify any published results in comparable patient populations on rituximab and IVIG. However, we identified one unpublished trial of rituximab (BeatMG)²⁵ and two unpublished trials of IVIG in ClinicalTrials.gov that met our inclusion criteria.^{26,27} Due to key differences across trials in patient characteristics and trial design, we did not compare the interventions to rituximab or IVIG. Detailed descriptions of these trials can be found in <u>Supplement Table D2.2</u>.

Table 3.1. Overview of Pivotal Randomized Trials

Drug	Trials	Ν	Outcomes	
Eculizumab REGAIN 125		125	Primary: Change from baseline in MG-ADL at 26 weeks	
		125	Secondary: QMG, MG-QoL15, MGC	
			Primary: Proportion of anti-AChR Ab+ patients with at least a 2-	
Efaortiaimod	ADAPT	129*	point reduction in MG-ADL for at least 4 consecutive weeks in	
Elgartiginiou			the first treatment cycle (8 weeks)	
			Secondary: QMG, MG-QoL15r, MGC	

MG-ADL: myasthenia gravis activities of daily living score, MGC: myasthenia gravis composite scale, MG-QOL15r: revised 15-item myasthenia gravis quality of life, QMG: quantitative myasthenia gravis score *Includes only adults with gMG positive for anti-AChR antibodies

	REGAI	N Trial	ADAPT Trial		
	Eculizumab	Placebo	Efgartigimod	Placebo	
Ν	62	63	65	64	
Age, years	47.5	46.9	44.7	49.2	
Sex- Female, %	66	65	71	63	
Duration MG, years	9.9	9.2	9.7	8.9	
MG-ADL, mean	10.5	9.9	9.0	8.6	
QMG, mean	17.3	16.9	16.0	15.2	
MGC, mean	20.4	18.9	18.6	18.1	
MGFA Class, %					
II	29	46.8	43.1	39.1	
	58.7	46.0	53.8	56.3	
IV	11.3	7.9	3.1	4.7	
Prior non-steroidal					
immunosuppressive	100	100	72.3	67.2	
therapy, %					

 Table 3.2. Baseline Characteristics of Anti-AChR Antibody Positive Participants in the Pivotal

 Randomized Trials

MG: myasthenia gravis, MG-ADL: myasthenia gravis activities of daily living score, MGFA: Myasthenia Gravis Foundation of America, N: total number, QMG: quantitative myasthenia gravis score

3.2. Results

Clinical Benefits

The Phase III trials of eculizumab (REGAIN) and efgartigimod (ADAPT) assessed four commonly used outcome measures (MG-ADL, QMG, MG-QOL15 or MG QOL15r, MGC) at multiple timepoints (<u>Supplement Table A1</u> for details of the measures, <u>Supplement Tables D2.6 to D2.14</u> for detailed results). We did not identify any data on remission, lost or delayed childbearing, mental health (anxiety, depression), corticosteroid side effects, and immunosuppressive side effects and burden on any of the interventions.

Eculizumab

In the Phase III REGAIN trial, patients with anti-AChR antibody positive, "refractory" gMG who received eculizumab did not significantly differ from placebo on the primary outcome as measured by the worst-rank ANCOVA (least-squares mean rank 56.6 [SEM 4.5]) vs. 68.3 [4.5]; rank- difference –11.7 [95% CI –24.3 to 0.96], p=0.698).¹⁶ The worst-rank analysis assigned the lowest rank to all patients who dropped out regardless of the reason for discontinuation. Of note, four discontinuations (2 in placebo arm and 2 in eculizumab arm) met the criteria for clinical worsening, while the remaining three discontinuations (all in eculizumab arm due to adverse events) were reported to have clinical improvements. However, in repeated-measures analysis that assessed

changes in MG-ADL from baseline, patients on eculizumab had significantly better improvement in MG-ADL score than those on placebo at 4 weeks and 8 weeks (Table 3.3), and the improvement was sustained at 26 weeks (-4.2 vs. -2.3; p=0.0058). Similar patterns of improvement that favored eculizumab compared to placebo were seen for the changes in QMG (Table 3.3), MG-QOL-15, and MGC (<u>Supplement Table D2.7</u>). For example, at week 4, the eculizumab group had a greater reduction in the 60-point MG-QOL15 scale (-7.2 vs. -3.6 points, p=0.0395). At week 26, the proportion of patients with minimal symptom expression (MG-ADL score of 0 or 1) was much greater in the eculizumab group (21.4% vs. 1.7%, p=0.0007).⁹ In the open label extension through 130 weeks of follow-up, the benefits were maintained and may have increased compared with 26 weeks.¹⁰

Intervention	Arms	Δ MG-ADL		∆QMG	
(Trial)	ATTIS	4 weeks	8 weeks	4 weeks	8 weeks
REGAIN	Eculizumab	-3.5	-3.7	-3.3	-4.0
	Placebo	-1.5	-1.8	-1.5	-1.4
ADAPT	Efgartigimod	-4.6	-2.2	-6.2	-2.9
	Placebo	-1.8	-1.7	-1.0	-1.2

Table 3.3. Pivotal Trial Results: Adults with gMG Positive for Anti-AChR Antibodies

MG-ADL: Myasthenia Gravis Activities of Daily Living score, QMG: Quantitative Myasthenia Gravis score Note: Numbers are digitized estimates.

Efgartigimod

In the Phase III ADAPT trial, patients with anti-AChR antibody positive gMG who received efgartigimod did significantly better than those who received placebo on the primary outcome (significant improvement in MG-ADL during the first treatment cycle (MG-ADL responder), 68% vs. 30%, p<0.0001).²³ In addition, at week 4, the efgartigimod group had a greater reduction in the 30-point MG-QOL15r scale (-7.3 vs. -2.3 points, p<0.05). Note that this quality-of-life scale is a revised version of the scale used in the REGAIN trial. The improvements in the efgartigimod group compared to the placebo group were better at 4 weeks than at 8 weeks (Table 3.3 above), reflecting the unusual dosing schedule in the trial. Patients received their second treatment cycle when they no longer had a clinically meaningful improvement on the MG-ADL. Thus, many patients were back near baseline at 8 weeks. The manufacturer provided academic in confidence results from ADAPT+, the long term extension study of the ADAPT trial, which demonstrated stability of the MG-ADL and QMG response that fluctuates up and down with dosing through one year of follow-up.²⁸

The subgroup analyses for patients in the ADAPT trial who were anti-AChR antibody negative did not report p-values or confidence intervals. Patients randomized to efgartigimod were only slightly more likely to respond based on the MG-ADL (68% vs. 63%, p=NR). There were trends towards greater benefits on other measures as well in exploratory analyses (<u>Supplement Table D2.6-D2.9</u>).

Rituximab

In the unpublished BeatMG Phase II study, rituximab did not significantly differ from placebo on the primary outcome of achieving at least a 75% reduction in daily prednisone dose after two cycles of rituximab separated by six months (60% vs. 55.6%, p=NR). Changes in QMG and MGC were nominally greater in the rituximab group (<u>Supplement Table D2.7</u>). As noted above, the patient population in the BeatMG trial was very different from the REGAIN and ADAPT study populations.

IVIG

In the unpublished trials of IVIG for maintenance therapy, IVIG failed to reduce prednisone dosing more than placebo in the first study²⁶ but appeared to lead to a greater reduction in the QMG in the second study (-4.6 vs. -2.7, p=NR, <u>Supplement Table D2.7</u>).²⁷

Network Meta-analyses Comparing Eculizumab, Efgartigimod, and Placebo at four weeks in anti-AChR antibody Positive Patients Refractory to Conventional Therapy Using the Definition of "Refractory" from the REGAIN Trial

Using academic-in-confidence data provided by the manufacturer, we compared efgartigimod to eculizumab in patients who were anti-AChR antibody-positive and "refractory" to conventional therapy, as defined by the REGAIN trial. The NMA evaluated improvement in MG-ADL and QMG at four weeks (Tables 3.4 and 3.5 below). Baseline characteristics of the subgroup of patients in the ADAPT trial who were anti-AChR antibody-positive and "refractory" to conventional therapy (academic-in-confidence) were similar to the REGAIN trial. NMA results showed that both eculizumab and efgartigimod significantly improved MG-ADL and QMG compared with placebo at four weeks. However, efgartigimod had significantly greater improvements compared with eculizumab. For instance, the mean improvement in MG-ADL was 1.0 points greater for efgartigimod than that for eculizumab (CrI: 0.8 to 1.2). At eight weeks, the results for efgartigimod had returned to near baseline due to the dosing schedule and were lower than those for eculizumab (data in confidence).

Table 3.4. NMA Results of Change in MG-ADL Score at Week Four from Baseline (Fixed EffectModel): Mean Difference (95% Credible Interval)

Efgartigimod		
1.0 (0.8 to 1.2)	Eculizumab	
3.0 (2.8 to 3.2)	2.0 (1.9 to 2.1)	Placebo

Table 3.5. NMA Results of Change in QMG Score at Week Four from Baseline (Fixed Effect Model):Mean Difference (95% Credible Interval)

Efgartigimod		_
3.5 (3.1 to 3.9)	Eculizumab	
5.3 (5 to 5.6)	1.8 (1.6 to 2.0)	Placebo

Harms

Eculizumab

In the REGAIN trial, Serious adverse events (SAEs) were less common in the patients randomized to eculizumab than those randomized to placebo (Supplement Tables D2.12-D2.14). There was one MG crisis in a patient in the eculizumab group who died from the crisis 90 days after the last eculizumab dose. Because the death occurred after the patient was discontinued from the study, it was not counted as a study death even though the death was directly due to an adverse event occurring while the patient was on active treatment. However, both hospitalizations (15% vs. 29%, p=NR) and MG exacerbations (10% vs. 24%, p NR) were numerically lower in the eculizumab group. Otherwise, the most common AEs (headache, upper respiratory tract infections, nausea, etc.) were similar or more common in the placebo group. However, there were more discontinuations because of AEs in the eculizumab group (6% vs. 0%). Eculizumab carries a black box warning for meningococcal infection, and patients are required to be vaccinated at least two weeks prior to the first dose of the drug. There were no cases of deaths associated with meningococcal infection in the REGAIN trial.

Efgartigimod

In the ADAPT trial, infections were more common in the efgartigimod group compared to the placebo group (46% vs. 37%). SAEs were less common in the patients randomized to efgartigimod than those randomized to placebo (<u>Supplement Tables D2.12-D2.14</u>). Similarly, the most common AEs (headache, upper respiratory infections, nausea, etc.) were similar or more common in the placebo group. However, the risk for discontinuations due to AEs was similar in both groups (4% vs. 4%). These results represent the full trial population; the adverse events were not presented for the anti-AChR receptor antibody positive and negative subgroups.

Rituximab

In the BeatMG trial, SAEs were slightly lower in the rituximab group compared with placebo (36.0% vs. 51.9%, p=NR). Treatment related discontinuations were not reported. Progressive multifocal leukoencephalopathy (PML) is a known, rare SAEs in patients treated with rituximab. The occurrence of PML was not measured in the BeatMG trial.

IVIG

In the two Phase II studies of IVIG, SAEs were higher in the IVIG group compared with placebo in one study (16.7% vs. 12.5%) and lower in the other (13.3% vs. 20.0%). In addition, treatment related discontinuations were slightly higher in the IVIG group compared with placebo in both trials (6.7% vs. 6.3%; 20.0% vs. 13.3%).

Subgroup Analyses and Heterogeneity

There are many subgroups of interest for which we had no data or very limited data. No results were presented by race/ethnicity nor were data broken out by patients positive for the MuSK or LRP4 antibodies. Eculizumab was studied only in treatment-resistant anti-AChR antibody positive patients with no data in patients who are not treatment resistant but who may benefit from early treatment with eculizumab. Finally, efgartigimod was studied in both anti-AChR antibody positive and negative patients, but the majority of patients (<u>Supplement Table D2.3</u>) were antibody positive, and their primary endpoint was in antibody positive patients.

Uncertainties and Controversies

Both eculizumab and efgartigimod share many uncertainties. First, it is not clear if or when to stop either of the drugs once initiated other than for patients not responding after some period of time. Additionally, their target population is uncertain. For instance, eculizumab was studied only in refractory patients using a specific definition of refractory, but the FDA label does not specify limiting use to refractory patients. Efgartigimod's pivotal trial included anti-AChR antibody positive and negative patients, but the primary outcome was in antibody positive patients. Should it be used to treat antibody negative patients? In general, there are insufficient data to assess their effectiveness in other important subgroups such as patients who are positive for the anti-MUSK antibody for efgartigimod (eculizumab may not work in this population due to its mechanism of action), LRP4 antibody positive patients, non-white populations, and those with disabling ocular disease. Finally, there are limited data on long-term safety, given that these drugs may be used for many years.

For efgartigimod, the primary uncertainty is the appropriate dosing regimen. In the ADAPT trial, subsequent cycles were started once patients lost clinical benefits. It seems likely that in routine practice, patients and clinicians will not want to wait until the benefits have receded before starting another round of therapy. At this time, there is also uncertainty about the long-term benefits of therapy.

Despite their use in clinical practice, there is a lack of comparative efficacy data for both rituximab and IVIG used as maintenance therapy for gMG.

3.3. Summary and Comment

An explanation of the ICER Evidence Rating Matrix (Figure 3.1) is provided in the Supplement.





Comparative Clinical Effectiveness

Adults with gMG Positive for Anti-AChR Antibodies

Eculizumab did not meet its primary endpoint in the Phase III REGAIN trial, which was studied in adults with gMG positive for anti-AChR antibodies refractory to conventional therapy. However, there were consistent, clinically important improvements in the MG-ADL and QMG scores at four weeks that were maintained through 26 weeks in the trial and through 130 weeks in long-term follow-up. There were no excess AEs, although more patients in the eculizumab group stopped treatment due to AEs, one died following an MG crisis, and it carries a black box warning for meningococcal infections. Overall, we have moderate certainty of a small or substantial net health benefit with high certainty of at least a small benefit for eculizumab added to conventional therapy compared with conventional therapy alone (B+) in adults with gMG positive for anti-AChR antibodies refractory to conventional therapy.

In the subgroup of the ADAPT trial with these patient characteristics (i.e., gMG positive for anti-AChR antibodies 'refractory' to conventional therapy using the REGAIN trial definition of refractory) and the broader population of patients with gMG positive for anti-AChR antibodies, efgartigimod treated patients had a greater response to therapy than those in the placebo group. However, the benefits decreased significantly at eight weeks because of the unusual dosing schedule. Given the uncertainties about dosing, the consistent long-term benefit of the therapy is not clear. AEs did not appear to be more common with efgartigimod in the clinical trial; however, new biologic therapies are frequently found to have safety concerns even after drug approval.²⁹ For example, there are long term concerns about infections with lowering IgG levels. Taking all these into consideration, on balance, we concluded that there is moderate certainty of a comparable, small, or substantial net health benefit of efgartigimod added to conventional therapy with high certainty of at least comparable net health benefit (C++).

In the NMA, efgartigimod had a greater improvement in MG-ADL and QMG scores than eculizumab. However, given the same uncertainties about dosing and long-term benefits and safety of efgartigimod and the limitations of indirect comparisons, we concluded that the evidence was insufficient (I) to distinguish the net health benefits of efgartigimod from eculizumab.

The evidence is insufficient (I) to distinguish the net health benefits of rituximab and IVIG from placebo, eculizumab, and efgartigimod.

Adults with gMG Negative for Anti-AChR Antibodies

Eculizumab is not approved for treatment in patients who test negative for anti-AChR antibodies and has not been studied in RCTs in this population.

While there is evidence for efgartigimod in this population, it is sparse and of uncertain clinical and statistical significance. Thus, we concluded that the evidence was insufficient to distinguish the net health benefits of efgartigimod added to conventional therapy from conventional therapy alone in this population.

Table 3.6. Evidence Ratings

Treatment	Comparator	Evidence Rating	
Adults with gMG positive for anti-AChR antibodies			
Eculizumab	Placebo	B+	
Efgartigimod	Placebo	C++	
Eculizumab	Efgartigimod	1	
Eculizumab/Efgartigimod	Rituximab	1	
Eculizumab/Efgartigimod	IVIG	I	
Adults with gMG negative for anti-AChR antibodies			
Efgartigimod	Placebo	1	

AChR: acetylcholine receptor, IVIG: intravenous immunoglobulin, QMG: quantitative myasthenia gravis score

New England CEPAC Votes

Table 3.7. New England CEPAC Votes on Comparative Clinical Effectiveness Questions

Question	Yes	No
Patient population: Adults with gMG, defined by MGFA clinical classes of II to IV for whom conventional immunosuppressive therapies have not been effective or have not been tolerated, and who are anti-AChR antibody positive.		
Given the currently available evidence, is the evidence adequate to demonstrate that the net health benefit of eculizumab added to conventional therapy is superior to that provided by conventional therapy alone ?	11	0
Given the currently available evidence, is the evidence adequate to demonstrate that the net health benefit of efgartigimod added to conventional therapy is superior to that provided by conventional therapy alone ?	10	1
Given the currently available evidence, is the evidence adequate to distinguish the net health benefit of eculizumab from that of efgartigimod ?	0	11
Given the currently available evidence, is the evidence adequate to distinguish the net health benefit of IVIG from that of eculizumab and efgartigimod ?	0	11*
Given the currently available evidence, is the evidence adequate to distinguish the net health benefit of rituximab from that of eculizumab and efgartigimod ?		10
Patient population: Adults with gMG, defined by MGFA clinical classes of II to IV for whom conventional immunosuppressive therapies have not been effective or have not been tolerated, and who are anti-AChR antibody negative.		
Given the currently available evidence, is the evidence adequate to demonstrate that the net health benefit of efgartigimod added to conventional therapy is superior to that provided by conventional therapy alone ?	0	11

*This count does not match that shown in the video recording of the voting session because one vote was entered incorrectly into the voting software.

In the population of patients with gMG who test positive for anti-AChR antibodies, the CEPAC voted that the evidence is adequate to demonstrate that when added to conventional therapy, both eculizumab and efgartigimod have superior net health benefit to that provided by conventional therapy alone. These votes were mainly driven by the consistent efficacy that was demonstrated in the clinical trials and the favorable safety profiles for the two drugs. The CEPAC judged that the evidence was not adequate to distinguish the net health benefit of the two drugs, or to distinguish between the two interventions and IVIG and rituximab, because of the absence of comparative efficacy data.

In the anti-AChR antibody negative population, the CEPAC unanimously judged that the evidence is not adequate to demonstrate that the net health benefit of efgartigimod is superior to that of conventional therapy, because of the limited data available for this population.

4.1. Methods Overview

Since the last report, the following changes were made to this version of the report:

- The prices of all treatments were estimated in the draft report using the Veterans Administration Federal Supply Schedule (FSS). In addition, a discount of 28% was inappropriately applied in the draft report. Since the FSS is already representative of a discounted price, this 28% discount was removed for all drugs, including when estimating the placeholder price of efgartigimod, for this report. This change resulted in increased incremental cost-effectiveness ratios for each treatment by 25-30%.
- Model programming updates were made to ensure accuracy between the model and its description within this report and supplementary material. Updates to model programming included within the estimation of cycle-level mean QMG, utility values assigned to efgartigimod in the scenario analysis involving 8-week redosing periods, and disutility assigned to hospitalizations and ED visits. These changes had minimal impact on incremental cost-effectiveness ratios.

The primary aim of this analysis was to estimate the cost effectiveness of eculizumab and, separately, efgartigimod, each added to conventional therapy versus conventional therapy alone. The base-case analysis evaluated eculizumab plus conventional therapy versus conventional therapy alone in patients with "refractory" anti-AChR antibody positive gMG, as defined in the REGAIN trial. We also evaluated efgartigimod plus conventional therapy versus conventional therapy alone in the broader population of patients with gMG, where the broader population includes patients with or without anti-AChR antibodies. Although we rated the evidence for efgartigimod as insufficient in anti-AChR negative antibody gMG, the base case for efgartigimod focused on the broader gMG population, in alignment with the studied population in the ADAPT trial.

To provide further context around the cost effectiveness of eculizumab and efgartigimod, we conducted several scenario analyses that are described in <u>Supplement Section E1</u>. Productivity changes and other indirect costs and effects were not available due to an absence of evidence on the impact of treatments on productivity, caregiver burden, and other costs and outcomes considered important from a societal perspective. Therefore, all analyses take the health care system perspective and although a modified societal perspective was explored, the absence of evidence does not differentiate the draft findings between the modified societal perspective and that of the health care system perspective (<u>Supplement Table E1</u>). The time horizon chosen for this analysis was two years. This horizon is shorter than the ICER reference case of a lifetime due to the

following reasons: 1) In discussion with clinical experts, we heard that MG was heterogeneous but not considered progressive; 2) The interventions or their comparators, within our scope, do not have evidence supporting differences in mortality; 3) The interventions of interest have evidence supporting an onset of action within one model cycle (i.e., 28 days) and a stable maximal effect within two model cycles and; 4) The cost-effectiveness findings are thought to stabilize within a two-year time period.

The following base-case analyses were conducted:

- Compared eculizumab plus conventional therapy to conventional therapy in patients with "refractory" anti-AChR antibody positive gMG, four-state model (Figure 4.1)
- Compared efgartigimod plus conventional therapy to conventional therapy in patients with gMG, four-state model (Figure 4.1)

The base-case analysis comparing eculizumab plus conventional therapy to conventional therapy alone in patients with "refractory" anti-AChR antibody positive gMG used a four-state Markov model, shown in Figure 4.1, and response definitions, shown in Table 4.1, with a four-week cycle length and two-year time horizon. Simulated patients entered the model through the Markov state, "Unimproved MG on initial treatment," and received eculizumab plus conventional therapy or conventional therapy alone. The QMG was chosen as the primary outcome measure for two reasons: experts suggested that there were significant floor and ceiling effects with the MG-ADL that were less problematic with the QMG; and the QMG was reported in studies evaluating the cost effectiveness of all therapies included in this review, while the MG-ADL was not reported in the included studies evaluating IVIG and rituximab. Patients with a minimum three-point improvement in QMG remained on the initial treatment (i.e., eculizumab or efgartigimod) and transitioned to the "Improved MG on initial treatment" Markov state. Those patients with less than a three-point improvement in QMG by week eight (two model cycles) discontinued the initial treatment and transitioned to the "Unimproved MG off-treatment" state. All living patients remained in the "Improved MG on initial treatment" or "Unimproved MG off-treatment" for all future cycles. Patients entered the "Death" state from any model state and in any cycle. In addition, simulated patients could experience MG-related hospitalizations and emergency room visits in any living state of the model. The probability of hospitalizations and emergency room visits were higher for patients in the "Unimproved MG off-treatment" Markov state. Costs, utilities, and effectiveness outcomes for each state were summed for each cycle.

The base-case analysis comparing efgartigimod versus conventional therapy in all patients used the same four-state Markov model structure, shown in the model schematic Figure 4.1, and response definitions shown in Table 4.1. Simulated patients with gMG (with or without anti-AChR antibody) enter the model through the Markov state, "Unimproved MG on the initial line of treatment," and received either efgartigimod plus conventional therapy or conventional therapy alone. Response,

defined as the proportion of patients with a minimum three-point improvement in QMG, was evaluated at four weeks for efgartigimod. Otherwise, patients moved through the model as described for the eculizumab analysis.

To provide further context around the cost effectiveness of eculizumab and efgartigimod, several scenario analyses were conducted. A modified societal perspective was explored, but due to an absence of evidence, this analysis could not be conducted.

All scenario analysis treatment strategies and comparisons that were conducted are described below:

- Efgartigimod plus conventional therapy versus conventional therapy alone, assessed in patients with "refractory" anti-AChR antibody positive gMG, as defined by the REGAIN trial (data was obtained as academic-in-confidence from the manufacturer).
- 2. Eculizumab plus conventional therapy versus efgartigimod plus conventional therapy, assessed in patients with "refractory" anti-AChR antibody positive gMG, as defined by the REGAIN trial.
- 3. Efgartigimod plus conventional therapy versus conventional therapy alone, assessed in all patients (i.e. "refractory" and non-"refractory") with anti-AChR antibody positive gMG, as enrolled in the ADAPT trial.
- 4. IVIG plus conventional therapy versus conventional therapy, represented by the placebo control group from the corresponding clinical trial, in patients with gMG.
- 5. Rituximab plus conventional therapy versus conventional therapy, represented by the placebo control group from the corresponding clinical trial, in patients with gMG.
- 6. Efgartigimod plus conventional therapy, using efficacy at four and eight weeks from the ADAPT trial (i.e., dosing scheme consistent with four weeks of efgartigimod, four weeks without efgartigimod), versus conventional therapy alone, assessed in all patients enrolled in the ADAPT trial.
- 7. Eculizumab or efgartigimod, followed by IVIG or rituximab in a mixed patient population. This scenario analysis was considered exploratory only.
- 8. Efgartigimod plus conventional therapy versus conventional therapy alone, assessed in all patients included in the ADAPT trial, using trial-derived utilities provided by argenx (data provided as academic in-confidence). Note that for this analysis, we averaged the values for non-responders, since non-responders would have their treatments discontinued and would not be expected to have different utility values.

Additional information about the methods used to evaluate the cost effectiveness of treatments for MG, including models and methods for scenario analyses, are located in <u>Supplement Section E1</u>.



Figure 4.1. Model Schematic: Four-State Model Depicting Treatment for Myasthenia Gravis

Table 4.1. Treatment Response Definitions Used in the Base-Case Model

Markov State	Definition	Calculation from Clinical Trials
Unimproved MG on	All patients are in this state in the	All patients start in this state in the
(initial) treatment	first cycle. For subsequent cycles,	first cycle. Transition out of this
	patients transition to either	state depends on the proportion of
	"Improved MG on treatment" or	patients with a less than or greater
	"Unimproved MG off treatment,"	than a three-point improvement in
	depending on whether a three-	QMG from baseline at four and
	point or greater improvement in	eight weeks (at four weeks only for
	QMG score was achieved.	efgartigimod).
Improved MG on (initial)	A three-point or greater	Proportion of patients with a three-
treatment	improvement in QMG while on	point or greater improvement in
	initial treatment.	QMG from baseline at four and
		eight weeks (at four weeks only for
		efgartigimod).
Unimproved MG, off-	A less than three-point	Proportion of patients with a less
treatment	improvement in QMG from	than three-point improvement in
	baseline, with initial treatment	QMG from baseline at eight weeks
	discontinued.	(at four weeks for efgartigimod).

QMG: quantitative myasthenia gravis score

4.2. Key Model Assumptions and Inputs

In order to estimate the cost effectiveness of eculizumab and efgartigimod, several assumptions were needed. These assumptions were based on clinical expert opinion, a review of the available evidence, and/or the investigators' experience with developing similar models. The key model assumptions and rationale for each assumption are listed in Table 4.2. Additional model assumptions are described in <u>Supplement Section E2</u>.

Assumption	Rationale
Base-case efgartigimod efficacy	Efgartigimod is not yet approved by the FDA. Therefore, the
assigned using the four-week ADAPT	recommended dosing frequency has not yet been determined,
trial estimates (after four weekly	requiring an assumption. The base-case is consistent with
doses of efgartigimod)	treatment efficacy (and management goals) as observed after
	four weekly doses. Given the placeholder price of
	efgartigimod and unknowns about the dosing schedule,
	annualized threshold-based prices may be useful in
	deliberations on efgartigimod's value. Other treatment
	efficacy time points were tested in scenario analyses to
	determine the impact on cost effectiveness.
Patients who do not respond to	Ineffective therapies would typically not be continued in a
treatment will have that treatment	real-world setting. Clinical trials were short term and did not
discontinued.	include sufficient information on treatment discontinuation to
	determine whether discontinuation was due to insufficient
	treatment effect. Furthermore, clinical trials are often
	designed to retain patients with insufficient response and may
	not reflect real-world medication use.
Differences in cost or utility are	There were very limited data available on the differences in
proportional to differences in the	costs and utilities for patients with differing health statuses.
QMG, regardless of the baseline	This assumption allows differential costs and utility be applied
QMG score. The relationships	to the "Unimproved MG" and "Improved MG" Markov states.
between cost or utility and QMG are	
linear.	
There are no differences in mortality	A thorough review of the literature did not identify differences
among living model states.	in mortality among patients with differing health status, as
	measured by MG-ADL or QMG. The impact of treatment on
	mortality was not evaluated in clinical trials.

Table 4.2. Key Model Assumptions

MG-ADL: Myasthenia Gravis Activities of Daily Living score, QMG: Quantitative Myasthenia Gravis score

The key model inputs are shown in Table 4.3. For both base-case analyses, the proportion of patients achieving a minimum three-point improvement in QMG was derived from clinical trials by bootstrapping mean change in QMG at four and eight weeks for eculizumab and four weeks for efgartigimod using the mean, standard deviation, and assuming a normal distribution.^{16,23,30} The bootstrapping method also allowed for changes in QMG score to be estimated for individuals. From

these, the proportion of patients with a minimum three-point improvement and the mean change in QMG for each of the "Improved MG" or "Unimproved MG" Markov states were estimated.

The probabilities of hospitalization and emergency department visits were obtained from a study evaluating patient health status and health care resource use for patients who were labeled as having ever-refractory or non-refractory MG.³¹

The probability of AEs was estimated from clinical trials evaluating eculizumab or efgartigimod in patients with MG.^{16,23} AEs were included in the model only if they occurred at a probability of at least 5% or would be expected to result in a substantial cost to treat, or decrease in utility, and were significantly higher than placebo. As a result, only the cost of meningococcal vaccine was included for all patients receiving eculizumab. There were no AEs included in patients receiving efgartigimod.

Mortality for patients from any Markov state was estimated using age- and gender-adjusted estimates for the general population sourced from the USA Human Mortality Database.³² As evidence suggesting that mortality is different among patients with differing severity of MG is lacking, and treatments have not been evaluated for their impact on mortality, treatments in the model were assumed to not have an impact on mortality.

Health state utilities were derived from a deidentified data source provided by Dr. Barnett.^{*33,34} In the dataset, the QMG and EuroQoL EQ5D-5L states were reported for a cohort of 257 patients with gMG. Utility was determined using the EQ5D-5L health states and the US-based societal value set developed by Pickard et al.³⁵ The association between QMG and EQ5D-5L was estimated using a univariate linear regression model, including 252 patients with complete QMG scores. The model estimated that patients with a QMG score of "0" had a starting utility of 0.97 and that each 1-point increase in QMG score was associated with a 0.03 decrease in utility.

Pricing for eculizumab was derived using FSS prices and is shown in Table 4.3.³⁶ Pricing for efgartigimod was not yet known at the time of this report. However, a public statement from argenx suggested that pricing for efgartigimod would be between the prices of IVIG and eculizumab.³⁷ We, therefore, used an annual placeholder price for efgartigimod that was the midpoint of these two annual prices for the model. Given uncertainty in the recommended dosing frequency, the same placeholder annual efgartigimod price was used regardless of scenarios where efgartigimod efficacy was varied. Thus, our analyses are most accurately framed by linking efficacy targets to annualized prices that are consistent with commonly cited cost-effectiveness thresholds. An added step would be needed to use this research to estimate weekly dosing unit prices that are consistent with commonly. Inking dosing frequency

^{*} Carolina Barnett-Tapia, MD, PhD is an Assistant Professor of Medicine in Neurology at the University of Toronto, and conducts research on patient-centered outcomes in neuromuscular disorders, including myasthenia gravis.

patterns with average effectiveness. Treatment administration costs were included in the model and are presented in <u>Supplement Table E2.4</u>.

Non-drug health care costs were derived from published literature. The cost of patients experiencing MG-related hospitalizations was derived from Omorodion et al.³⁸ The cost for an MG-related emergency visit was not available through a literature search or other public sources. Therefore, the mean cost for an emergency department visit in the US, obtained from the Healthcare Cost and Utilization Project, was used.³⁹

All costs were adjusted for inflation to 2021 US dollars as per ICER's Reference Case. Additional key model inputs, supporting the sensitivity and scenario analyses, are presented in <u>Supplement Section</u> <u>E2</u>.

Parameter	Input	Source
Proportion of patients achieving 3 point or more reduction in QMG with eculizumab plus CT at 4 weeks (i.e., transition probability from unimproved to improved state)	0.53	Bootstrapped value derived from Howard 2017 ¹⁶
Proportion of patients achieving 3 point or more reduction in QMG with eculizumab plus CT at 8 weeks (i.e., transition probability from unimproved to improved state)	0.58	Bootstrapped value derived from Howard 2017 ¹⁶
Proportion of patients achieving 3 point or more reduction in QMG with CT (eculizumab comparator) at 4 weeks (i.e., transition probability from unimproved to improved state)	0.37	Bootstrapped value derived from Howard 2017 ¹⁶
Proportion of patients achieving 3 point or more reduction in QMG with efgartigimod plus CT at 4 weeks (i.e., transition probability from unimproved to improved state)	0.73	Bootstrapped value derived from Howard 2021 ²³
Proportion of patients achieving 3 point or more reduction in QMG with CT (efgartigimod comparator) at 4 weeks (i.e., transition probability from unimproved to improved state)	0.38	Bootstrapped value derived from Howard 2021 ²³
Hospitalizations per cycle among those with unimproved MG	0.04	Harris 2020 ³¹
Hospitalizations per cycle among those with improved MG	0.02	Harris 2020 ³¹
Emergency visits per cycle among those with unimproved MG	0.04	Harris 2020 ³¹
Emergency visits per cycle among those with improved MG	0.03	Harris 2020 ³¹
Utility at baseline	0.47	Barnett 2021 ^{33,34}
Increase in utility for each 1 point reduction in QMG score	0.03	Barnett 2021 ^{33,34}
Mean utility change in responders to eculizumab plus CT at week 4	0.68	Calculated from QMG and association between QMG and utility
Mean utility change in non-responders to eculizumab plus CT at week 4	0.44	Calculated from QMG and association between QMG and utility
Mean utility change in responders to eculizumab plus CT at week 8 and beyond	0.67	Calculated from QMG and association between QMG and utility

Table 4.3. Key Model Inputs

Mean utility change in non-responders to eculizumab plus CT at week 8 and beyond	0.42	Calculated from QMG and association between QMG and utility
Mean utility change in responders to CT (eculizumab comparator)	0.69	Calculated from QMG and association between QMG and utility
Mean utility change in non-responders to CT (eculizumab comparator)	0.45	Calculated from QMG and association between QMG and utility
Mean utility change in responders to efgartigimod plus CT	0.74	Calculated from QMG and association between QMG and utility
Mean utility change in non-responders to efgartigimod plus CT	0.46	Calculated from QMG and association between QMG and utility
Mean utility change in responders to CT (efgartigimod comparator)	0.68	Calculated from QMG and association between QMG and utility
Mean utility change in non-responders to CT (efgartigimod comparator)	0.41	Calculated from QMG and association between QMG and utility
Eculizumab cost for first cycle (induction)	\$72,376	Federal Supply Schedule 2021 ³⁶
Eculizumab cost per cycle for subsequent cycles	\$48,251	Federal Supply Schedule 2021 ³⁶
Cost of vaccination for meningococcal infection (all patients receiving eculizumab)	\$107	Federal Supply Schedule 2021 ³⁶
Efgartigimod cost per cycle (placeholder price)*	\$32,099	The Motley Fool 2020, assumption ³⁷
Cost per hospitalization	\$109,609	Omorodion 2017 ³⁸
Cost per emergency visit	\$563	Healthcare Cost and Utilization Proiect 2021 ³⁹

CT: conventional therapy, MG: myasthenia gravis, QMG: quantitative myasthenia gravis score *Placeholder price: midpoint between annual cost of eculizumab and IVIG

4.3. Results

Base-Case Results

The total discounted lifetime costs, QALYs, and time in an improved state over the two-year time horizon are shown for eculizumab and its comparator and for efgartigimod and its comparator in Tables 4.4 and 4.5, respectively. Note that administration costs associated with eculizumab and efgartigimod are included in total cost (but not drug cost). The mean undiscounted QMG score was 12.41 for eculizumab versus 14.52 for its CT comparator and 9.85 for efgartigimod versus 14.52 for its CT comparator. Undiscounted base-case results are presented in <u>Supplement Section E3</u>. As previously noted, all base-case results take the health care system perspective.
Table 4.4. Results for the Base-Case for Eculizumab plus Conventional Therapy Compared toConventional Therapy Alone, in Patients with Refractory anti-AChR Antibody Positive gMG

Treatment	Drug Cost	Total Cost	QALYs	Life Years	evLYs	Time in Improved State (years)
Eculizumab plus CT	\$760,700	\$855 <i>,</i> 400	1.13	1.93	1.13	1.13
CT alone	\$0	\$95,500	0.98	1.93	0.98	0.71

CT: conventional therapy, evLYG: equal value of life years, QALY: quality-adjusted life year

 Table 4.5. Results for the Base-Case for Efgartigimod plus Conventional Therapy Compared to

 Conventional Therapy Alone, in All Patients

Treatment	Drug Cost	Total Cost	QALYs	Life Years	evLYs	Time in Improved State (years)
Efgartigimod plus CT*	\$595,100	\$692,700	1.27	1.93	1.27	1.41
CT alone	\$0	\$94 <i>,</i> 800	0.98	1.93	0.98	0.74

CT: conventional therapy, evLY: equal value of life years, QALY: quality-adjusted life year *Efgartigimod evaluated using a placeholder price

Incremental cost per QALY over the two-year time horizon are shown in Table 4.6 for eculizumab plus conventional therapy versus conventional therapy alone and for efgartigimod plus conventional therapy versus conventional therapy alone.

Table 4.6. Incremental Cost-Effectiveness Ratios for the Base Case
--

Treatment	Comparator	Cost per QALY Gained (same as Cost per evLYG)	Cost per Life Year Gained*	Cost per Year in Improved State
Eculizumab plus CT	CT alone	\$5,210,000	n/a	\$1,831,000
Efgartigimod plus CT**	CT alone	\$2,076,000	n/a	\$891,500

CT: conventional therapy, evLYG: equal value of life years gained, QALY: quality-adjusted life year

*There were no differences in survival. Cost per life-year gained could not be calculated whereas cost per evLYG is equal to the cost per QALY gained;

**Efgartigimod evaluated using a placeholder price

Sensitivity Analyses

The model was sensitive to several inputs, including the QMG improvement values assigned to improved and unimproved MG and the proportion of patients achieving at least a three-point reduction in the QMG for efgartigimod or its comparator, or for eculizumab and its comparator. Despite the large impact of changing these inputs on the results, the incremental cost-effectiveness ratio did not go below \$3.8 million per QALY gained for eculizumab and \$1.7 million per QALY

gained for efgartigimod, when using the placeholder price for efgartigimod. One-way sensitivity analysis results are shown in Figures 4.2 and 4.3.

The probabilistic sensitivity analysis shows the overall variability in the models comparing efgartigimod or its comparator and eculizumab and its comparator. Results of the sensitivity analyses showed that neither therapy was considered preferred compared with conventional therapy in any of the Monte Carlo runs using willingness-to-pay thresholds of up to \$200,000 per QALY gained (Table 4.7). The full cost-effectiveness acceptability curves are shown in the <u>Supplement Section E4</u>.

Figure 4.2. One-Way Sensitivity Tornado Diagram Varying Model Inputs for Eculizumab plus Conventional Therapy vs. Conventional Therapy

Parameter	Low input Value	High Input Value	3000	000	4000000	5000000	6000000	7000000	8000000	9000	0000
Proportion of patients achieving 3 point or more QMG reduction week 4, eculizumab	0.25	0.48								1	
Proportion of patients achieving 3 point or more QMG reduction week 8, eculizumab	0.40	0.76									
Mean QMG change, unimproved MG, week 4	0.61	2.20									
Mean QMG change, improved MG, week 8	-8.03	-6.47									
Slope of the linear regression between QMG and EQ-5D	-0.036	-0.026									
Mean QMG change, unimproved MG, week 8	-0.16	1.17									
Mean QMG change, improved MG, week 4	-7.20	-5.86									
Hospitalization probability per cycle, unimproved MG	0.01	0.07									
Proportion of patients achieving 3 point or more QMG reduction, at week 4,	0.40	0.65									
Hospitalization probability per cycle, improved MG	0.01	0.04				1					
Mean change in QMG of improved MG at week 4	-7.70	-6.20				1					
Cost per hospitalization	\$74,500	\$151,400				1		Lo	w Input Va	alue	
Mean Change in QMG of unimproved MG at week 4	0.07	1.46				1		■ Hi	gh Input V	alue	
Emergency Care visit rate in unimproved MG per month	0.01	0.08				T					
Emergency Care visit rate in improved MG per month	0.01	0.04				I.					
Cost per ED visit	\$280	\$2,250				1					

CT: conventional therapy, MG: myasthenia gravis, QMG: quantitative myasthenia gravis score

Figure 4.3. One-Way Sensitivity Tornado Diagram Varying Model Inputs for Efgartigimod plus Conventional Therapy vs. Conventional Therapy

Parameter	Low input I Value	High Input Value	1600000	1800000	2000000	2200000	2400000	2600000
Proportion of patients achieving 3 point or								
more reduction in QMG at week 4	0.28	0.49						
Slope of the linear regression between QMG								
and EQ-5D	-0.036	-0.026						
Mean Change in QMG of improved MG at							_	
week 4	-9.69	-8.19						
Mean Change in QMG of unimproved MG at								
week 4	1.05	2.64						
Proportion of patients achieving 3 point or								
more reduction in QMG at week 4	0.63	0.82						
Hospitalization rate in unimproved MG per								
month	0.01	0.07						
Mean Change in QMG of improved MG at								
week 4	-7.61	-6.27						
Mean Change in QMG of unimproved MG at								
week 4	-0.38	1.00						
Hospitalization rate in improved MG per								
month	0.01	0.04						
Cost per hospitalization								
	\$74,500	\$151,400						
Emergency Care visit rate in unimproved MG							Hig	h Input Value
per month	0.01	0.08			1			
Emergency Care visit rate in improved MG per								_
month	0.01	0.04					Lov	v Input Value
Cost per ED visit								
	\$280	\$2,252						

CT: conventional therapy, MG: myasthenia gravis, QMG: quantitative myasthenia gravis score

Table 4.7. Probabilistic Sensitivity Analysis Cost per QALY Gained Results: Eculizumab plusConventional Therapy vs. Conventional Therapy and Efgartigimod plus Conventional Therapy vs.Conventional Therapy

	Cost Effective at \$50,000 per QALY	Cost Effective at \$100,000 per QALY	Cost Effective at \$150,000 per QALY	Cost Effective at \$200,000 per QALY
Eculizumab plus CT	0%	0%	0%	0%
Efgartigimod plus CT*	0%	0%	0%	0%

CT = Conventional therapy, QALY: quality-adjusted life year *Efgartigimod evaluated using a placeholder price

Scenario Analyses

The incremental cost-effectiveness ratios for each of the scenario analyses by treatment and comparator are shown in Table 4.8. Due to an absence of evidence, a modified societal perspective was not conducted. The evidence review found insufficient evidence comparing efgartigimod and eculizumab (Scenario 2) and we did not compute an incremental cost-effectiveness ratio for this comparison. Treatment with eculizumab was expected to be more costly, when using the placeholder price for efgartigimod, and had point estimates consistent with being less effective

than efgartigimod at four weeks in the network meta-analysis. Full results of all scenario analyses are presented in <u>Supplement Section E3</u>.

Treatment	Comparator	Cost per QALY Gained
Efgartigimod plus CT in refractory anti- AChR antibody positive gMG (Scenario 1)	CT alone	\$1,976,000*
Efgartigimod plus CT in refractory anti- AChR antibody positive gMG (Scenario 2)	Eculizumab plus CT	Not computed
Efgartigimod plus CT in all patients with anti-AChR antibody positive gMG (Scenario 3)	CT alone	\$1,893,000
IVIG plus CT (Scenario 4)	CT alone	\$1,504,000
Rituximab plus CT (Scenario 5)	CT alone	\$358,500
Efgartigimod plus CT, efficacy based on 4 and 8 week ADAPT assessments (Scenario 6)	CT alone	\$2,442,000*
Eculizumab or efgartigimod, followed by IVIG or rituximab (Scenario 7)	No comparator	Analyses were exploratory; incremental analysis not conducted
Efgartigimod plus CT, using argenx- provided utilities (Scenario 8)	CT alone	\$2,436,000

Table 4.8. Incremental Cost-Effectiveness Ratios for the Scenario Analys
--

CT: conventional therapy, IVIG: intravenous immunoglobulin, QALY: quality-adjusted life year

*Efgartigimod evaluated using a placeholder price (same annualized placeholder price assumed with 8-week ADAPT assessment as in base case that used efficacy at 4 weeks)

Threshold Analyses

The annualized prices required to achieve thresholds of \$50,000 to \$200,000 per QALY gained are shown in Table 4.9. These annualized prices do not include administration costs.

 Table 4.9. QALY-Based Threshold Analysis Results

	Annual Net Price (FSS)	Annual Price to Achieve \$50,000 per QALY	Annual Price to Achieve \$100,000 per QALY	Annual Price to Achieve \$150,000 per QALY	Annual Price to Achieve \$200,000 per QALY
Eculizumab	\$653,100	\$6,900	\$13,200	\$19,400	\$25,700
Efgartigimod	\$418,400*	\$8,200	\$18,300	\$28,400	\$38,600

QALY: quality-adjusted life year, FSS: Federal Supply Schedule FSS

*Efgartigimod evaluated using a placeholder price

Model Validation

Model validation steps are described in the Supplement, Section E7.

Uncertainties and Controversies

Eculizumab has only been evaluated in a single Phase III RCT of 125 patients with "refractory" generalized anti-AChR antibody positive MG.¹⁶ Efgartigimod has been evaluated in a single Phase III RCT of 167 patients with gMG.²³ Similarly, the results of small clinical trials of IVIG and rituximab as chronic treatments have only recently become available and are still unpublished. The small study sample sizes resulted in greater uncertainty in the true effectiveness of treatments evaluated and prevented subgroup analysis of patients with specific antibodies. Furthermore, studies primarily reported change from baseline QMG and MG-ADL as the primary outcome. Since Markov models require estimates of the proportion of patients benefitting from a treatment at specific times and the impact of that treatment in those patients, we had to bootstrap the needed model inputs. The bootstrapped results may not precisely replicate the study's results due to assumptions needed to conduct the bootstrapping, such as the assumption that the change in QMG from baseline was normally distributed.

Differences in the timing of assessments in clinical trials also limited the ability to compare treatments to each other. For example, eculizumab and efgartigimod outcomes were evaluated at 4 weeks, while IVIG and rituximab were evaluated at 24 and 52 weeks, respectively. Therefore, it was necessary to make assumptions about when the onset of each treatment occurred and when the peak effect was reached, using evidence from other studies.

The longer-term effects of treatments on clinical outcomes, including reductions in concurrent therapies such as oral corticosteroids and immunosuppressive treatments, have not been well elucidated. Both IVIG and placebo resulted in a 52-54% reduction in the dose of steroids at week 39 in one randomized clinical trial (NCT02473952).⁴⁰ With a mean follow up of 972 days, the REGAIN open-label extension study resulted in steroid use reductions in 45/94 (47.9%) patients and increases in 10/94 (10.6%) patients, with a mean prednisone dose reduction of 16.4% in the entire cohort.⁴¹ In one case series of 15 patients on eculizumab, a mean prednisone dose reduction of 23.33 mg/day was achieved at one year.⁴² However, given the high prednisone dose reductions observed in placebo-treated patients in the IVIG clinical trial NCT02473952, the impact of eculizumab on steroid dose reductions is difficult to quantify given the current evidence. Therefore, a potential steroid-sparing effect of these agents was not assumed in the model.

Another uncertainty encountered was that there were no published studies evaluating associations between MG-ADL or QMG and utility. However, we were able to identify unpublished data that could be used to estimate this association.

There were very limited studies evaluating the association between QMG or MG-ADL and the costs of MG treatment. We identified a single study that assessed differences in hospitalizations and emergency care visits in patients who were classified as ever-refractory or non-refractory. While we were able to identify the cost of hospitalization, we were not able to identify a study quantifying the cost of an emergency care visit in patients with gMG. Additionally, we were unable to identify studies quantifying the impact of treatment on productivity, caregiver burden, or other societal costs or benefits. It is likely that there are additional differences in the direct and indirect cost of care for MG patients with differing health status that might be impacted by effective treatment.

Finally, there remains uncertainty surrounding the dosing frequency of efgartigimod. We focused on summarizing annualized prices needed to achieve commonly cited cost-effectiveness thresholds. Changes in dosing frequency were explored in scenario threshold analyses (<u>Supplement Table E5.1</u>).

4.4 Summary and Comment

The cost effectiveness of eculizumab, at its current price, is well beyond typical thresholds. A substantial discount would be needed to meet commonly used cost-effectiveness thresholds. The cost effectiveness of IVIG and rituximab were also well above commonly used cost-effectiveness thresholds, although rituximab was substantially closer to cost-effectiveness thresholds versus eculizumab or IVIG. The cost-effectiveness of efgartigimod will depend on its price.

Sensitivity analyses identified that the uncertainty in utility and treatment effectiveness estimates had a large impact on estimated incremental cost effectiveness. However, at the current (for eculizumab) and placeholder (for efgartigimod) prices, the treatments remained well above common cost-effectiveness thresholds across a range of analyses.

5. Contextual Considerations and Potential Other Benefits

Our reviews seek to provide information on potential other benefits offered by the intervention to the individual patient, caregivers, the delivery system, other patients, or the public that was not available in the evidence base nor could be adequately estimated within the cost-effectiveness model. These elements are listed in the table below, with related information gathered from patients and other stakeholders. Following the public deliberation on this Report, the appraisal committee will vote on the degree to which each of these factors should affect overall judgments of long-term value for money of the interventions in this review.

Contextual Consideration	Relevant Information
Acuity of need for treatment of individual	MG is a serious illness with potentially large
patients based on the severity of the condition	effects on quality of life, and 60% to 80% of
being treated	patients with gMG do not achieve treatment goals
	with conventional therapy.
Magnitude of the lifetime impact on individual	MG is a lifelong disease with periodic
patients of the condition being treated	exacerbations that impacts vision, mobility,
	speech, swallowing, and breathing.
Other (as relevant)	Patients with gMG are particularly vulnerable
	during the COVID-19 pandemic as they are
	typically on immunosuppressive medications
	(poor vaccine response, higher risk for severe
	disease) and because infection is a known trigger
	for MG exacerbations.

Table 5.1. Contextual Considerations

Potential Other Benefit or Disadvantage	Relevant Information
Patients' ability to achieve major life goals	MG affects particularly women in their early
related to education, work, or family life	working lives leading to reduced working hours,
	slow career progression, and early retirement. It
	also impacts women during childbearing years and
	may lead to delayed childbearing due, in part, to
	the toxicities of the treatments.
Caregivers' quality of life and/or ability to	Caregivers may be needed to help with travel,
achieve major life goals related to education,	feeding, and communication.
work, or family life	
Patients' ability to manage and sustain	Not applicable
treatment given the complexity of regimen	
Society's goal of reducing health inequities	MG tends to present at younger ages in women
	and later ages in men. It also presents
	significantly earlier for Black Americans, and they
	may have a more severe disease course.
Other (as relevant)	Not applicable

New England CEPAC Votes

At the public meeting, the New England CEPAC deliberated and voted on the relevance of specific potential other benefits and contextual considerations on judgments of value for the interventions under review. The results of the voting are shown below. Further details on the intent of these votes to help provide a comprehensive view on long-term value for money are provided in the <u>ICER</u> <u>Value Assessment Framework</u>.

When making judgments of overall long-term value for money, what is the relative priority that should be given to <u>any</u> effective treatment for gMG, on the basis of the following contextual considerations:

Contextual Consideration	Very Low Priority	Low priority	Average priority	High priority	Very high priority
Acuity of need for treatment of individual patients based on the severity of the condition being treated	0	2	2	7	0
Magnitude of the lifetime impact on individual patients of the condition being treated	0	0	1	7	3

The majority of the CEPAC voted that an effective treatment for gMG should be given high priority on the bases of acuity of need for treatment and magnitude of lifetime impact when making judgments of overall long-term value for money. The patient experts at the public meeting emphasized that even patients who are stable on treatment can still have a myasthenic crisis, and that patients are often diagnosed at a young age and are therefore affected throughout their lives.

What are the relative effects of eculizumab versus conventional therapy on the following outcomes that inform judgment of the overall long-term value for money of eculizumab?

Potential Other Benefit or Disadvantage	Major Negative Effect	Minor Negative Effect	No Difference	Minor Positive Effect	Major Positive Effect
Patients' ability to achieve major life goals related to education, work, or family life	0	0	0	8	3
Caregivers' quality of life and/or ability to achieve major life goals related to education, work, or family life	0	0	1	8	2
Society's goal of reducing health inequities	3	0	7	1	0

The New England CEPAC voted that eculizumab has a positive effect on patients' and caregivers' quality of life and their ability to achieve major life goals. In addition to the impact of MG on patients' lives, the patient representatives discussed how MG can have a great impact on the lives of caregivers, who may be required to take patients to their hospital visits or take on additional responsibilities to care for the patient.

The majority of the CEPAC voted that eculizumab has no impact on society's goal of reducing health inequities. In making their judgment, some CEPAC members considered the cost of eculizumab, which they thought would have the potential to increase health inequities because patients who are uninsured or underinsured may not be able to access it. In the other direction, CEPAC members discussed how women, and particularly Black women, are more likely to be diagnosed with MG, so eculizumab could also have a positive impact on reducing health inequities.

What are the relative effects of efgartigimod versus conventional therapy on the following outcomes that inform judgment of the overall long-term value for money of efgartigimod?

Potential Other Benefit or Disadvantage	Major Negative Effect	Minor Negative Effect	No Difference	Minor Positive Effect	Major Positive Effect
Patients' ability to achieve major life goals related to education, work, or family life	0	0	1	10	0
Caregivers' quality of life and/or ability to achieve major life goals related to education, work, or family life	0	0	2	9	0
Society's goal of reducing health inequities	3	0	7	1	0

For similar reasons as discussed above for eculizumab, the majority of the New England CEPAC voted that efgartigimod would have a minor positive impact on the ability of patients and caregivers to achieve major life goals and would have no impact on society's goal of reducing health inequities.

6. Health Benefit Price Benchmarks

Health Benefit Price Benchmarks (HBPBs) for the annual cost of treatment with the interventions are presented in Table 6.1 below. The HBPB for a drug is defined as the drug price range that would achieve incremental cost-effectiveness ratios between \$100,000 and \$150,000 per QALY gained or per evLYG.

Note that administration costs are included as a part of the cost-effectiveness analysis total costs. For the base case, efgartigimod weekly dosing yielded \$12,000 in annual administration costs. Given the modeled health gains associated with the efgartigimod base case and assuming a \$150,000 per QALY threshold, the annualized costs that could be attributed to efgartigimod and its administration amounted to no more than \$40,400. After accounting for the administration costs, this leaves an annualized efgartigimod HBPB of no more than \$28,400. See <u>Supplement Table E5.1</u> for threshold-based findings by dosing schedule scenarios.

	Annual FSS	Annual Price at \$100,000 Threshold	Annual Price at \$150,000 Threshold	Discount from FSS to Reach Threshold Prices
Eculizumab				
QALYs Gained	\$653,100	\$13,200	\$19,400	97.0-98.0%
evLYG*	\$653,100	\$13,200	\$19,400	97.0-98.0%
Efgartigimod**				
QALYs Gained	NA	\$18,300	\$28,400	NA
evLYG*	NA	\$18,300	\$28,400	NA

Table 6.1. Annual Health Benefit Price Benchmarks for Eculizumab and Efgartigimod

evLYG: equal value life year gained; QALY: quality-adjusted life year; FSS: Federal Supply Schedule

*There were no differences in survival. Cost per evLYG is equal to the cost per QALY gained.

**Efgartigimod evaluated using an annual placeholder price of \$418,400

New England CEPAC Votes

Table 6.2. New England CEPAC Votes on Long-Term Value for Money at Current or Assumed Prices

Question	Low	Intermediate	High
Patient Population: Adults with gMG, defined by MGFA clinical classes of	ll to IV j	for whom conver	itional
immunosuppressive therapies have not been effective or have not been to	lerated	and who are an	ti-
AChR antibody positive.			
Given the available evidence on comparative effectiveness and			
incremental cost-effectiveness, and considering other benefits,			
disadvantages, and contextual considerations, what is the long-term	10	1	0
value for money of treatment at current pricing with eculizumab added			
to conventional therapy versus conventional therapy alone?			
Patient Population: Adults with gMG, defined by MGFA clinical classes of	II to IV j	for whom conver	itional
immunosuppressive therapies have not been effective or have not been to	lerated		
Given the available evidence on comparative effectiveness and			
incremental cost-effectiveness, and considering other benefits,			
disadvantages, and contextual considerations, what is the long-term	11	0	0
value for money of treatment at assumed pricing with efgartigimod			
added to conventional therapy versus conventional therapy alone?			

Given the evidence surrounding comparative effectiveness and incremental cost-effectiveness, and considering potential other benefits, disadvantages, and contextual considerations, the majority of the New England CEPAC voted that eculizumab presents low long-term value for money at current pricing, and all New England CEPAC members voted that efgartigimod presents low long-term value for money at assumed pricing. The calculated incremental cost-effectiveness ratios for both drugs are well above commonly cited thresholds for cost effectiveness, though the cost effectiveness of efgartigimod will depend on its price.

7. Potential Budget Impact

7.1. Overview of Key Assumptions

ICER used results from the cost-effectiveness model to estimate the potential total budgetary impact of efgartigimod in the treatment of patients with MG and MGFA clinical classification II-IV disease. We used an estimate of net price (FSS-derived price for eculizumab and IVIG, from which a placeholder price for efgartigimod was calculated), and the three threshold prices (at \$50,000, \$100,000, and \$150,000 per QALY) in our estimates of efgartigimod's potential budget impact. Consistent with the cost-effectiveness analysis, efgartigimod was assigned a placeholder price equal to the average between IVIG and eculizumab annual net prices derived from FSS. The placeholder price will be updated in future versions of the report should actual pricing information become available.

The aim of the potential budgetary impact analysis is to document the percentage of patients who could be treated at select prices without crossing a potential budget impact threshold that is aligned with overall growth in the US economy. For 2021-2022, the five-year annualized potential budget impact <u>threshold</u> that should trigger policy actions to manage access and affordability is calculated to be approximately \$734 million per year for new drugs.

ICER's methods for estimating potential budget impact are described in detail in the report <u>Supplement Section F</u>. For this analysis, we calculated the budget impact of efgartigimod added to conventional therapy (i.e., thymectomy when appropriate, acetylcholinesterase inhibitor, corticosteroids and/or non-steroidal immunosuppressive therapy) given its displacement of eculizumab (assumed 2.27% market share by patient volume) and conventional therapy (97.73% market share by patient volume) and by assigning an additional 9,374 new individuals to efgartigimod treatment per year for five years (46,870 individuals in total over five years).

7.2. Results

Report <u>Supplement Section F</u> displays the average annual per patient budget impact findings across the four unit prices (placeholder price, and the prices that achieve three different cost-effectiveness thresholds) for efgartigimod. Further, Report <u>Supplement Section F</u> details the cumulative perpatient budget impact estimates for efgartigimod.

Figures 7.1 illustrates the potential budget impact of efgartigimod treatment for the eligible population based on the four respective unit prices (placeholder price, and the prices that achieve three different cost-effectiveness thresholds) as a function of the percent of the eligible population that can be treated without crossing the potential budget impact threshold.

In accordance with Figure 7.1, the percentage of the eligible population that can be treated with efgartigimod without passing the updated potential budget impact threshold is 8.8% at placeholder price (\$418,000* per year). In contrast, 100% of the eligible population could be treated at health benefit price benchmarks aligned with each of the incremental cost-effectiveness ratios of \$150,000/QALY (\$28,400 per year), \$100,000/QALY (\$18,300 per year), and \$50,000/QALY (\$8,200 per year).

* This is an unvalidated placeholder price that is assumed to be the midpoint between calculated IVIG price and calculated eculizumab price; this methodology is partially sourced from argenx Q2 and Q3 earnings calls.^{37,43} Interpret findings for this placeholder plotted point with caution.





8. Policy Recommendations

Following its deliberation on the evidence, the New England CEPAC engaged in a moderated discussion with a policy roundtable about how best to apply the evidence on the use of eculizumab and efgartigimod. The policy roundtable members included two patient advocates, two clinical experts, two payers, and one representative from a drug maker. The discussion reflected multiple perspectives and opinions, and therefore, none of the statements below should be taken as a consensus view held by all participants.

All Stakeholders

All stakeholders have a responsibility and an important role to play in ensuring that effective new treatment options for patients with generalized myasthenia gravis are introduced in a way that will help reduce health inequities.

Safe and effective treatment for gMG remains a significant unmet health care need. Efforts are needed to ensure that new therapies for myasthenia gravis such as eculizumab and efgartigimod, improve the health of patients and families and do not aggravate existing health inequities. Clinical experts and patients highlighted that the high cost of new therapies may worsen disparities in accessing care. This may be due to lack of health insurance that limits access to specialists and the new therapies that they prescribe, or high deductible payments even for those with insurance may result in steep out of pocket costs. The cost of care is not the only factor that may contribute to health inequities. Patient representatives at the meeting noted that Black and African American women are diagnosed at earlier ages and carry a particularly high lifetime burden of disease, but this population is particularly vulnerable to access challenges both to neuromuscular specialist care and to expensive new therapies.

To address these concerns:

Manufacturers should take the following actions:

- Set the price for new treatments for gMG in alignment with added benefits for patients.
- Take steps necessary to include a more diverse patient population in clinical trials, including an adequate number of patients with diverse ages, genders, and ethnic and racial backgrounds.

Payers should take the following actions:

• Ensure that benefit designs developed in conjunction with employers and other plan sponsors do not create requirements for out-of-pocket spending that create major barriers

to appropriate access for vulnerable patients when the price is in alignment with the clinical benefits for patients

Clinical specialty societies should take the following actions:

- Develop and disseminate educational materials and create measurable goals to demonstrate that clinicians are aware of the challenges of diagnosing gMG with particular attention given to providers caring for diverse patient populations
- Share learned protocols for medical treatments which have been successful, and unsuccessful, for treatment of diverse patient populations

Payers

Payers should use the FDA label as the guide to coverage policy and engage clinical experts and diverse patient representatives in considering how to address coverage issues for which there is limited or no evidence at the current time.

Given the significant uncertainty that remains about the new therapies for gMG, it is reasonable for payers to use prior authorization as a component of coverage. Prior authorization criteria should be based on the FDA label, clinical trial eligibility criteria, specialty society guidelines, and input from clinical experts and patient groups. The process for authorization should be clear and efficient for providers and patients. General Fair Access Design Criteria set out in ICER's previous work are shown below, with perspectives on specific elements of coverage criteria for new therapies for gMG provided in the section on drug-specific considerations.

Cost Sharing

- Patient cost sharing should be based on the net price to the plan sponsor, not the unnegotiated list price.
- If all drugs in a drug class are priced so that they represent a fair value, it remains reasonable for payers to use preferential formulary placement with tiered cost sharing to help achieve lower overall costs.

Coverage Criteria: General

 Payers should offer alternatives to prior authorization protocols such as programs that give feedback on prescribing patterns to clinicians or exempt them from prior authorization requirements ("gold carding") if they demonstrate high fidelity to evidence-based prescribing.

- Payers should document at least once annually that clinical eligibility criteria are based on high quality, up-to-date evidence, with input from clinicians with experience in the same or similar clinical specialty.
- Clinical eligibility criteria should be developed with explicit mechanisms that require payer staff to document using an open and transparent process that is readily accessible to the public that they have:
 - a. Considered limitations of evidence due to systemic under-representation of minority populations; and
 - b. Sought input from clinical experts on whether there are distinctive benefits and harms of treatment that may arise for biological, cultural, or social reasons across different communities; and
 - c. Confirmed that clinical eligibility criteria have not gone beyond reasonable use of clinical trial inclusion/exclusion criteria to interpret or narrow the FDA label language in a way that disadvantages patients with underlying disabilities unrelated to the condition being treated.
- If an initial request for coverage is denied, access to a peer-to-peer call should be rapid. Management of gMG is urgent. In many clinicians' experience, access to peer-to-peer calls is onerous and prolonged. Peer to peer calls facilitate the communication of individual patients' unique clinical characteristics and need for therapy. The physician peer should be knowledgeable and experienced in the management of gMG.

Drug-Specific Considerations

The lack of standardization of treatment protocols, substantial uncertainty about which patients will benefit most from which treatments, and high annual prices for newer treatments for gMG will all lead payers to develop prior authorization criteria and to consider other limits on utilization.

None of these limits, however, should undermine the tenets of fair access to which all patients have a fundamental right.⁴⁴ To explore the appropriate application of evidence to coverage policy, and to reflect the views of patient experts and clinicians on specific ways that payers might appropriately use coverage policy to manage resources prudently, we present the following perspectives on specific elements of cost sharing and coverage criteria for eculizumab and efgartigimod.

Coverage Criteria: Eculizumab

- **Diagnosis:** Payers have taken different approaches to diagnostic criteria. Some simply indicate that coverage is provided for gMG. Others specify that coverage is provided for gMG that is not limited to ocular only symptoms and persistent. And some payers include a requirement for one of the following, although clinical experts advised that these criteria are not highly specific for gMG:
 - History of abnormal neuromuscular transmission test demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation
 - History of positive anticholinesterase test, e.g., a Tensilon/edrophonium chloride test (NB: as of 2018 FDA rescinded approval for edrophonium in the US due to high levels of false positive results and the growing use of AChR antibody testing as the new gold standard)
 - Patient has demonstrated improvement in MG signs on oral cholinesterase inhibitors, as assessed by the treating neurologist
- Age: Age criteria in payer coverage policies follow the FDA label, which is for adults ages 18 years and older. However, gMG can present at earlier ages and coverage may be appropriate in select cases. Payers should have efficient mechanisms, such as peer to peer communication with someone knowledgeable in treatments for gMG, to allow clinicians to seek coverage exceptions for patients with serious unmet need who are below the cutoff for the age necessary for coverage.
- **Clinical eligibility**: Coverage criteria across all insurers follow the FDA label and limit coverage to patients with gMG who test positive for antibodies to the AChR. Since the price of eculizumab far exceeds reasonable willingness to pay thresholds, it is reasonable for payers to focus coverage by using clinical trial eligibility criteria that are narrower than the FDA label language. In particular, eculizumab was tested in what is considered "refractory" gMG, and most payers will therefore apply the following trial eligibility criteria as part of insurance criteria:
 - \circ $\,$ MGFA clinical classification class II to IV at initiation of therapy
 - MG-ADL total score \geq 6 at initiation of therapy

and

- Failure of treatment with at least two immunosuppressive agents OR failed treatment with at least one immunosuppressive agent and the patient has required chronic plasma exchange of IVIG.
- **Exclusion criteria**: Patients must receive vaccination for meningococcus prior to starting therapy. Although history of thymoma or other neoplasms of the thymus and a history of thymectomy within 12 months of treatment initiation were exclusion criteria in clinical trials, clinical experts advising ICER suggested that there are circumstances in clinical practice in which the use of eculizumab would be appropriate for such patients.
- Duration of coverage and renewal criteria: There are no data to guide decisions on if or when to taper patients to lower doses of eculizumab. Clinical experts advised that it would be reasonable to require attestation of patient benefit (≥ 2 point improvement in the MG-ADL) for continuation of coverage.
- **Provider restrictions**: Clinical experts agreed that it is reasonable to restrict prescriptions for neurologists with expertise in the treatment of gMG (neuromuscular specialists). Given the limited supply of these specialists, allowing telehealth consultation for approval of prescribing by generalists would help to avoid disparities, particularly in rural areas with few specialists. Specialty clinicians are better suited to identify patients who are most likely to benefit, provide sufficient information for patients to make a well-informed decision, and monitor for response and side effects.

Coverage Criteria: Efgartigimod

- **Diagnosis:** Payers have taken different approaches in the past to diagnostic criteria in coverage policy for eculizumab for gMG. Some payers simply indicate that coverage is provided for gMG. Others specify that coverage is provided for gMG that is not limited to ocular involvement and persistent. And some payers include a requirement for one of the following, although clinical experts advised that these criteria are not highly specific for gMG:
 - History of abnormal neuromuscular transmission test demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation
 - History of positive anticholinesterase test, e.g., a Tensilon/edrophonium chloride test (NB: FDA rescinded approval for edrophonium in the US due to high levels of false positive results and the growing use of AChR antibody testing as the new gold standard)
 - Patient has demonstrated improvement in MG signs on oral cholinesterase inhibitors, as assessed by the treating neurologist

- Age: Age criteria are likely to follow the inclusion criteria for the pivotal trial, which will likely be for adults ages 18 years and older. However, gMG can present at earlier ages and coverage may be appropriate in select cases. Payers should have efficient mechanisms, such as peer to peer communication with someone knowledgeable in treatments for gMG, so that clinicians can seek coverage exceptions for patients with serious unmet need who are near the cutoff for the age necessary for coverage.
- Clinical eligibility: Prior to the FDA regulatory decision on efgartigimod it is not known whether the label will include all patients with gMG or whether it will be limited to patients with positive AChR antibodies. Coverage for treatment of antibody-negative patients would create a difficult choice for payers given that clinical trial data provided by the company on this relatively small subpopulation are "exploratory" and did not provide evidence of clinically significant benefits. Clinical experts advised that given the undoubted efficacy of plasmapheresis in patients with AChR negative gMG, and considering that efgartigimod has a functionally similar mechanism of action, that efgartigimod would be an appropriate therapy for select patients who have failed other therapies. Pending further data, payers deciding to limit coverage to the AChR-positive population should therefore ensure rapid consideration of exceptions through peer-to-peer conversation.

Since the expected price of efgartigimod far exceeds a reasonable cost-effectiveness range, it is not unreasonable for payers to focus coverage by using clinical trial eligibility criteria that are narrower than the FDA label language. Most payers will therefore apply the following trial eligibility criteria as part of insurance criteria:

- MGFA clinical classification class II to IV at initiation of therapy
- MG-ADL total score \ge 5, with \ge 50% of the total score due to non-ocular symptoms at initiation of therapy

and

 Receiving a stable dose ≥ 1 of the following: acetylcholinesterase inhibitors, steroids (at least 3 months of treatment), or at least 6 months of treatment with nonsteroidal immunosuppressive therapy (NSIST).

Of note, the efgartigimod trial eligibility criteria were broader than that of eculizumab, and patients were not required to be "refractory" to IVIG and/or immunosuppressive therapies. This distinction may expand requests for use of efgartigimod over eculizumab and may lead payers to consider step therapy with less expensive agents (see section on step therapy below).

- **Exclusion criteria**: Although clinical trial exclusion criteria include history of thymectomy within 3 months, clinical experts advising ICER suggested that there are circumstances in clinical practice in which the use of efgartigimod would be appropriate for such patients.
- **Dosing criteria**: Some payers may wish to explore negotiating formal payment mechanisms that cap reimbursements to manufacturers. The goal would be to allow clinicians greater flexibility in dosing of efgartigimod to match patient clinical response while providing payers with a mechanism to manage total costs.
- Duration of coverage and renewal criteria: There are no data to guide decisions on if or when to taper patients to lower doses of efgartigimod. Clinical experts advised that it would be reasonable to require attestation of patient benefit (≥ 2-point improvement in the MG-ADL) for continuation of coverage.
- **Provider restrictions**: Clinical experts agreed that it is reasonable to restrict prescriptions for neurologists with expertise in the treatment of gMG (neuromuscular specialists). Given the limited supply of these specialists, allowing telehealth consultation for approval of prescribing by generalists would help to avoid disparities, particularly in rural areas with few specialists. Specialty clinicians are better suited to identify patients who are most likely to benefit, provide sufficient information for patients to make a well-informed decision, and monitor for response and side effects.

Step Therapy

Payers should use step therapy based on clinical trial eligibility and/or authoritative evidencebased clinical specialty guidelines as they become available. Given the limited current evidence base for efgartigimod, payers should not require therapy with efgartigimod prior to coverage of eculizumab. However, as additional clinical evidence accumulates, it may be reasonable to require step therapy based on price.

Given the limited evidence and cost, it is likely that health plans may choose to continue step therapy for eculizumab, limiting coverage to patients who are refractory to standard therapy as defined in the Phase 3 trial. While it is possible to tailor step therapy in a clinically responsible fashion, it is often administered with documentation burdens and inadequate procedures for exceptions that make step therapy a source of great frustration and the cause of poor outcomes for some patients due to the discontinuation of medicine/missed doses.

For efgartigimod, many payers will follow the clinical trial eligibility criteria as the sole basis for step therapy, but some payers may consider instituting step therapy through immunosuppressive agents, as they do for eculizumab, even though efgartigimod was not tested in a specifically refractory population. Clinical experts accustomed to using immunosuppressive treatments and IVIG prior to eculizumab may not find this approach unreasonable, but clinical experts advising ICER noted that some patients cannot safely use chronic corticosteroids, and steroid sparing agents (mycophenolate and azathioprine for instance) take six to 12 months to work. Therefore, payers should consider creating an explicit pathway for early coverage with eculizumab or efgartigimod for patients who have failed IVIG and corticosteroids, or who cannot take the latter, while waiting for an immunosuppressive agent to take effect.

Manufacturers

Manufacturers should set prices that will foster affordability and good access for all patients by aligning prices with the patient-centered therapeutic value of their treatments. In the setting of these new interventions for gMG, there remains substantial uncertainty regarding their longerterm safety and effectiveness. Manufacturer pricing should reflect these considerations in more moderate launch pricing.

The price for eculizumab is extremely high and is distinctive for the amount by which it exceeds the price needed to reach traditional cost-effectiveness thresholds in the US. Eculizumab was first approved for paroxysmal nocturnal hemoglobinuria and hemolytic uremic syndrome, ultra-rare conditions with a cumulative prevalence of less than 4 per million. The population with gMG is 14-20 per 100,000, and if only 15% of this population is considered to have refractory gMG, the population now eligible for treatment with eculizumab is more than seven times as large as when the drug was first approved, yet the price has not come down. There is no excuse for this level of pricing, and it should not be used as a benchmark or standard for future therapies in this clinical area or others.

Pricing is not just a matter of cost. It is a matter of harm to patients and others throughout the health system. Drug prices that are set well beyond the cost-effective range cause not only financial toxicity for patients and families using the treatments, but also contribute to general health care cost growth that pushes families out of the insurance pool, and that causes others to ration their own care in ways that can be harmful. Prices should not be set based on historical pricing for therapies that are more expensive to produce or have been priced beyond their value to patients.

Manufacturers should therefore price novel treatments in accordance with the demonstrated benefits to patients. In settings of substantial uncertainty, initial pricing should err on the side of being more affordable. This would allow more patients access, generating additional data on the real-world effectiveness of novel treatments that could be used in future assessment updates. With accumulation of evidence of substantial patient benefit, manufacturers should be allowed to increase pricing in accordance with benefit.

Clinicians and Clinical Societies

Clinical specialty societies should continue to bear witness to the impact of high prices for novel therapies on patients.

Doctors need to engage with affordability and pricing as it affects their patients. The AAN has been a leader in highlighting these issues for patients that their clinicians care for, through public outreach including a formal position statement on Ethical Perspectives on Costly Drugs and Health Care,⁴⁵ the <u>Neurology Podcast</u>, and <u>statement to the California Technology Assessment Forum</u> on the FDA approval of aducanumab.

Patient Organizations

Patient organizations have a vital role to play by complementing existing clinical research with patient focused surveys collecting data on the impact of gMG on the diversity of patient experiences and the impact on caregivers.

Patient groups continue their efforts to collect data on the impact of gMG on patients and their caregivers. There is a dearth of information on the impacts of gMG on patient and caregiver productivity and importantly on the changes in these measures made by effective therapies. In addition, patient organizations can add important contextual information on the differential impact of gMG on important patient sub-populations such as children, women, and race/ethnicity subgroups. These data could round out the picture on the societal impact of novel therapeutics, which would allow better modeling of both the health care and societal impacts of these therapies.

Researchers/Regulators

Researchers should continue to explore the potential effectiveness of less expensive therapies for patients with gMG.

Many clinicians believe that rituximab can be an effective therapy for patients with gMG, but highquality comparative effectiveness data have not yet been published, although the results of the BEAT MG study may soon appear. Studies evaluating the effectiveness of maintenance IVIG are also needed to guide clinical practice and insurance coverage.

Researchers should collect data on the larger societal impact of novel therapeutics used to treat patients with gMG, not just the immediate impacts on patients.

Patients told us that managing gMG often led to reduced work hours, decreased responsibilities at work, less income and early retirement for themselves and for their caregivers. Studies of treatments for gMG should collect data documenting changes in missed days of school and work, return to work, and changes in caregiver needs and responsibilities.

References

- 1. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. *BMC Neurol.* 2010;10:46.
- 2. Howard Jr J. Myasthenia Gravis Clinical Overview. <u>https://myasthenia.org/Professionals/Clinical-Overview-of-MG</u>. Published 2015. Accessed.
- 3. Hendricks TM, Bhatti MT, Hodge DO, Chen JJ. Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study. *Am J Ophthalmol.* 2019;205:99-105.
- 4. Gilhus NE. Myasthenia Gravis. *N Engl J Med.* 2016;375(26):2570-2581.
- 5. Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. *Neurology*. 2021;96(3):114-122.
- 6. Phillips G. argenx Public Comment Submission. In:2021.
- 7. FDA. SOLIRIS[®] (eculizumab) injection, for intravenous use. In: Administration FaD, ed. Food and Drug Administration2017.
- 8. argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis [press release]. March 2, 2021 2021.
- 9. Vissing J, Jacob S, Fujita KP, et al. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. *Journal of Neurology.* 2020;267:1991-2001.
- 10. Mantegazza R, Wolfe GI, Muppidi S, et al. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. *Neurology*. 2021;96:e610-e618.
- 11. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. *Muscle Nerve.* 2008;37(2):141-149.
- 12. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology*. 2016;87(4):419-425.
- 13. Guptill JT, Sharma BK, Marano A, Soucy A, Krueger A, Sanders DB. Estimated cost of treating myasthenia gravis in an insured U.S. population. *Muscle Nerve.* 2012;45(3):363-366.
- 14. Kaplan M. Eculizumab (Alexion). *Curr Opin Investig Drugs.* 2002;3(7):1017-1023.
- 15. Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. *J Clin Invest*. 2018;128(10):4372-4386.
- 16. Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in antiacetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. *The Lancet Neurology*. 2017;16:976-986.
- 17. Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. *Muscle Nerve.* 2019;60(1):14-24.
- 18. Andersen H, Mantegazza R, Wang JJ, et al. Eculizumab improves fatigue in refractory generalized myasthenia gravis. *Quality of Life Research.* 2019;28:2247-2254.
- 19. Nowak RJ, Muppidi S, Beydoun SR, O'Brien FL, Yountz M, Howard JF. Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study. *Frontiers in Neurology*. 2020;11:1-8.
- 20. Siddiqi Z, Howard J, Jacob S, et al. Relieving the burden of myasthenia gravis: eculizumab reduces exacerbation, hospitalization, and rescue therapy. Canadian Journal of Neurological Sciences; 2019.

- 21. Howard JF, Jr., Karam C, Yountz M, O'Brien FL, Mozaffar T. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses. *Ann Clin Transl Neurol.* 2021.
- 22. Howard JF, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. *Muscle and Nerve.* 2013;48:76-84.
- 23. Howard J, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet Neurology.* 2021.
- 24. Howard JF, Jr., Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. *Neurology.* 2019;92(23):e2661-e2673.
- 25. BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis. U.S. National Library of Medicine; 2021. Accessed May 23, 2021.
- 26. ClinicalTrials.Gov. Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients with Generalized Myasthenia Gravis (NCT02473965). https://clinicaltrials.gov/ct2/show/NCT02473965. Published 2021. Accessed2021.
- 27. ClinicalTrials.Gov. A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis (NCT02473952). https://clinicaltrials.gov/ct2/show/NCT02473952. Published 2021. Accessed2021.
- 28. Argenx. Data on File. 2021.
- 29. Downing NS, Shah ND, Aminawung JA, et al. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. *Jama*. 2017;317(18):1854-1863.
- 30. argenx. Data request from Institute for Clinical and Economic Review to argenx. In: Review IfCaE, ed2021.
- 31. Harris L, Allman PH, Sheffield R, Cutter G. Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States. *J Clin Neuromuscul Dis.* 2020;22(1):11-21.
- 32. Human Mortality Database. 2021. Accessed June 4, 2021.
- 33. Barnett C. EQ-5D-5L, MG-ADL, and QMG scores in 254 patients with generalized myasthenia gravis. In: Institute for Clinical and Economic Review, ed2021.
- 34. Barnett C, Bril V, Bayoumi AM. EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis. *Eur J Neurol.* 2019;26(3):452-459.
- 35. Pickard AS, Law EH, Jiang R, et al. United States Valuation of EQ-5D-5L Health States Using an International Protocol. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.* 2019;22(8):931-941.
- 36. US Department of Veterans Affairs. Office of Procurement AaLO. Pharmaceutical Prices. https://www.va.gov/opal/nac/fss/pharmPrices.asp. Published 2021. Accessed.
- 37. The Motley Fool. argenx SE (ARGX) Q3 2020 Earnings Call Transcript. The Motley Fool,. Published 2020. Accessed June 30, 2021, 2021.
- 38. Omorodion JO, Pines JM, Kaminski HJ. Inpatient cost analysis for treatment of myasthenia gravis. *Muscle Nerve.* 2017;56(6):1114-1118.
- 39. Agency for Healthcare Research and Quality. Costs of Emergency Department Visits in the United States, 2017. <u>https://www.hcup-us.ahrq.gov/reports/statbriefs/sb268-ED-Costs-</u>2017.jsp. Published 2021. Accessed June 30, 2021, 2021.
- 40. Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis. U.S. National Library of Medicine; 2021. Accessed May 23, 2021.

- 41. Nowak RJ, Muppidi S, Beydoun SR, O'Brien FL, Yountz M, Howard JF, Jr. Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study. *Front Neurol.* 2020;11:556104.
- 42. Katyal N, Narula N, Govindarajan R. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. *J Neuromuscul Dis.* 2021;8(2):287-294.
- 43. The Motley Fool. argenx SE (ARGX) Q2 2020 Earnings Call Transcript. 2020.
- 44. Pearson SD, Towse A, Lowe M, Segel CS, Henshall C. Cornerstones of 'fair' drug coverage: appropriate cost sharing and utilization management policies for pharmaceuticals. *J Comp Eff Res.* 2021;10(7):537-547.
- 45. Tsou AY, Graf WD, Russell JA, et al. Ethical Perspectives on Costly Drugs and Health Care. AAN *Position Statement*. 2021;97(14):685-692.
- 46. Jaretzki A, 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. *Neurology.* 2000;55(1):16-23.
- 47. Hehir MK, Silvestri NJ. Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and Epidemiology. *Neurol Clin.* 2018;36(2):253-260.
- 48. Li M, Ge F, Guo R, et al. Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis. *Therapeutic Advances in Neurological Disorders*. 2019;12:1-8.
- 49. Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. *Ther Adv Neurol Disord.* 2019;12:1756286419832242.
- 50. Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. *Ther Adv Neurol Disord.* 2018;11:1756285617749134.
- 51. Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? *Expert Rev Clin Immunol.* 2012;8(5):427-438.
- 52. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. *Lancet Neurol.* 2015;14(10):1023-1036.
- 53. CADTH. *CADTH Common Drug Review Clinical Review Report eculizumab (Soliris)*. Canadian Agency for Drugs and Technologies in Health;2020.
- 54. Muppidi S, Wolfe GI, Conaway M, Burns TM, Mg C, Mg-Qol15 Study G. MG-ADL: still a relevant outcome measure. *Muscle Nerve.* 2011;44(5):727-731.
- 55. Thomsen JLS, Andersen H. Outcome measures in clinical trials of patients with myasthenia gravis. *Frontiers in Neurology.* 2020;11.
- 56. Barnett C, Herbelin L, Dimachkie MM, Barohn RJ. Measuring clinical treatment response in myasthenia gravis. *Neurologic clinics.* 2018;36(2):339-353.
- 57. Burns TM, Conaway MR, Cutter GR, Sanders DB. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. *Muscle Nerve.* 2008;38(2):957-963.
- 58. Burns TM, Sadjadi R, Utsugisawa K, et al. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. *Muscle & nerve.* 2016;54(6):1015-1022.
- 59. Burns TM, Conaway M, Sanders DB. The MG Composite: A valid and reliable outcome measure for myasthenia gravis. *Neurology*. 2010;74(18):1434-1440.
- 60. Drugs CAf, Health Ti. CADTH Canadian Drug Expert Committee Recommendation. In:2021.
- 61. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. *Ann Intern Med.* 1997;126(5):376-380.

- 62. Higgins J, Thomas, J, Chandler, J, Cumpston, M, Li, T, Page, MJ, Welch, VA. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). <u>https://training.cochrane.org/handbook/current</u>. Published 2020. Accessed.
- 63. Higgins JP. Cochrane Collaboration Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. 2008.
- 64. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLOS Medicine*. 2009;6(7):e1000097.
- 65. Agency for Healthcare Research and Quality. U.S. Preventive Services Task Force Procedure Manual. Published 2008. Accessed.
- 66. Ollendorf DA, Pearson SD. An integrated evidence rating to frame comparative effectiveness assessments for decision makers. *Medical care.* 2010;48(6 Suppl):S145-152.
- 67. Ollendorf D, Pearson, SD. ICER Evidence Rating Matrix: A User's Guide. <u>https://icer-review.org/methodology/icers-methods/icer-evidence-ratingmatrix/</u> Published 2020. Updated January 31, 2020. Accessed2021.
- 68. ClinicalTrials.Gov. BeatMG: Phase II Trial of Rituximab in Myasthenia Gravis (NCT02110706). https://clinicaltrials.gov/ct2/show/NCT02110706. . Published 2021. Accessed2021.
- 69. Brauner S, Eriksson-Dufva A, Hietala MA, Frisell T, Press R, Piehl F. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis. JAMA Neurol. 2020;77(8):974-981.
- 70. Griffin R, Chen J, Hanna K, Mondou E. A Randomized Placebo-Controlled Clinical Trial Evaluating Efficacy and Safety of IGIV-C in Symptomatic Subjects with Generalized Myasthenia Gravis. Neurology; 2017.
- 71. Griffin R, Chen J, Hanna K, Mondou E. A Randomized Placebo-Controlled Clinical Trial Evaluation Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients with Generalized Myasthenia Gravis. Muscle & Nerve; 2017.
- 72. Howard J, Bril V, Mantegazza R, et al. Additional Analyses of the Phase 2 Efgartigimod Study in Myasthenia Gravis (4484). Neurology; 2020.
- 73. Banerjee S, Adcock L. Rituximab for the Treatment of Myasthenia Gravis: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. *CADTH Rapid Response Reports.* 2018:1-41.
- 74. Young C, McGill SC. CADTH Health Technology Review Rituximab for the Treatment of Myasthenia Gravis: A 2021 Update. *Canadian Journal of Health Technologies.* 2021.
- 75. Wang L, Huan X, Xi JY, et al. Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: A network meta-analysis. *CNS Neurosci Ther.* 2019;25(5):647-658.
- 76. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. *Jama*. 2016;316(10):1093-1103.
- 77. HCPCS.codes. HCPCS Codes: 2021 Healthcare Common Procedure Coding System. https://hcpcs.codes/. Published 2021. Accessed June 30, 2021, 2021.
- 78. Centers for Medicare and Medicaid Services (CMS). CMS.gov physician fee schedule lookup. https://www.cms.gov/medicare/physician-fee-schedule/search. Accessed.
- 79. Wang L, Zhang Y, He M. Clinical predictors for the prognosis of myasthenia gravis. *BMC Neurol.* 2017;17(1):77.
- 80. Apinyawasisuk S, Chongpison Y, Thitisaksakul C, Jariyakosol S. Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients With Positive Acetylcholine Receptor Antibody. *Am J Ophthalmol.* 2020;209:10-17.
- 81. Sakai W, Matsui N, Ishida M, et al. Late-onset myasthenia gravis is predisposed to become generalized in the elderly. *eNeurologicalSci.* 2016;2:17-20.

- 82. Chicaiza-Becerra LA, Garcia-Molina M, Gamboa O, Castaneda-Orjuela C. The cost-effectiveness of open or thoracoscopic thymectomy compared to medical treatment in managing Myasthenia gravis without thymomas. *Rev Salud Publica (Bogota).* 2012;14(2):260-270.
- 83. Heatwole C, Johnson N, Holloway R, Noyes K. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. *J Clin Neuromuscul Dis.* 2011;13(2):85-94.
- 84. Canadian Agency for Drugs and Technologies in Health. CADTH Drug Reimbursement Review: Pharmacoeconomic Report on Eculizumab (Soliris). <u>https://www.ncbi.nlm.nih.gov/books/NBK567510/</u>. Published 2021. Accessed June 30, 2021, 2021.
- 85. McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. *Neuroepidemiology*. 2010;34(3):171-183.
- 86. Suzuki Y, Utsugisawa K, Suzuki S, et al. Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study. *BMJ Open.* 2011;1(2):e000313.
- 87. Helfand C. Alexion's Soliris wins \$1B myasthenia gravis approval with broader-than-expected label. 2017.
- 88. Research ZM. Global Myasthenia Gravis Market Is Expected To Reach Around USD 2091 Million By 2025. 2019.
- 89. Liu A. Alexion crowns myasthenia gravis as its best Soliris launch ever. 2018.
- 90. Institute for Clinical and Economic Review. 2020-2023 Value Assessment Framework. <u>https://icer-review.org/wp-content/uploads/2019/05/ICER_2020_2023_VAF_013120-4.pdf</u>. Published 2020. Accessed.
- 91. Pearson SD. The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.* 2018;21(3):258-265.

Supplemental Materials

A. Background: Supplemental Information

A1. Definitions

The Myasthenia Gravis Foundation of America (MGFA) Clinical Classification⁴⁶: The MGFA clinical classification was established to create a uniform approach to classifying MG disease severity for research and the clinical management of patients. Patients are classified by the following disease severity and localization of symptoms:

Class I: Any ocular muscle weakness; may have weakness of eye closure. All other muscle strength is normal.

Class II: Mild weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.

- IIa. Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.
- IIb. Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or both.

Class III: Moderate weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.

- Illa. Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.
- IIIb. Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or both.

Class IV: Severe weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.

- IVa. Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.
- IVb. Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or both.

Class V: Defined as intubation, with or without mechanical ventilation, except when employed during routine postoperative management. The use of a feeding tube without intubation places the patient in class IVb.

Generalized Myasthenia Gravis: Generalized MG is a subset of the disease that progresses beyond initial manifestation of weakness in the ocular muscles (ocular MG) to other regions of the body.⁴⁷ Patients with ocular MG typically develop generalized MG within the first two years of disease; early diagnosis and immunosuppressive treatment may delay progression of ocular MG to gMG.^{11,48}

Refractory Myasthenia Gravis⁴⁹: The 2016 MGFA international consensus guidance for MG defines refractory MG as no improvement or worsening of symptoms after an adequate trial of corticosteroids and two or more immunosuppressive agents.¹² There are other definitions for refractory MG which include a patient's inability to reduce immunosuppressive therapy, the need for ongoing rescue therapy (intravenous immunoglobulin G (IVIg) or plasma exchange [PE]), or the inability to tolerate the side-effects of conventional treatment.⁵⁰ Approximately 10 to 20 percent of patients with MG are considered refractory; they have a greater burden of illness and experience greater rates of myasthenic crises and hospitalization.⁴⁹

Minimal Manifestations (MM)⁴⁶: A subset of the MGFA Post-intervention Status used to assess the clinical state of a patient after treatment for MG. A patient with MM has no symptoms of functional limitations from MG but has some weakness on examination of some muscles.

Anti-Acetylcholine Receptor Antibody (AChR-Ab+)-associated Myasthenia Gravis: Patients with anti-AChR-Ab+-associated MG have antibodies against the AChR in the neuromuscular junction.⁴ This disrupts neuromuscular transmission in the body and leads to muscle weakness and fatigability.⁴ Anti-AChR antibodies are highly specific for MG disease and are used as part of the diagnostic evaluation.⁵¹ Approximately 80% of generalized MG patients have AChR autoantibodies.⁵² They are less common (50-75%) in ocular MG patients.⁵¹ Other less common autoantibodies associated with MG include those against the muscle-specific kinase (MuSK) and low density lipoprotein receptor-related protein 4 (LRP4) receptors.⁵²

Myasthenia Gravis–specific Activities of Daily Living scale (MG-ADL): The MG-ADL scale is an eightitem instrument consisting of patient reported outcomes assessing two ocular, three bulbar, one respiratory, and two limb symptoms of MG.⁵³ A two-point improvement in the MG-ADL scale is considered clinically significant.⁵⁴ The MG-ADL is an increasingly common primary endpoint used in MG-related clinicals trials.⁵⁵

Quantitative Myasthenia Gravis Score (QMG): The QMG is a 13-item instrument that assesses disease severity via physical examination of ocular (two items), facial (one item), bulbar (two items), gross motor (six items), axial (one item), and respiratory (one item) function.⁵³ In patients with mild to moderate MG (baseline QMGS≤16), a 2-point change in score is considered clinically significant; for patients with severe MG (baseline QMG ≥16) a three-point change in score is considered clinically significant.⁵⁶ The QMG evaluation requires use of two medical instruments (spirometers, dynamometer) and can take up to 25 minutes to perform, making it better suited for research settings versus routine clinical assessments.⁵⁶

Myasthenia Gravis Quality of Life 15 scale (MG-QOL15): The MG-QOL15 scale is a patient-reported 15-item instrument derived from the 60-item Myasthenia Gravis Quality of Life Scale. It assesses MG health-related quality of life via the following criteria: mobility (nine items), symptoms (three items), and emotional well-being (three items).⁵⁷ The MG-QOL15 scale provides added context to

the MG patient experience beyond symptom expression and is sensitive to the fluctuations in MG symptoms that may not be apparent on physical examination.

Myasthenia Gravis Quality of Life scale revised (MG-QOL15r): The revised MG-QOL15 scale is a patient-reported 15-item instrument that assesses MG health-related quality of life via the following criteria: mobility (nine items), symptoms (three items), and emotional well-being (three items).⁵⁶ The MG-QOL15r scale provides added context to the MG patient experience beyond symptom expression and is sensitive to the fluctuations in MG symptoms that may not be apparent on physical examination.⁵⁸

Myasthenia Gravis Composite (MGC) scale: The MGC scale is a 10-item instrument that derives patient reported outcomes from MG-ADL and physical examination outcomes from the QMGS and Manual Muscle Test.⁵⁶ It include three ocular, three bulbar, one respiratory, one neck, and two limb items and is weighted to highlight the increased relevance of bulbar and respiratory symptoms.⁵⁶ A three-point improvement in total MGC score represents both a clinical improvement and a meaningful improvement to patients.⁵⁹

	MG-ADL	QMG	MGC	MG-QOL15r
Items	8	13	10	15
Score Range	0-24	0-39	0-50	0-30
Interpretation	Higher indicates	Higher indicates	Higher indicates	Higher indicates
	worse	worse	worse	a worse quality
	functioning and	functioning and	functioning and	of life and more
	greater disability	greater disability	greater disability	severe disease
Minimum	2 points	2 points for mild-	3 points	Depends on
Clinically		moderate		disease severity
Important				
Difference		3 points for		
		severe disease		
Key Features	100% patient	Objective, no	4/10 patient	100% patient
	reported	patient reported	reported; 6/10	reported
		symptoms:	clinician	
		spirometer,	assessed.	
		dynamometer		

Table A1 Cumanaan	v of the Key	· Outcome	Magguras	: N/I.	vacthania	Crowie
Table AL. Summar	v oi the key	VOULCOME	weasures	יועו ווו	vastnema	Gravis

MG-ADL: Myasthenia gravis activities of daily living, MGC: Myasthenia gravis composite scale, MG-QOL15r: Revised 15-item myasthenia gravis quality of life, QMG: Quantitative Myasthenia Gravis score

A2. Potential Cost-Saving Measures in Myasthenia Gravis

ICER includes in its reports information on wasteful or lower-value services in the same clinical area that could be reduced or eliminated to create headroom in health care budgets for higher-value innovative services (for more information, see <u>https://icer.org/wp-</u>

content/uploads/2021/03/ICER_2020_2023_VAF_013120-4-2.pdf). These services are not ones that would be directly affected by eculizumab or efgartigimod (e.g., use of azathioprine), as these services will be captured in the economic model. Rather, we are seeking services used in the current management of myasthenia gravis beyond the potential offsets that arise from a new intervention. ICER encourages all stakeholders to suggest services (including treatments and mechanisms of care) that could be reduced, eliminated, or made more efficient. We have reviewed the Choosing Wisely recommendations of the Neurology professional societies and none of them seem to apply.

We have received two recommendations from clinical experts:

- Stop serial monitoring of anti-AChR antibodies as there is little correlation with disease severity or response to therapy
- Decrease lab monitoring for side effects of immunosuppressive agents
- Reduce frequent swallow evals or pulmonary tests in the absence of clinical symptoms

B. Patient Perspectives: Supplemental Information

B1. Methods

During ICER's scoping, open input, and public comment periods, we received public comment submissions from eight stakeholders (two patient advocacy groups, two manufacturers, two clinicians, and one individual) and participated in conversations with 19 key informants (five patients, two patient advocacy groups, eight clinical experts, one industry analyst, one manufacturer, and two researchers). The feedback received from written input and scoping conversations helped us to discuss the impact on patients described in Chapter 2 of the Report.

C. Clinical Guidelines

Myasthenia Gravis Foundation of America (MGFA)

A task force of 15 international experts was appointed by the MGFA to develop consensus guidance on the diagnosis and treatment of MG.¹² An updated version of the consensus guidance was published in 2021 to incorporate new evidence, including new recommendations for the use of eculizumab and rituximab.⁵

Goals of Therapy:

MMs or remission with no more than grade 1 AEs from medications used for treatment.

Symptomatic and Immunosuppressive Treatment of MG

- 1. Pyridostigmine should be first-line treatment with dose adjustments based on symptom severity. If treatment goals are not met, then corticosteroids or immunosuppressive therapies should be considered.
- Nonsteroidal immunosuppressive agents should be used with corticosteroids in patients to minimize the steroid dose to reduce steroid side effects. If corticosteroids are contraindicated or refused, a nonsteroidal immunosuppressive agent should be used alone.
- 3. Nonsteroidal immunosuppressive agents for MG include azathioprine, cyclosporine, MMF, methotrexate, and tacrolimus.
 - a. There is limited evidence on the comparative effectiveness of the above agents.
 - b. Azathioprine is supported by expert consensus and randomized control trial (RCT) evidence as a first-line agent.
 - c. Cyclosporine has potential SAEs and drug interactions.
 - d. MMF and tacrolimus are widely used despite limited RCT evidence.
- 4. Patients with refractory MG may be treated with:
 - a. Immunosuppressive agents as described above.
 - b. Maintenance IVIG and chronic plasma exchange (PLEX)
 - c. Cyclophosphamide
 - d. Eculizumab for severe, refractory, AChR-Ab+ generalized MG.
 - i. Until more evidence is available, eculizumab should be used after failure with other immunotherapies.
 - e. Rituximab is an option for refractory AChR-Ab+ MG after failure/medication intolerance of other immunosuppressive agents, but evidence of efficacy is uncertain.

- 5. After Treatment Goal is met:
 - a. Corticosteroid dose should be gradually tapered. Long-term low dose usage of corticosteroids may be necessary to maintain treatment goal.
 - b. Once the treatment goal is achieved and maintained for 6 months to 2 years, nonsteroidal immunosuppressive agents should be tapered to the minimal effective amount. Rapid tapering is associated with the risk of relapse, particularly for symptomatic patients. Therefore, dose adjustments should be limited to every 3-6 months.

Canadian Agency for Drugs and Technologies in Health^{53,60}

In their 2020 review of eculizumab, the CADTH review team convened a panel of seven clinical experts from across Canada to characterize unmet therapeutic needs, identify gaps in the evidence, identify potential implementation challenges, gain further insight into the clinical management of patients living with the condition, and explore the drug's potential place in therapy.

Goals of Therapy:

- 1. Achieving remission, defined as the reduction of MG disease to mild or moderate symptoms, and maintaining this state for as long as possible.
- 2. Improvement in QoL and daily activities.

In refractory MG patients, goals of treatment also include:

- 1. Reducing the quantity and severity of relapses
- 2. Shortening the duration of hospital visits
- 3. Using the lowest possible medication dosage
- 4. Minimizing adverse effects, particularly from corticosteroids and other long term-use therapies

Role of Eculizumab in Refractory MG Patients

Eculizumab was deemed useful for patients with refractory MG as an adjunct to other therapies or as a last line of treatment.

The CADTH Drug Expert Committee recommended that eculizumab be reimbursed for treatment of refractory generalized MG after satisfaction of a 6-point initiation criteria⁶⁰:
- 1. The patient has refractory gMG defined as not achieving symptom control after:
 - an adequate trial of two or more immunosuppressive therapies (ISTs), either in combination or as monotherapy in the previous 12 months, OR
 - an adequate trial of at least one IST and chronic plasmapheresis or PLEX or IVIG at least four times (every three months) in the previous 12 months.
- 2. The patient has all of the following:
 - AChR-Ab+ status
 - Baseline MG-ADL score of ≥ 6
 - MGFA class II to IV disease
- 3. The patient does not have a thymoma or is within 12 months of thymectomy.
- 4. Eculizumab should not be initiated during a gMG exacerbation or crisis.
- 5. MG-ADL and QMG score must be measured and provided by the physician at baseline.
- 6. Maximum duration of initial authorization is six months

D. Comparative Clinical Effectiveness: Supplemental Information

D1. Detailed Methods

Population, Intervention, Comparators, Outcomes, Timing, and Settings Framework (PICOTS)

Population

The population of focus for the review was adults with gMG, defined by Myasthenia Gravis Foundation of America (MGFA) clinical classes of II to IV for whom conventional immunosuppressive therapies have not been effective or have not been tolerated.⁴⁶

We evaluated the evidence on the following subpopulations:

- Patients with anti-AChR antibodies
- Patients with anti- AChR antibodies who are refractory to treatment

Due to lack of data, we were unable to evaluate patients with MuSK, LRP4, or triple seronegative autoantibodies.

Interventions

The two interventions of interest for this review are:

- Eculizumab (Soliris[®], Alexion Pharmaceuticals, Inc.)
- Efgartigimod (argenx)

Both were added to conventional therapy (thymectomy when appropriate, acetylcholinesterase inhibitor, corticosteroids and/or non-steroidal immunosuppressive therapy) for maintenance therapy in patients with generalized MG.

Comparators

We compared the agents to each other and to the following:

- Conventional therapy
- Maintenance IVIG therapy (GAMUNEX[®]-C, Grifols Therapeutics LLC)
- Rituximab (Rituxan[®], Roche Holding AG, Biogen, Inc.)

Outcomes

The outcomes of interest are described in the list below.

- Patient-Important Outcomes
 - o Remission
 - Minimal symptom expression
 - Measures of treatment response (e.g., Myasthenia Gravis Activities of Daily Living [MG-ADL], Quantitative MG score [QMG], etc.)
 - Quality of life (MG Quality of Life, 15, revised [MG-QoL15]; EQ-5D; etc.)
 - Fatigue (Neurology Quality of Life, etc.)
 - o MG-related hospitalizations
 - Myasthenic crisis
 - Return to work
 - Lost or delayed childbearing
 - Mental health (anxiety, depression)
 - Corticosteroid side effects (weight gain, acne, diabetes, osteoporosis, cataracts, glaucoma, infections, psychological, etc.)
 - Immunosuppressive side effects and burden (hepatitis, cytopenia, teratogenicity, infusion reactions, etc.)
 - Corticosteroid dose ≤ 5mg prednisone equivalents
 - AEs including:
 - Treatment-related AEs
 - SAEs
 - AEs leading to drug discontinuation
 - Infections including meningococcal disease
 - Malignancies
 - Death
- Other Outcomes
 - MGFA Post-Intervention Status (MGFA-PIS)
 - Complete Stable Remission (CSR)
 - Pharmacologic Remission (PR)
 - Minimal Manifestations (MM)

Timing

Evidence on intervention effectiveness and harms was derived from studies of at least four weeks duration.

Setting

All relevant settings were considered, with a focus on patients treated in outpatient settings in the United States.

		Checklist Items
TITLE		
Title	1	Identify the report as a systematic review, meta-analysis, or both.
ABSTRACT		
Structured	2	Provide a structured summary including, as applicable: background;
summary		objectives; data sources; study eligibility criteria, participants, and
		interventions; study appraisal and synthesis methods; results;
		limitations; conclusions and implications of key findings; systematic
		review registration number.
INTRODUCTION		T
Rationale	3	Describe the rationale for the review in the context of what is already
		known.
Objectives	4	Provide an explicit statement of questions being addressed with
		reference to participants, interventions, comparisons, outcomes, and
		study design (PICOS).
METHODS		
Protocol and	5	Indicate if a review protocol exists, if and where it can be accessed
registration		(e.g., Web address), and, if available, provide registration information
		including registration number.
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and
		report characteristics (e.g., years considered, language, publication
	_	status) used as criteria for eligibility, giving rationale.
Information	/	Describe all information sources (e.g., databases with dates of
sources		coverage, contact with study authors to identify additional studies) in
Casuah	0	the search and date last searched.
Search	8	Present full electronic search strategy for at least one database,
	0	State the presses for selecting studies (i.e. screening, sligibility
Study selection	9	state the process for selecting studies (i.e., screening, englobility,
		analysis)
Data collection	10	dialysis).
	10	independently, in duplicate) and any processes for obtaining and
process		confirming data from investigators
Data items	11	List and define all variables for which data were sought (e.g. PICOS
		funding sources) and any assumptions and simplifications made
Risk of bias in	12	Describe methods used for assessing risk of bias of individual studies
individual studies		(including specification of whether this was done at the study or

		outcome level), and how this information is to be used in any data
		synthesis.
Summary	13	State the principal summary measures (e.g., risk ratio, difference in
measures		means).
Synthesis of	14	Describe the methods of handling data and combining results of
results		studies, if done, including measures of consistency (e.g., I2) for each
		meta-analysis.
Risk of bias	15	Specify any assessment of risk of bias that may affect the cumulative
across studies		evidence (e.g., publication bias, selective reporting within studies).
Additional	16	Describe methods of additional analyses (e.g., sensitivity or subgroup
analyses		analyses, meta-regression), if done, indicating which were pre-
		specified.
RESULTS	I	T
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included
		in the review, with reasons for exclusions at each stage, ideally with a
		flow diagram.
Study	18	For each study, present characteristics for which data were extracted
characteristics		(e.g., study size, PICOS, follow-up period) and provide the citations.
Risk of bias	19	Present data on risk of bias of each study and, if available, any outcome
within studies		level assessment (see item 12).
Results of	20	For all outcomes considered (benefits or harms), present, for each
individual studies		study: (a) simple summary data for each intervention group (b) effect
		estimates and confidence intervals, ideally with a forest plot.
Synthesis of	21	Present results of each meta-analysis done, including confidence
results		intervals and measures of consistency.
Risk of bias	22	Present results of any assessment of risk of bias across studies (see
across studies		Item 15).
Additional	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup
analysis		analyses, meta-regression [see Item 16]).
DISCUSSION		
Summary of	24	Summarize the main findings including the strength of evidence for
evidence		each main outcome; consider their relevance to key groups (e.g.,
		healthcare providers, users, and policymakers).
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at
		review-level (e.g., incomplete retrieval of identified research, reporting
		bias).
Conclusions	26	Provide a general interpretation of the results in the context of other
		evidence, and implications for future research.
FUNDING		
Funding	27	Describe sources of funding for the systematic review and other
-		support (e.g., supply of data); role of funders for the systematic review.
From: Moher D Libera	tiΔ Τα	atzlatt L Altman DG The PRISMA Group (2009) Preferred Reporting Items for

From: Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

Data Sources and Searches

Procedures for the systematic literature review assessing the evidence on new therapies for MG followed established best research methods.⁶¹⁻⁶³ We conducted the review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.⁶⁴ The PRISMA guidelines include a checklist of 27 items, which are described further in Table D1.

We searched MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials for relevant studies. Each search was limited to English-language studies of human subjects and excluded articles indexed as guidelines, letters, editorials, narrative reviews, case reports, or news items. We included abstracts from conference proceedings identified from the systematic literature search. All search strategies were generated utilizing the Population, Intervention, Comparator, and Study Design elements described above. The proposed search strategies included a combination of indexing terms (MeSH terms in MEDLINE and EMTREE terms in EMBASE), as well as free-text terms.

To supplement the database searches, we performed manual checks of the reference lists of included trials and systematic reviews and invited key stakeholders to share references germane to the scope of this project. We also supplemented our review of published studies with data from conference proceedings, regulatory documents, information submitted by manufacturers, and other grey literature when the evidence met ICER standards (for more information, see https://icer.org/policy-on-inclusion-of-grey-literature-in-evidence-reviews/). Where feasible and deemed necessary, we also accepted data submitted by manufacturers "in-confidence," in accordance with ICER's published guidelines on acceptance and use of such data.

 Table D2. Search Strategy of Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily, Ovid MEDLINE and Versions(R) 1946 to Present

1	myasthenia gravis/
2	(myasthenia gravis OR generalized myasthenia gravis OR myasthen\$).ti,ab
3	1 OR 2
4	(efgartigimod OR ARGX-113 OR ARGX113 OR ARGX 113).ti,ab
5	(eculizumab OR soliris OR 5G11 OR h5G11).ti,ab
6	Immunoglobulin, intravenous/ OR ('intravenous immunoglobulin' OR 'IV immunoglobulin' OR 'IVIG').ti,ab
7	(rituximab OR Rituxan OR IDECC2B8 OR IDEC C2B8).ti,ab OR (mabthera OR Rituxan hycela OR RG105 OR RG 105).ti,ab
8	4 OR 5 OR 6 OR 7
9	3 AND 8
10	(addresses or autobiography or bibliography or biography or clinical trial, phase I or comment or congresses or consensus development conference or duplicate publication or editorial or guideline or in vitro or interview or lecture or legal cases or legislation or letter or news or newspaper article or patient education handout or periodical index or personal narratives or portraits or practice guideline or review or video audio media).pt.
11	9 NOT 10
12	(animals not (humans and animals)).sh.
13	11 NOT 12
14	Limit 13 to English language

Table D3. Search Strategy of EMBASE SEARCH

#1	(myasthonia gravis) / ava
#1	
#2	('myasthenia gravis' OR 'generalized myasthenia gravis' OR 'myasthen\$'):ti,ab
#3	#1 OR #2
#4	('efgartigimod' OR 'ARGX-133' OR 'ARGX113' OR 'ARGX 113'):ti,ab
#5	('eculizumab' OR 'soliris' OR '5G11' OR 'h5G11'):ti,ab
#6	(intravenous immunoglobulin OR IV immunoglobulin OR IVIG):ti,ab
#7	('rituximab' OR 'Rituxan' OR 'IDECC2B8' OR 'IDEC C2B8'):ti,ab OR ('mabthera' OR 'Rituxan
	hycela' OR 'rituximab and hyaluronidase' OR 'RG105' OR 'RG 105'):ti,ab
#8	#4 OR #5 OR #6 OR #7
#9	#3 AND #8
#10	'human tissue'/de OR 'nonhuman'/de OR 'practice guideline'/de OR 'questionnaire'/de OR
	'chapter'/it OR 'conference review'/it OR 'editorial'/it OR 'letter'/it OR 'note'/it OR
	'review'/it OR 'short survey'/it
#11	#9 NOT #10
#12	('animal'/exp OR 'nonhuman'/exp OR 'animal experiment'/exp) NOT 'human'/exp
#13	#11 NOT #12
#14	#13 AND [English]/lim
#15	##14 AND [medline]/lim
#16	#14 NOT #15





Study Selection

We performed screening at both the abstract and full-text levels. Two investigators independently screened all abstracts identified through electronic searches using DistillerSR (Evidence Partners, Ottawa, Canada) according to the inclusion and exclusion criteria described earlier. We did not exclude any study at abstract-level screening due to insufficient information. We retrieved the citations that were accepted during abstract-level screening for full-text appraisal. Two investigators reviewed full papers and provided justification for the exclusion of each excluded study.

Data Extraction and Quality Assessment

Two reviewers extracted key information from the full set of accepted trials. We used criteria published by the US Preventive Services Task Force (USPSTF) to assess the quality of RCTs and comparative cohort studies, using the categories "good," "fair," or "poor" (see Appendix Table F2)⁶⁵ Guidance for quality ratings using these criteria is presented below, as is a description of any modifications we made to these ratings specific to the purposes of this review .

Good: Meets all criteria: Comparable groups are assembled initially and maintained throughout the study; reliable and valid measurement instruments are used and applied equally to the groups; interventions are spelled out clearly; all important outcomes are considered; and appropriate attention is paid to confounders in analysis. In addition, intention to treat analysis is used for RCTs.

Fair: Studies were graded "fair" if any or all of the following problems occur, without the fatal flaws noted in the "poor" category below: Generally comparable groups are assembled initially but some question remains whether some (although not major) differences occurred with follow-up; measurement instruments are acceptable (although not the best) and generally applied equally; some but not all important outcomes are considered; and some but not all potential confounders are addressed. Intention to treat analysis is done for RCTs.

Poor: Studies were graded "poor" if any of the following fatal flaws exists: Groups assembled initially are not close to being comparable or maintained throughout the study; unreliable or invalid measurement instruments are used or not applied equally among groups (including not masking outcome assessment); and key confounders are given little or no attention. For RCTs, intention to treat analysis is lacking.

Note that case series are not considered under this rating system – because of the lack of comparator, these are generally considered to be of poor quality.

Assessment of Level of Certainty in Evidence

We used the <u>ICER Evidence Rating Matrix</u> to evaluate the level of certainty in the available evidence of a net health benefit among each of the interventions of focus (see Figure 3.1).^{66,67}

Assessment of Bias

We performed an assessment of publication bias for eculizumab, efgartigimod, rituximab, and maintenance IVIG using the clinicaltrials.gov database of trials. We scanned the site to identify studies completed more than two years ago that would have met our inclusion criteria and for which no findings have been published. We found two instances of potential publication bias: the results of the rituximab BeatMG Phase II trial (NCT02110706) and the IVIG Phase II trial (NCT02473952).

Data Synthesis and Statistical Analyses

Data on key outcomes were summarized in evidence tables (see Section D2 below) and synthesized quantitatively and qualitatively in the body of the review. We evaluated the feasibility of conducting a quantitative synthesis by exploring the differences in study populations, study design, analytic methods, and outcome assessment for each outcome of interest. Based on data availability, we created networks to compare change from baseline in MG-ADL and QMG scores at 4 weeks in two trials of eculizumab and efgartigimod. We used a subpopulation from the ADAPT trial that met the eculizumab REGAIN trial inclusion criteria of anti-AChR antibody positive, refractory MGFA Class II-IV generalized MG patients. This data was provided in confidence by the manufacturer. The network-meta-analyses (NMAs) were conducted using a Bayesian framework with fixed effects on the treatment parameters using the IndiRect NMA platform (CRG-EVERSANA, 2020TM). The outcomes were continuous and were analyzed using a generalized linear model and identity link. League tables were presented for the treatment effects (mean difference of each drug versus each other and placebo, along with 95% credible intervals (95% CrI). Due to inconsistent or limited data reporting, other outcomes are either described narratively or presented in tables.

D2. Evidence Tables

Table D2.1. Study Quality Metrics

Study	Comp. Groups	Non- Differential Follow-Up	Patient/Investi gator Blinding (Double-Blind)	Clear Def. of Intervention	Clear Def. of Outcomes	Selective Outcome Reporting	Valid Measure- ments	ITT Analysis	Approach to Missing Data	USPSTF Rating		
	Efgartigimod											
Phase III ADAPT ²³	Yes	Yes	Yes	Yes	Yes	No	Yes	mITT	NR	Good		
Phase II ²⁴	Yes	Yes	Yes	Yes	Yes	No	Yes	mITT	MMRM	Good		
	•			Εсι	ılizumab					•		
REGAIN ¹⁶	Yes	Yes	Yes	Yes	Yes	No	Yes	mITT	LOCF	Good		
REGAIN OLE ¹⁷	No	No	No	Yes	Yes	No	Yes	mITT	LOCF	NA		
Phase II ²²	Yes	Yes	Yes	Yes	Yes	No	Yes	mITT	NR	Good		
				Rit	tuximab							
Phase II: BeatMG ⁶⁸	Yes	Yes	Yes	Yes	Yes	No	Yes	ITT	MI, LOCF	Good		
			·	Maint	enance IVIG							
Phase II NCT 02473952 ²⁷	No	No	Yes	Yes	Yes	No	Yes	mITT	LOCF	Poor		
Phase II NCT024739 65 ²⁶	Yes	Yes	Yes	Yes	Yes	No	Yes	mITT	LOCF	Good		

ITT: intention-to-treat, LOCF: last observation carried forward, MI: Multiple imputation approach, mITT: modified intention-to-treat, MMRM: mixed-model repeated-measures analysis, NA: Not Applicable, not RCT or comparative cohort study, NR: not reported, USPSTF: United States Preventive Services Task Force

Table D2.2. Study Design

Trial Name Ref & NCT #	N	Design	Population	Primary Outcome(s)	Arms & Dosing Regimen	Inclusion / Exclusion Criteria
		·		Efgart	igimod	
Phase III ADAPT Howard 2021 ²³ NCT03669588	167	Phase III, DB, PC, MC RCT	Patients with diagnosis of MG with generalized muscle weakness (AChR+/-)	[Time frame: week 8] Efficacy of efgartigimod as assessment by the percentage of MG- ADL responders in the AChR+ population	1. Efgartigimod (IV) 2. Placebo Dosing: 4 weekly IV infusions (10 mg/kg) in cycle 1. followed by individualized treatment cycles (up to 3 cycles in 26 weeks) with time between cycles determined by duration of clinically meaningful improvement	 Inclusion Adult patients with gMG. All serotypes, regardless of Ab status and including MuSK, LRP4, and AChR-Ab- in addition to AChR-Ab+. MGFA Class II-IV gMG. MG-ADL score ≥5, with ≥50% of the total score due to non-ocular symptoms Receiving a stable dose of ≥1 of the following gMG treatments prior to randomization: acetylcholinesterase inhibitors (no dose change for 2 weeks prior to screening), steroids (at least 3 months of treatment, no dose change for 1 month) or NSIST (at least 6 months of treatment, no dose change for 3 months) Exclusion MGFA class I and V patients Patients with worsening muscle weakness secondary to concurrent infections or medications Patients with known seropositivity or who test positive for an active viral infection at screening with HBV, HCV, or HIV Received rituximab or eculizumab in the 6 months before screening, undergone thymectomy within 3
						months, had IVIG or plasma exchange within 1 month of screening
Phase II	24	Phase II DB,	Patients	[Time Frame: day	1. Efgartigimod (IV)	Inclusion
Howard		PC RCT	with diagnosis of	78]	(10 mg/kg) 2. Placebo	 Patients ≥ 18 years Diagnosis of autoimmune MG with generalized
2019 ²⁴			MG with	Number of patients		muscle weakness meeting clinical criteria for
			generalized	with TEAEs and TE-		diagnosis of MG as defined by MGFA classification
NCT02965573			muscle	SAEs	Patients received	class II, III, IVa and not in need of a respirator
			weakness		ARGX-113 at a dose	 Positive serologic test for anti-AChR antibodies

©Institute for Clinical and Economic Review, 2021 Final Report – Myasthenia Gravis

					of 10 mg/kg in 4 intravenous (IV) infusions, administered 1 week apart, in addition to SoC. Patients received matching placebo in 4 IV infusions, administered 1 week apart, in addition to SoC.	 Total score of ≥5 on MG-ADL at screening and baseline with more than 50% attributed to non-ocular items Required to be on stable dose of MG treatment prior to randomization (e.g. AZA, other NSAIDs, steroids, and/or cholinesterase inhibitors) <i>Exclusion</i> MGFA class I, IVb and V. Active or recent serious infection within 8 weeks prior to screening History of HIV, HBV, and HCV or mycobacterium tuberculosis Clinically significant laboratory abnormalities at screening (e.g. AST and ALT > 2x ULN, clinically significant proteinuria, hemoglobin ≤9 g/L, et.c) Use of rituximab, belimumab, eculizumab or any monoclonal antibody within 6 months prior to first dosing
						• BIVII ≥35 Kg/m2
	105			Eculiz	umab	
Phase III	125	DB, PC, MC	AcHR+	[Time trame: week	1. Eculizumab 900	Inclusion
KEGAIN		KUI	positive	20j Chango in MC ADI	mg iv weekly for 4	 Patients ≥ 18 With IVIG diagnosis AChPL at screening and at least one of the
Howard			with	total score from	induction and 1200	ACHK+ at screening and at least one of the following: history of abnormal nouromyscular
2017 ¹⁶			refractory	baseline	mg IV every 2 weeks during weeks 4-26	transmission test or repetitive nerve stimulation,
NCT01997229			MG		of maintenance	demonstrated improvement in MG signs on oral
					2. Placebo	cholinesterase inhibitors
						• MGFA clinical classification class II to IV at screening
						 MG-ADL total score ≥6 at screening and
						randomization
						• Failed treatment with at least 2 immunosuppressive
						agents or failed treatment with at least one
						nlasma exchange or IVIg
						Exclusion

						 MGFA class I or MG crisis at screening (MGFA class V) History of thymoma or other neoplasms of the thymus History of thymectomy within 12 months prior to screening Use of rituximab within 6 months of screening Use of IVIg within 4 weeks of randomization
REGAIN OLE	117	OL Extension	AcHR+	[Time frame week	Blinded induction	Inclusion
Munnidi		Of REGAIN	positive	208]	phase [4 weeks]	• Patients who completed study ECU-MG-301
		trial	patients	Participants with	I. ECU IN REGAIN:	(REGAIN)
2019			refractory	TEALS	day 1 and week 2	Patients who withdrew from REGAIN as a result of
NCT02301624			generalized		and placebo at	an AE due to study drug
			MG		weeks 1 and 3	 Unresolved meningococcal infection
					2. PBO in REGAIN:	• Hypersensitivity to murine proteins or to one of the
					ECU 900 mg and	excipients of eculizumab
					placebo on day 1	
					and at weeks 1, 2,	
					and 3.	
					OLE	
					1. ECU 1.200 every 2	
					weeks up to week	
					208	
Phase II	14	DB, PC,	Patients	[Time frame: week	1. Eculizumab: 600	Inclusion
		Cross-over,	with	16]	mg IV weekly for 4	 Patients ≥ 18 years
Howard		MC, RCT	refractory	Percentage of	doses followed by	Generalized MG with MGFA clinical classification
201322			generalized	patients with a 3-	900 mg IV every 2	class II, III, IVa
NOTOOTOTACA			MG	point reduction in	weeks for 7 doses	• QMG total score ≥12 with minimum score of 2 in 4
NCT00727194				the QMG total score	2 Dissehar IV	or more tests in the QMG
				from baseline	2. Placebo: IV	 nave railed at least two immunosuppressants after one year of treatment
					then every 2 weeks	• AChR+ at screening and one of the following:
					for 7 doses	history of abnormal neuromuscular transmission test
						or repetitive nerve stimulation, history of positive
						anticholinesterase test, or has demonstrated

						 improvement in MG signs on oral cholinesterase inhibitors <i>Exclusion</i> History of thymoma or other neoplasms of the thymus History of thymectomy within 12 months of screening Current or chronic use of plasmapheresis/plasma exchange IVIG treatment within 8 weeks prior to screening Use of etanercept or rituximab within 2 or 6 months of screening, respectively
						MGFA class I, IVb, V
				Ritux	imab	
Phase II	52	Phase II, DB,	generalized	[Time frame: week	1. Treatment group	Inclusion
BeatMG		PC, RCT	MG, AChR+,	48]	received two cycles	 Subjects 21 to 90 generalized MG, class II to IV at
			class II-IV	Percent of subjects	of rituximab	screening, AChR+
Nowak 2019				that achieve a ≥ 75%	(375mg/m2 iv),	 Subject on stable standard immunosuppressive
[Abstract] 68				reduction in mean	separated by 6	regimen: a. Prednisone only b. Prednisone plus
				daily prednisone	months. Each cycle	another immunosuppressive therapy (IST).
NCT02110706				dose in the 4 weeks	defined as one	Exclusion
				prior to week 52	infusion per week	 No history of thymoma, tumor, infection, or
				and have clinical	for four consecutive	interstitial lung disease on chest CT, MRI, or chest x-
				improvement or no	weeks.	ray.
				significant		 Thymectomy in the previous six months.
				worsening of	2. Placebo group	Subjects who have been medicated with
				symptoms (≤ 2 point	received infusion	immunosuppressive drugs not listed in inclusion #5
				increase in MGC	containing only	within the last 8 weeks (56 days) prior to the baseline
				score) as compared	vehicle components	visit
				to 4-week period	of rituximab	 medicated with an immunosuppressive agent such
				prior to	solution. Infusion	as azathioprine, mycophenolate mofetil,
				randomization and	was done in 2	cyclosporine, tacrolimus or methotrexate, that is
				initiation of	cycles, separated by	withdrawn within 8 weeks (56 days) of the Baseline
				treatment.	6 months. Each	Visit.
					cycle defined as one	 Subjects who have received IVIg or PLEX treatment
					infusion per week	within the last 4 weeks (28 days) prior to the baseline
						visit.

					for four consecutive	 Unstable dose or a stable dose of > 480 mg/day of
					weeks	pyridostigmine in 2 weeks prior to screening visit.
						 Previous treatment with rituximab
						 Subjects that do not record daily prednisone doses
						for at least 28 days before the Baseline Visit, or
						subjects whose prednisone dose varies by >6mg/day
						on average.
						Prednisone dose of more than 100 mg/day (or 200
						mg over a two day period
Brauner	98	Retrospective	Refractory	[Time frame: New-	1. Treatment with	Inclusion
2020 ⁶⁹		cohort study	, and new-	onset MG= 44	Rituximab (most	• patients residing in Stockholm County who received
		,	onset gMG,	months average,	often 500mg every	1 or more dose of rituximab before December 31,
			AChR+	treatment	6 months)	2018.
			-	refractorv= 40mol	2. Conventional	Exclusion
					immuno.	 Presence of anti-MuSK+ antibodies.
						 less than 12months' observation time.
				1. Time to remission		• a maximum (OMG) score of less than 4 during the
				2. Use of rescue		vear preceding treatment start.
				therapies/additional		 less than 2 recorded follow-up visits.
				immuno.		 initiation or follow-up of rituximab treatment
				3. Time spent in		outside of Stockholm County.
				remission		 concurrent neurologic diseases interfering with the
						assessments, and immunosuppressive therapy for
						other indications during the observation period.
	l			Mainten	ance IVIG	
Phase II	62	Phase II, DB,	Generalized	[Time frame: week	1. IGIV-C, initial	Inclusion
		PC, RCT	MG, AChR+,	24]	loading dose of	 AChR+ Confirmed diagnosis of generalized
Griffin 2017		-	class II-Iva	-	2g/kg at baseline	mvasthenia gravis (MG). MGFA Class II. III. or IVa
[Abstract] ⁷⁰				Mean change in	(week 0, visit 1)	inclusive at Screening. QMG >= 10 at Screening.
				QMG score from	followed by 1g/kg	Note: Subjects who only have a history of ocular MG
				baseline. An	maintenance doses	may not enroll.
NCT02473952				average 3-point	every third week	• Receiving standard of care MG treatment at a
				improvement in	through Week 21	stable dose (including cholinesterase inhibitors,
				QMG score	(visit 8)	prednisone, azathioprine, mycophenolate mofetil.
				indicates clinically		cyclosporine, tacrolimus)
				, meaningful	2. Placebo infusion	Exclusion
				improvement.		

		1				
					at same intervals as	 Have received cyclophosphamide or any other
					treatment arm	immunosuppressive agent apart from the ones
						allowed per inclusion criteria within the past 6
						months
						 Any change in MG treatment regimen between
						Screening (Week -3, Visit 0) and Baseline (Week 0,
						Visit 1)
						 Greater than two point change in QMG score,
						increased or decreased, between Screening (Week -
						3, Visit 0) and Baseline (Week 0, Visit 1)
						 Any episode of myasthenic crisis in the one month
						prior to Screening
						 Thymectomy within the preceding 6 months
						 Rituximab, belimumab, eculizumab or any
						monoclonal antibody used for immunomodulation
						within the past 12 months
						 Have received immune globulin (Ig) treatment
						given by intravenous (IV), subcutaneous, or
						intramuscular route within the last 3 months
						 Current known hyper viscosity or hypercoagulable
						state
						Documented diagnosis of thrombotic complications
						to polyclonal intravenous immunoglobulin (IVIG)
						therapy in the past
						PLEX performed within the last 3 months
Phase II	60	Phase II, DB,	Generalized	[Time frame: Week	1. IGIV-C, Run-	Inclusion
0.101 0017		PC, RCI	MG, AChR+,	39]	Phase: 1 loading	• AChR+
Griffin 2017			class II-V		dose of 2 g/kg IGIV-	Confirmed diagnosis of generalized MG historically
[Abstract]/*				Percent of Subjects	C and 2	meeting the clinical criteria for diagnosis of MG
NCT02472065				Achieving a 50% or	maintenance doses	defined by the Myasthenia Gravis Foundation of
NC102473965				Greater Reduction	OF 1 g/kg IGIV-C	America (MGFA) classification of Class II, III, IV, or V
				III CS DOSE	Continentorsia	historically
				(Preanisone or	Corticosteroid	At Screening, subjects may have symptoms
				Equivalent) From	Agintonana Dhaga	controlled by CS or were MGFA Class II-IVa inclusive
				Baseline to week 39	1 g/kg/GIV/C over	(Class IVb and Class V excluded). Subjects who only
					I g/kg IGIV-C every	have a history of ocular MG may not enroll.
					3 weeks for up to 36	• On systemic CS for a minimum period of at least 3

		weeks	months and on a stable CS dose of >=15 mg/day and
			<=60 mg/day (prednisone equivalent) for the month
		2. Placebo	prior to Screening.
			 Had a tapering CS dose that the study investigator
			considered to be appropriate.
			• At least 1 previous completed attempt to taper CS
			in order to minimize CS dose (lowest feasible dose
			based on observed MG signs and symptoms)
			Exclusion
			 Any dose change in concomitant
			immunosuppressant therapy, other than CS, in the
			prior 6 months
			• Any change in CS dose or acetylcholinesterase
			inhibitor (e.g. pyridostigmine) dose in the 1 month
			nrior to Screening
			• A 3-noint change in Quantitative Myasthenia Gravis
			score increased or decreased between the
			Screening/Week -3 (Visit 0) and Baseline (Week 0
			[Visit 1])
			• Any enisode of myasthenic crisis (MC) in the 1
			month prior to Screening, or (at any time in the past)
			MC or hospitalization for MG exacerbation
			associated with a provious CS taper attempt
			• Thymostomy within the presiding 6 months prior
			• Thymectomy within the preceding o months phot
			o Scieening
			• Rituximab, belimumab, ecuizumab or any
			monocional antibody used for immunomodulation
			within the past 12 months prior to Screening
			Have received immune globulin treatment given by
			IV, subcutaneous, or intramuscular route within the
			last 3 months prior to Screening
			Received plasma exchange performed within the
			last 3 months prior to Screening

AChR+/-: acetylcholine receptor positive/negative, AE: adverse events, AZA: azathioprine, CS: corticosteroids, DB: double blind, ECU: eculizumab, gMG: generalized myasthenia gravis, HBV: hepatitis B, HCV: hepatitis C, HIV: human immunodeficiency viruses, IGIV-C: immune globulin intravenous -c, Immuno.: Immunosuppressants, IV: intravenous, IVIG: intravenous immunoglobulin, Kg/m2: kilogram per meter squared, MC: multicenter, MG: myasthenia gravis, MG-ADL: myasthenia gravis- activities of daily living, MGFA: myasthenia gravis foundation of America, Mg/kg: milligram per kilogram, MRI: magnetic resonance

imaging, N: total number, NSAIDs: non-steroidal anti-inflammatory drugs, OL: open label, PBO: placebo, PC: placebo controlled, PLEX: plasma exchange, QMG: quantitative myasthenia gravis , RCT: randomized controlled trial, SoC: standard of care, TEAE: treatment emergent adverse event

Table D2.3. Key Baseline Characteristics I

Study Name /	Develotion			Age at Baselin	Sex, r	n (%)	Sco	ores at Base	line, mean	(SD)	MGFA	Class at scr n (%)	eening,
Trial Identifier	Population	n + Arms	N	e, mean (SD)	Female	Male	MG- ADL	QMG	MGC	MG- QOL15*	Class II	Class III	Class IV
						Efgartigim	od						
		EFGART	65	44.7 (15.0)	46 (70.8)	19 (29.2)	9.0 (2.5)	16.0 (5.1)	18.6 (6.1)	15.7 (6.3)	28 (43.0)	35 (54.0)	2 (3.0)
		РВО	64	49.2 (15.5)	40 (62.5)	24 (37.5)	8.6 (2.1)	15.2 (4.4)	18.1 (5.2)	16.6 (5.5)	25 (39.0)	36 (56.0)	3 (5.0)
	AChR Ab+	EFGART	41	43.6 (14.0)	31 (75.6)	10 (24.4)	9.3 (2.1)	16.0 (5.7)	NR	16.0 (5.8)	17 (41.5)	24 (58.5)	0 (0)
Phase III ADAPT ^{21,28}	Refract.	РВО	45	48.6 (14.6)	28 (62.2)	17 (37.8)	8.9 (1.8)	15.4 (4.7)	NR	17.7 (5.4)	16 (35.6)	26 (57.7)	3 (6.7)
		EFGART	84	45.9 (14.4)	63 (75.0)	21 (25.0)	9.2 (2.6)	16.2 (5.0)	18.8 (6.1)	16.1 (6.4)	34 (40.0)	47 (56.0)	3 (4.0)
	Overall	РВО	83	48.2 (15.0)	55 (66.3)	28 (33.7)	8.8 (2.3)	15.5 (4.6)	18.3 (5.5)	16.8 (5.7)	31 (37.0)	49 (59.0)	3 (4.0)
		Total	167	47.0 (14.7)	118 (70.7)	49 (29.3)	9.0 (2.5)	15.9 (4.8)	NR	16.4 (6.0)	65 (39.0)	96 (57.5)	6 (3.6)
	Overall	EFGART	12	55.3 (13.6)	7 (58.3)	5 (41.7)	8.0 (3.0)	14.5 (6.3)	16.7 (8.7)	19.7 (5.7)	6 (50.0)	6 (50.0)	0 (0)
Phase II Howard 2019 ²⁴	(AChR	РВО	12	43.5 (19.3)	8 (66.7)	4 (33.3)	8.0 (2.2)	11.8 (5.4)	14.5 (4.5)	14.5 (6.1)	7 (58.4)	4 (33.3)	1 (8.3)
	AUTJ	Total	24	49.4 (17.4)	15 (62.5)	9 (37.5)	8.0 (2.6)	13.2 (5.9)	15.6 (6.9)	17.1 (6.4)	13 (54.2)	10 (41.7)	1 (4.2)
						Eculizum	ab						
	Overall	ECU	62	47.5 (15.7)	41 (66.1)	21 (33.9)	10.5 (3.1)	17.3 (5.1)	20.4 (6.1)	33.6 (12.2)	18 (29.0)	37 (59.7)	7 (11.3)
REGAIN Phase III ¹⁶	(Refract.	РВО	63	46.9 (18.0)	41 (65.1)	22 (34.9)	9.9 (2.6)	16.9 (5.6)	18.9 (6.0)	30.7 (12.7)	29 (46.0)	29 (46.0)	5 (7.9)
		Total	125	47.2 (16.8)	82 (65.6)	43 (34.4)	10.2 (2.8)	17.1 (5.3)	19.6 (6.1)	32.1 (12.5)	47 (37.6)	66 (52.8)	12 (9.6)

	0	ECU/EC U	56	47.2 (15.5)	38 (67.9)	18 (32.1)	10.3 (3.0)	NR	NR	32.5 (12.0)	NR	NR	NR
REGAIN OLE ¹⁷	(Refract.	PBO/EC U	61	47.5 (17.9)	41 (67.2)	20 (32.8)	9.9 (2.6)	NR	NR	30.8 (12.9)	NR	NR	NR
	ACRK AD+)	Total	117	47.4 (16.7)	79 (67.5)	38 (32.5)	10.1 (2.8)	NR	NR	31.6 (12.5)	NR	NR	NR
Phase II Howard 2013 ²²	Overall (Refract.)	Total	14	Median (range): 48 (30- 72)	8 (57.0)	6 (43.0)	NR	Median: 18 (12- 36)	NR	NR	4 (28)	8 (57)	2 (14)
		PRED	90	48.3 (16.5)	56 (62.2)	34 (37.8)	NR	NR	NR	NR	83 (92.2)	7 (7.8)
Nowak 2020	Overall	AZA	39	46.7 (16.9)	25 (64.1)	14 (35.9)	NR	NR	NR	NR	34 (87.2)	5 (12.8)
19	(Refract. AchR Ab+)	MMF	30	49.4 (17.5)	21 (70)	9 (30.0)	NR	NR	NR	NR	28 (93.3)	2 (6.7)
		All Patients	117	47.4 (16.7)	79 (67.5)	38 (32.5)	NR	NR	NR	NR	105	(89.7)	12 (10.2)
						Rituxima	ıb						
Phase II	Overall	RTX	25	53.2 (17.5)	11 (44)	14 (56)	5.8 (3.6)	11.0 (5.1)	11.1 (6.1)	22.7 (14.1)	15 (60)	9 (36)	1 (4)
BeatMG ⁶⁸	Ab+)	РВО	27	56.8 (17.0)	12 (44.4)	15 (55.6)	4.0 (3.4)	9.2 (3.9)	8.5 (4.0)	17.7 (10.6)	16 (59.3)	9 (33.3)	1 (3.7)
Brauner 2020 ⁶⁹	Treated	New- Onset MG	24	58 (20)	10 (42)	14 (58)	NR	8 (4)	NR	NR	NR	NR	NR
		Refract ory MG	34	63 (16)	14 (41)	20 (59)	NR	7 (5)	NR	NR	NR	NR	NR
	Control	New- Onset MG	26	68 (11)	3 (12)	23 (88)	NR	8 (5)	NR	NR	NR	NR	NR

					Ma	aintenanco	e IVIG						
		IGIV-C	30	54.6 (17.1)	14 (46.7)	16 (53.3)	NR	NR	NR	NR	NR	NR	NR
Phase II NCT02473952 ²⁷	Overall (AChR	РВО	32	48.0 (13.7)	19 (59.4)	13 (40.6)	NR	NR	NR	NR	NR	NR	NR
	AD+)	Total	62	51.2 (15.6)	33 (53.2)	29 (46.8)	NR	NR	NR	NR	NR	NR	NR
Phase II NCT02473965 ²⁶	Querell	IGIV-C	30	47.6 (17.0)	16 (53.3)	14 (46.7)	NR	12.1 (6.98)	NR	NR	NR	NR	NR
	(AChR	РВО	30	48.5 (14.5)	18 (60.0)	12 (40.0)	NR	11.2 (6.48)	NR	NR	NR	NR	NR
	AUTJ	Total	60	48.1 (15.7)	34 (56.7)	26 (43.3)	NR	11.6 (6.7)	NR	NR	NR	NR	NR

%: percent, AChR Ab+: acetylcholine receptor antibody positive, AIC: academic in confidence, Efgart: efgartigimod, MG-ADL: myasthenia gravis -activities of daily living, MGC: myasthenia gravis composite, MG_QOL15: myasthenia gravis quality of life 15 scale, QMG: quantitative myasthenia gravis, MGFA: myasthenia gravis foundation of america, n: number, N: total number, NR: not reported, PBO: placebo, Refract.: refractory, RTX: rituximab, SD: standard deviation

* Eculizumab trials use MG-QoL non-revised (scale 0-60) and Efgartigimod trials use MG-QoL revised (scale 0-30)

Table D2.4. Key Baseline Characteristics II

Study Name / Trial Identifier					Race,	n (%)		Anti-	MG	Drovieve	Mean	BMI	History
Trial Identifier	Populatio	on + Arms	N	White	Black	Asian	Other	AChR+ , n(%)	years mean (SD)	thym.	thym., years (SD)	(kg/m²) mean (SD)	exacerb ations
						Efgar	tigimod						
		EFGART	65	54 (83.0)	1 (2.0)	7 (11.0)	3 (5.0)	129	9.7 (8.3)	45 (69.2)	NR	28.1 (8.1)	NR
		РВО	64	56 (88.0)	3 (5.0)	4 (6.0)	1 (2.0)	(100)	8.9 (8.2)	30 (46.9)	NR	28.1 (6.0)	NR
	AChR Ab+	EFGART	41	NR	NR	NR	NR	41 (100)	10.5 (9.4)	32 (78.0)	NR	26.8 (6.3)	NR
Phase III ADAPT ^{21,28}	Refract.	РВО	45	NR	NR	NR	NR	45 (100)	10.3 (7.9)	25 (55.6)	NR	28.3 (6.0)	NR
		EFGART	84	69 (82.0)	3 (4.0)	9 (11.0)	3 (4.0)	65 (77.0)	10.1 (9.0)	59 (70.0)	NR	28.8 (8.0)	NR
	Overall	РВО	83	72 (87.0)	3 (4.0)	7 (8.0)	1 (1.0)	64 (77.0)	8.8 (7.6)	36 (43.0)	NR	28.0 (5.9)	NR
		Total	167	141 (84.4)	6 (3.6)	16 (9.6)	4 (2.4)	129 (77.0)	9.5 (8.4)	95 (57.0)	NR	28.4 (7.0)	NR
	Overall	EFGART	12	11 (91.7)	0 (0)	1 (8.3)	0 (0)	12 (100)	8.2 (9.0)	5 (41.7)	11.6 (12.6)	NR	NR
Phase II Howard 2019 ²⁴	(AChR	РВО	12	11 (91.7)	1 (8.3)	0 (0)	0 (0)	12 (100)	13.3 (11.2)	7 (58.4)	9.8 (8.1)	NR	NR
	ן יאר	Total	24	22 (91.7)	1 (4.2)	1 (4.2)	0 (0)	24 (100)	10.8 (10.3)	12 (50.0)	10.0 (9.7)	NR	NR
						Eculi	zumab						
	Queral	ECU	62	53 (85)	0 (0)	3 (5)	6 (10)	62 (100)	9.9 (8.1)	37 (60)	11 (8.51)	31.4 (9.0)	46 (74.0)
REGAIN Phase III ¹⁶	(Refract.	РВО	63	42 (67)	3 (5)	16 (25)	2 (3)	63 (100)	9.2 (8.4)	31 (49)	11.3 (9.67)	30.5 (8.4)	52 (83.0)
Phase III ¹⁶	ACHR AD+)	Total	125	95 (76)	3 (2)	19 (15)	8 (6)	125 (100)	9.6 (8.2)	68 (54)	11.1 (8.99)	30.9 (8.7)	98 (78.0)

	Overall	ECU/ECU	56	47 (83.9)	0 (0)	3 (5.4)	4 (7.1)	56 (100)	10.7 (7.9)	NR	NR	NR	NR
REGAIN OLE ¹⁷	(Refract.	PBO/ECU	61	41 (67.2)	2 (3.3)	16 (26.2)	2 (3.3)	61 (100)	9.8 (8.5)	NR	NR	NR	NR
	ACIIK AD+)	Total	117	88 (75.2)	2 (1.7)	19 (16.2)	6 (5.1)	117 (100)	10.2 (8.2)	NR	NR	NR	NR
Phase II Howard 2013 ²²	Overall (Refract.)	Total	14	NR	NR	NR	NR	14 (100)	Median (range): 7.0 (1.5- 30.1)	6 (42.9)	NR	NR	12 (85.7)
		PRED	90	67 (74.4)	0 (0)	18 (20)	4 (4.4)	90 (100)	9.9 (8.1)	NR	NR	NR	NR
Nowak 2020	Overall (Pefrect	AZA	39	34 (87.2)	0 (0)	2 (5.1)	2 (5.1)	39 (100)	9.7 (8.2)	NR	NR	NR	NR
19	AchR Ab+)	MMF	30	26 (86.7)	1 (3.3)	1 (3.3)	2 (6.7)	30 (100)	10.3 (8.6)	NR	NR	NR	NR
		All Patients	117	88 (75.2)	2 (1.7)	19 (16.2)	6 (5.1)	117 (100)	10.2 (8.2)	NR	NR	NR	NR
						Ritu	ximab						
Phase II	Overall	RTX	25	20 (80)	2 (8)	0 (0)	NR	25 (100)	NR	8 (32)	NR	NR	NR
BeatMG ⁶⁸	Ab+)	РВО	27	15 (55.6)	9 (33)	1 (3.7)	NR	27 (100)	NR	4 (14.8)	NR	NR	NR
Brauner 2020 ⁶⁹	Treated	New- Onset MG	24	NR	NR	NR	NR	20 (83)	NR	9 (38)	NR	NR	NR
	WILLING	Refracto ry MG	34	NR	NR	NR	NR	28 (82)	NR	16 (47)	NR	NR	NR
	Control	New- Onset MG	26	NR	NR	NR	NR	24 (92)	NR	11 (42)	NR	NR	NR

						Mainter	nance IVI	G					
	Quarall	IGIV-C	30	29 (96.7)	1 (3.3)	0 (0)	0 (0)	30 (100)	NR	NR	NR	NR	NR
Phase II NCT02473952 ²⁷	(AChR	РВО	32	30 (93.8)	0 (0)	1 (3.1)	1 (3.1)	32 (100)	NR	NR	NR	NR	NR
	AUT)	Total	62	59 (95.2)	1 (1.6)	1 (1.6)	1 (1.6)	62 (100)	NR	NR	NR	NR	NR
Phase II NCT02473965 ²⁶	Querell	IGIV-C	30	27 (90.0)	0 (0.0)	3 (10.0)	0 (0)	30 (100)	NR	NR	NR	NR	NR
	(AChR	РВО	30	27 (90.0)	1 (3.3)	2 (6.7)	0 (0)	30 (100)	NR	NR	NR	NR	NR
	AD+)	Total	60	54 (90.0)	1 (1.7)	5 (8.3)	0 (0)	60 (100)	NR	NR	NR	NR	NR

%: percent, AChR Ab+: acetylcholine receptor antibody positive, AIC: academic in confidence, AZA: azathioprine, Efgart: efgartigimod, IGIV-C: immune globulin intravenous -c, kg/m2: kilogram per meter squared, MG: myasthenia gravis, MMF: mycophenolate mofetil, n: number, N: total number, NR: not reported, PBO: placebo, Pred: prednisone, Refract.: refractory, RTX: rituximab, SD: standard deviation

Table D2.5. Key Baseline Characteristics III

				Previous	Prior	MG The	rapies at Bas	eline (Stan (%)	dard of Car	re), n	Prior	· IST use,	n(%)
Study Name / Trial Identifier	Populatio	n + Arms	N	long-term IVIG therapy, n (%)	plasma exchange use, n (%)	NSIST	Cholin. Inhibitors	Any Steroids	No Steroid or NSIST	Othe r	≥2 ISTs	≥3 ISTs	≥4 ISTs
					Efgar	tigimod							
		EFGART	65	15 (23.1)	24 (36.9)	40 (62.0)	49 (75.4)	46 (71.0)	13 (20.0)	NR	NR	NR	NR
		РВО	64	18 (28.1)	28 (43.8)	37 (58.0)	57 (89.1)	51 (80.0)	6 (9.0)	NR	NR	NR	NR
	AChR Ab+	EFGART	41	12 (29.3)	16 (39.0)	40 (97.6)	37 (90.2)	37 (90.2)	NR	NR	NR	NR	NR
Phase III ADAPT ^{21,28}	Refract.	РВО	45	16 (35.6)	23 (51.1)	38 (84.4)	41 (91.1)	40 (88.9)	NR	NR	NR	NR	NR
		EFGART	84	21 (25.0)	29 (34.5)	51 (61.0)	61 (72.6)	60 (71.0)	16 (19.0)	NR	NR	NR	NR
	Overall	РВО	83	23 (27.7)	36 (43.4)	51 (61.0)	66 (79.5)	67 (81.0)	7 (8.0)	NR	NR	NR	NR
		Total	167	44 (26.3)	65 (38.9)	119 (71.3)	127 (76.0)	131 (78.4)	23 (14.0)	NR	NR	NR	NR
Dhara II		EFGART	12	NR	NR	9 (75.0)	12 (100.0)	8 (66.7)	NR	NR	NR	NR	NR
Phase II Howard	Overall	РВО	12	NR	NR	3 (25.0)	10 (83.3)	5 (41.7)	NR	NR	NR	NR	NR
2019 ²⁴	(AChR Ab+)	Total	24	NR	NR	12 (50.0)	22 (91.7)	13 (54.2)	NR	NR	NR	NR	NR
	1	1		1	Ecul	izumab				•			
	Overall	ECU	62	18 (29.0)	4 (6.0)	56 (90.3)	NR	47 (76.0)	NR	2 (3.0)	61 (98.0)	31 (50.0)	NR
REGAIN Phase III ¹⁶	(Refract.	РВО	63	17 (27.0)	10 (16.0)	56 (88.9)	NR	51 (81.0)	NR	0 (0)	62 (98.0)	34 (54.0)	NR
		Total	125	35 (28.0)	14 (11.0)	112 (89.6)	NR	98 (78.0)	NR	2 (2.0)	123 (98.0)	65 (52.0)	NR

REGAIN OLE	Overall	ECU/ECU	56	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
REGAIN OLE Munnidi 2019 ¹⁷	(Refract.	PBO/ECU	61	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
	AchR Ab+)	Total	117	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Phase II Howard 2013 ²²	Overall (Refract.)	Total	14	NR	NR	7 (50)	12 (85.7)	7 (50)	1 (7.1)	NR	NR	NR	NR
		PRED	90	70 (77.8)	39 (43.3)	NR	NR	NR	NR	NR	42 (46.7)	27 (30.0)	20 (22.2)
Nowek 2020 ¹⁹	Overall (Defrect	AZA	39	29 (74.4)	17 (43.6)	NR	NR	NR	NR	NR	32 (82.1)	5 (12.8)	2 (5.1)
NOWAK 2020	AchR Ab+)	MMF	30	24 (80.0)	17 (56.7)	NR	NR	NR	NR	NR	9 (30.0)	14 (46.7)	6 (20.0)
		All Patients	117	92 (78.6)	57 (48.7)	NR	NR	NR	NR	NR	52 (44.4)	39 (33.3)	24 (20.5)
	Rituximab												
Phase II	Overall	RTX	25	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BeatMG ⁶⁸	(AChR Ab+)	РВО	27	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
	Treated	New-Onset MG	24	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Brauner 2020 ⁶⁹	with RTX	Refract. MG	34	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
	Control	New-Onset MG	26	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
		•			Maintenance I	VIG							
Dhasa U	Overall	IGIV-C	30	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
NCT02473952 ²⁷	(AChR Ab+)	РВО	32	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
		Total	62	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
		IGIV-C	30	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Phase II		РВО	30	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
140102475505	(ACIIK AD+)	Total	60	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

%: percent, AChR Ab+: acetylcholine receptor antibody positive, AIC: academic in confidence, AZA: azathioprine, Cholin.: cholinesterase, Efgart: efgartigimod, IGIV-C: immune globulin intravenous -c, IST: immunosuppressant therapy, IVIG: intravenous immunoglobulin, kg/m2: kilogram per meter squared, MG: myasthenia gravis, MMF: mycophenolate mofetil, n: number, N: total number, NR: not reported, PBO: placebo, Pred: prednisone, Refract.: refractory, RTX: rituximab, SD: standard deviation

Table D2.6. Key Efficacy Outcomes I

Study Name /			Base-		Change from baseli	ne in MG	-ADL		Change from base	eline in Q	MG
Trial Identifier	A	irms	line N	n	mean (95% CI)	SE	p-value	n	mean (95% Cl)	SE	p-value
					Efgartigimod						
						Week	4				
		Efgart	65	63	-4.6 (NR)	0.4	<0.05	62	-6.2 (NR)	0.7	<0.05
		Placebo	64	60	-1.8 (NR)	0.3	-	58	-1.0 (NR)	0.4	-
						Cycle	1				
		Efgart	65	63	-2.2 (NR)	0.4	NS	62	-2.9 (NR)	0.5	<0.05
		Placebo	64	59	-1.7 (NR)	0.4	-	55	-1.2 (NR)	0.3	-
						Cycle	2				
Phase III ADAPT ^{21,28}						NR					
						Week	4				
	ACRK AD+ Refractory	Efgart	41	40	-4.8 (NR)	0.52	NR	40	-6.1 (NR)	0.87	NR
	nendetory	Placebo	45	44	-1.8 (NR)	0.36	NR	42	-0.8 (NR)	0.41	NR
						Cycle	1				
	ACIIK AD-					NR					
						Cycle	1				
	Overall					NR					
	Overall					Cycle	2				
						NR					
Phase II	0				We	eek 11 (D	ay 80)				
Howard	Overall (AChR Ab+)	Efgart	12	NR	-3.5 (NR)	1.1	NS	NR	-4.8 (NR)	2.4	NS
2019 ²⁴		Placebo	12	NR	-1.8 (NR)	1.2	NS	NR	-2.1 (NR)	1.5	NS

					Eculizumab						
						Week	4				
		ECU	62	62	-3.5 (-4.3 to -2.7)	0.4	0.0008	62	-3.3 (-4.4 to -2.2)	0.6	0.0256
		Placebo	63	63	-1.5 (-2.3 to -0.7)	0.4	_	63	-1.5 (-2.6 to -0.4)	0.6	_
	Overall					Week	8				
REGAIN Phase III ¹⁶	(Refractory	ECU	62	62	-3.7 (-4.6 to -2.7)	0.5	0.0046	62	-4 (-5.2 to -2.8)	0.6	0.0021
i nase m	AchR Ab+)	Placebo	63	63	-1.8 (-2.7 to -0.8)	0.5	-	63	-1.4 (-2.5 to -0.3)	0.6	_
						Week 2	26				
		ECU	62	NR	-4.2 (-5.2 to -3.3)	0.5	0.0058	NR	-4.6 (-5.8 to -3.4)	0.61	0.0006
		Placebo	63	NR	-2.3 (-3.2 to -1.4)	0.5	-	NR	-1.6 (-2.8 to -0.5)	0.59	_
						Week	4				
		ECU/ECU	56	56	-0.3 (-0.8 to -0.3)	0.1	≤ 0.0001	56	-0.1 (-0.8 to 0.7)	0.38	≤ 0.0001
		PBO/ECU	60	60	-2.5 (-3.2 to -1.7)	0.4	-	60	-3.0 (-4.1 to -2.0)	0.54	_
						Week	8				
		ECU/ECU	56	53	5 (-1.0 to 0)	0.3	≤ 0.0001	52	-0.3 (-1 to 0.5)	0.38	≤ 0.0001
REGAIN OLE	Overall (Pofractory	PBO/ECU	60	60	-2.7 (-3.4 to -1.9)	0.4	-	60	-2.9 (-4 to -1.8)	0.56	-
17 IVIUPPIOI 2019	AchR Ab+)					Week 2	26				
	,	ECU/ECU	56	49	5 (-1.0 to .1)	0.3	≤ 0.0001	48	-0.1 (09 to .07)	0.41	≤ 0.0001
		PBO/ECU	60	55	-2.5 (-3.3 to -1.8)	0.4	-	55	-2.8 (-3.8 to -1.6)	0.56	-
						Week 5	52				
		ECU/ECU	56	49	3 (9 to .3)	0.2	≤ 0.0001	48	-0.4 (-1.2 to 0.3)	0.38	≤ 0.0001
		PBO/ECU	60	54	-2.9 (-3.7 to -2.2)	0.4	_	53	-3.9 (-4.9 to -2.7)	0.56	-

					We	ek 16 (Pe	riod 1)				
Phase II Howard	Overall (Refractory)	ECU	7	NR	NR	NR	NR	7	-7.4	SD: 5.7	NR
2013 ²²	(Renactory)	РВО	7	NR	NR	NR	NR	7	-2.7	SD: 4.8	-
					We	ek 16 (Pe	riod 2)				
		ECU	6	NR	NR	NR	NR	6	-7.7	SD: 4.8	NR
		РВО	6	NR	NR	NR	NR	6	-4.5	SD: 2.5	Ι
					Start of OLE to Las	st Assessr	nent				
	Total		117	117	-3.6 (SD: 4.1)	0.38	NR	117	-4.1 (SD: 5.8)	0.54	NR
		Patients who decreased and/or stopped	45	45	-4.7 (SD: 3.9)	0.58	NR	45	-5.6 (SD: 5.2)	0.78	NR
	PRED	Patients with no change	36	36	-2.3 (SD: 4.1)	0.68	NR	36	-1.5 (SD: 5)	0.83	NR
Nowak 2020 ¹⁹		Patients who increased and/or started	10	10	-0.7 (SD: 4.2)	1.33	NR	10	0.2 (SD: 4.9)	1.55	NR
		Patients who decreased and/or stopped	16	16	-3.4 (SD: 4.0)	1	NR	16	-3.8 (SD: 6.8)	1.7	NR
	AZA	Patients with no change	20	20	-4.7 (SD: 3.8)	0.85	NR	20	-5.1 (SD: 5.3)	1.19	NR
		Patients who increased and/or started	3	3	0.3 (SD: 2.3)	1.33	NR	3	-2.7 (SD: 4.9)	2.83	NR

	MMF	Patients who decreased and/or stopped	13	13	-5.1 (SD: 3.6)	1	NR	13	-4.9 (SD: 3.5)	0.97	NR		
		Patients with no change	14	14	-2.5 (SD: 3.4)	0.91	NR	14	-1.6 (SD: 4.0)	1.07	NR		
		Patients who increased and/or started	7	7	-5.3 (SD: 3.6)	1.36	NR	7	-7.9 (SD: 5.2)	1.97	NR		
	Rituximab												
Dhara II	Week 52												
Phase II BeatMG ⁶⁸	RTX	25	NR	NR	NR	NR	25	-3.95	1.1	0.39			
beating	РВО	27	NR	NR	NR	NR	27	-1.7	0.8	Ι			
					Maintenance IVIG								
Phase II	Week 24												
NCT02473952 ²	IGIV-C	30	NR	NR	NR	NR	30	-4.6 (SD: 5.11)	0.9	NR			
7	РВО	3		NR	NR	NR	NR	32	-2.7 (SD: 6.23)	1.1	NR		
Phase II	Week 39												
NCT02473965 ²	NR												

95% CI: 95% confidence interval, AChR Ab+: acetylcholine receptor antibody positive, AIC: academic in confidence, Aza: azathioprine, Efgart.: efgartigimod,

ECU: eculizumab, IGIV-C: immune globulin intravenous -c, MG-ADL: myasthenia gravis - activities of daily living, MMF: mycophenolate mofetil, n: number, N: total number, NR: not reported, NS: not significant, OLE: open-label extension, PBO: placebo, Pred: prednisone, QMG: quantitative myasthenia gravis, SE: standard error, SD: standard deviation, RTX: rituximab

Note: Italicized numbers are digitized estimates

Table D2.7. Key Efficacy Outcomes II

Study Name / Trial Identifier	Arms		Baseline N	e Change from baseline in MGC				Change from baseline in MG-QoL15r				
				n	mean (95% CI)	SE	p-value	n	mean (95% CI)	SE	p-value	
					Efgartigimod							
		Week 4										
		Efgart	65	63	-9.3 (NR)	1.0	<0.05	63	-7.3 (NR)	0.8	<0.05	
		Placebo	64	60	-3.4 (NR)	0.7	_	60	-2.3 (NR)	0.5	-	
		Cycle 1										
		Efgart	65	63	-3.8 (NR)	0.8	NS	63	-4.6 (NR)	0.8	<0.05	
		Placebo	64	59	-3.2 (NR)	0.6	-	59	-2.2 (NR)	0.5	-	
		Cycle 2										
		Efgart					NR					
	AChR Ab+ Refractory	Week 4										
Phase III		Efgart	41	40	-9.1 (NR)	1.18	NR	40	-7.4 (NR)	1.04	NR	
ADAPT ^{21,28}		Placebo	45	44	-3.2 (NR)	0.69	NR	44	-2.6 (NR)	0.63	NR	
	AChR Ab-	Cycle 1										
		NR										
		Cycle 1										
	Overall											
						1	NR					
						Cy	cle 2					
						1	NR					
						Week 1	1 (Day 80)					
Phase II	Overall	Efgart	12	NR	-7.1 (NR)	2.8	NS	NR	-2.7 (NR)	1.7	NS	
	(ACIIK AD+)	Placebo	12	NR	-3.7 (NR)	2	NS	NR	-1.5 (NR)	1	NS	

©Institute for Clinical and Economic Review, 2021 Final Report – Myasthenia Gravis

Eculizumab													
				•		We	eek 4				•		
		ECU	62	62	-7.2 (-8.8 to -5.8)	0.8	0.0007	62	-7.2 (-9.5 to -4.7)	1.2	0.0395		
		Placebo	63	63	-3.5 (-5 to -2)	0.8	-	63	-3.6 (-5.9 to -1.1)	1.2	-		
	Overall	Week 8											
Phase III ¹⁶	(Refractory AchR Ab+)	ECU	62	62	-8.1 (-9.8 to -6.4)	0.9	0.0003	62	-10.2 (-12.8 to - 10.2)	0.7	0.0002		
		Placebo	63	63	-3.5 (-5.2 to -1.8)	0.9	-	63	-2.8 (-5.4 to -0.3)	1.3	-		
			Week 26										
		ECU	62	NR	-8.1 (-10 to -6.2)	0.97	0.0134	NR	-12.6 (-15.7 to - 9.6)	1.56	0.001		
		Placebo	63	NR	-4.8 (-6.6 to -2.9)	0.94	-	NR	-5.4 (-8.4 to -2.5)	1.51	-		
	Overall (Refractory AchR Ab+)	Week 4											
		ECU/ECU	56	56	-0.3 (-1.4 to 0.7)	0.54	≤ 0.0001	56	-0.1 (-2.1 to 1.8)	0.99	≤ 0.0001		
		PBO/ECU	60	60	-4.7 (-6.1 to -3.3)	0.71	-	60	-5.3 (-8.0 to -2.8)	1.33	-		
		Week 8											
		ECU/ECU	56	52	5 (-1.5 to 0.5)	0.51	≤ 0.0001	53	-0.9 (-3.0 to 0.9)	0.99	≤ 0.0001		
Muppidi		PBO/ECU	60	59	-4.8 (-6.2 to -3.4)	0.71	_	60	-6.8 (-9.4 to -4.2)	1.33	-		
2019 ¹⁷		Week 26											
		ECU/ECU	56	49	-0.9 (-1.9 to 0.1)	0.51	≤ 0.0001	47	-0.8 (-2.9 to 1.2)	1.05	≤ 0.0001		
		PBO/ECU	60	55	-4.7 (-6.0 to -3.2)	0.71	-	56	5.7 (-8.3 to -3.1)	1.33	-		
			[1		We	ek 52			[
		ECU/ECU	56	49	-1.0 (-1.9 to 0.2)	0.54	≤ 0.0001	49	-0.6 (-2.6 to 1.4)	1.02	≤ 0.0001		
		PBO/ECU	60	54	-5.2 (-6.5 to -3.7)	0.71	_	54	-6.2 (-8.9 to -3.6)	1.35	-		
						Week 16	(Period 1)						
Phase II	Overall						NR						
Howard 2013 ²²	(Refractory)					Week 16	(Period 2)						
							NR						

	9 Total Start of OLE to Last Assessment NR											
Nowak 2020 ¹⁹												
					Rituximab							
Dhara II	Week 52											
Phase II BeatMG ⁶⁸	RTX		25	25	-5.7 (NR)	1.5	0.93	NR	NR	NR	NR	
Deating	РВО		27	27	-4 (NR)	0.8	-	NR	NR	NR	NR	
	Maintenance IVIG											
Phase II	Week 24											
NCT02473952 ²⁷	NR											
Phase II NCT02473965 ²⁶					v	Veek 39						
		NR										

95% CI: 95% confidence interval, AChR Ab+: acetylcholine receptor antibody positive, AIC: academic in confidence, Efgart.: efgartigimod, ECU: eculizumab, IGIV-C: immune globulin intravenous -c, MGC: ,myasthenia gravis composite, MG-QoL15/r: myasthenia gravis - quality of life / revised, n: number, N: total number, NR: not reported, NS: not significant, OLE: open-label extension, PBO: placebo, QMG: quantitative myasthenia gravis, SE: standard error, RTX: rituximab Note: Italicized numbers are digitized estimates

* Eculizumab trials use MG-QoL non-revised (scale 0-60) and Efgartigimod trials use MG-QoL revised (scale 0-30)

Table D2.8. Key Efficacy Outcomes III

Study Name / Trial	tudy Name / Trial Arms Identifier		Deceline N	MG-ADL Re	sponders*	QMG Responderst					
Identifier			Baseline N	n (%)	p-Value	n (%)	p-Value				
			Efgartigimo	bd							
		Week 4									
		NA									
		Cycle 1									
		Efgart	65	44 (68.0)	< 0.0001	41 (63.0)	< 0.0001				
		Placebo	64	19 (30.0)	_	9 (14.0)	_				
		Cycle 2									
		Efgart	51	36 (70.6) †	< 0.0001	NR	NR				
		Placebo	43	11 (25.6)	NR	NR	NR				
	AChR Ab+ Refractory	Week 4									
Phase III		Efgart	41	NR	NR	NR	NR				
ADAPT ^{21,28}		Placebo	45	NR	NR	NR	NR				
	AChR Ab-	Cycle 1									
		Efgart	19	13 (68.0)	NR	10 (53.0)	NR				
		Placebo	19	12 (63.0)	_	7 (37.0)	_				
		Cycle 1									
		Efgart	84	57 (68.0)	< 0.0001	NR	NR				
	Overall	Placebo	83	31 (37.0)	_	NR	NR				
	Overail		1	Cycl	e 2						
		Efgart	51	36 (71.0)	NR	NR	NR				
		Placebo	43	11 (26.0)	NR	NR	NR				
Phase II	Overall (AChR	Week 11 (Day 80)									
Howard 2019 ²⁴	Ab+)	NR									

			Eculizuma	b							
		Week 4									
	Overall (Defreeters: Ask D	NR									
REGAIN Phase III ¹⁶				Weel	k 8						
	(Refractory Actik Ab+)			NR							
				Week	26						
		NR									
				Weel	« 4						
				NR							
		Week 8									
REGAIN OLE	Overall	NR									
Muppidi 2019 ¹⁷	(Refractory AchR Ab+)	Week 26									
		NR									
		Week 52									
		NR									
	Overall (Refractory)	Week 16 (Period 1)									
		ECU	7	6 (85.7)	NR	6 (86)	NR				
Phase II		РВО	7	4 (57.1)	NR	4 (57)	NR				
Howard 2013 ²²		Week 16 (Period 2)									
		ECU	6	NR	NR	5 (83)	NR				
		РВО	6	NR	NR	NR	NR				
No	Start of OLE to Last Assessment										
Nowak 2020 ²³		NR									
			Rituximal)							
Phase II				Week 52							
BeatMG ⁶⁸		NR									
			IVIG								
Phase II				Week 24							
NCT02473952 ²⁷	NR										

©Institute for Clinical and Economic Review, 2021 Final Report – Myasthenia Gravis
Phase II	Week 39
NCT02473965 ²⁶	NR

AChR Ab+: acetylcholine receptor antibody positive, Efgart.: efgartigimod, ECU: eculizumab, IVIG: intravenous immunoglobulin,

MG-ADL: myasthenia gravis - activities of daily living, QMG: quantitative myasthenia gravis, n: number, N: total number,

NA: not applicable, NR: not reported, NS: not significant, OLE: open-label extension, PBO: placebo,

QMG: quantitative myasthenia gravis, SE: standard error, RTX: rituximab

* Efgartigimod trials defined MG-ADL Responders as having ≥2 point improvement (reduction) in total MG-ADL score over at least 4 consecutive time points

+ Efgartigimod trials defined QMG Responders as having ≥ 3 point improvement (reduction) in total QMG Score over at least 4 consecutive time points

Includes both responders and non-responders from cycle 1

Table D2.9. Key Secondary Efficacy Outcomes I

Study Name / Trial Identifier	Arm	15	Base- line N	Mir Sym Expr	nimal Iptom ession	Early MG Resp (wit we	Onset -ADL onder hin 2 eks)	Cumulative pati with a resp	e number of ents ponse n(%)	D M	uration of G-ADL res	MG-ADL	. Respons , weeks r	se in n (%)
				%	p- Value	n (%)	p- Value	MG-ADL Early Response	QMG Early Response	4 to < 6	6 to <8	8 to ≤ 12	12+	Median
						Efg	artigimo	d						
								Cycle :	1					
Phase III ADAPT ²¹		Efgart	65	40	< 0.000 1	37 (57.0)	NR	NR	NR	5 (11.4)	14 (31.8)	10 (22.7)	15 (34.1)	NR
	AChR Ab+	РВО	64	11.1	_	16 (25.0)	_	NR	NR	NR	NR	NR	NR	NR
								Cycle	2					
		Efgart	51	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
		РВО	43	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
	AChP				1		1	Cycle	1	1				
	Ab-	Efgart	19	32	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
		РВО	19	16	_	NR	NR	NR	NR	NR	NR	NR	NR	NR
			1		1		1	Cycle	1	1				
	Overall	Efgart	84	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
		РВО	83	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Phase II	Overall	-			1			Week 11 (D	ay 80)		1 51			0 (05)
Phase II Howard 2019 ²⁴ 72	(AChR	Efgart	12	42	NR	NR	NR	NR	NR	2 6 w Diff∙ 50	eeks: Efga 34%: 95%	art: 9 (75) SCI: 15 93) Placebo 8 - 84 74·	: 3 (25) n=0 0391
	Ab+)	РВО	12	8	NR	NR	NR	NR	NR	8 We	eks after	last dose	: Efgart: (6 (50.0)

						Ec	ulizumab)						
								Week	4					
		ECU	62	12.3	<0.01	NR	NR	NR	NR	NR	NR	NR	NR	NR
REGAIN	Overall (Refract	РВО	63	0	-	NR	NR	NR	NR	NR	NR	NR	NR	NR
Phase III ^{9,16}	AchR							Week 2	26					
	Ab+)	ECU	62	21.4	0.000 7	NR	NR	NR	NR	NR	NR	NR	NR	NR
		РВО	63	1.7	-	NR	NR	NR	NR	NR	NR	NR	NR	NR
								Week	4					
		ECU/ ECU	55	16.4	NS	NR	NR	NR	NR	NR	NR	NR	NR	NR
REGAIN OLE	Overall (Refract.	PBO/ ECU	61	21.3	-	NR	NR	NR	NR	NR	NR	NR	NR	NR
Muppidi 2019 ^{9,17}	AchR							Week 2	26					
	Ab+)	ECU/ ECU	49	24.1	NS	NR	NR	NR	NR	NR	NR	NR	NR	NR
		PBO/ ECU	55	23.5	_	NR	NR	NR	NR	NR	NR	NR	NR	NR
								Week	52					
		ECU /EC U	49	22.4	NS	NR	NR	NR	NR	NR	NR	NR	NR	NR
		PBO /EC U	54	23.9	_	NR	NR	NR	NR	NR	NR	NR	NR	NR
								Week 1	L 30					
		ECU /EC U	35	22.9	0.786 1	NR	NR	NR	NR	NR	NR	NR	NR	NR
		PBO /EC U	36	27.8	_	NR	NR	NR	NR	NR	NR	NR	NR	NR

								Week 16 (P	eriod 1)					
			-		ND		NID	WEEK ID (FO		NID	ND			ND
		ECU	/	NR	NK	NR	NR	NR	NR	NR	NK	NK	NK	NR
Phase II	Overall	РВО	7	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Howard 2013 ²²	(Refract.)							Week 16 (Pe	eriod 2)					
		ECU	6	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
		РВО	6	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
				•				Week	4					
		ECU	98	NR	NR	NR	NR	56 (57.1)	46 (46.9)	NR	NR	NR	NR	NR
Howard 2021 ²¹	Overall (Pofract							Week	8					
	AchR Ab+)	ECU	98	NR	NR	NR	NR	63 (64.3)	52 (53.1)	NR	NR	NR	NR	NR
	,							Week	26					
		ECU	98	NR	NR	NR	NR	72 (73.5)	61 (62.2)	NR	NR	NR	NR	NR
						Ri	tuximab							
Brauner 2020 ⁶⁹	gMG								NR					
						Maint	enance l	VIG						
Phase II	Overall								NP					
NCT02473952 ²⁷	(AChR Ab+))												
Phase II NCT02473965 ²⁶	Overall (AChR Ab+))							NR					

%: percent, AChR Ab+: acetylcholine receptor antibody positive, Efgart.: efgartigimod, ECU: eculizumab, gMG: generalized myasthenia gravis, IVIG: intravenous immunoglobulin, MG-ADL: myasthenia gravis - activities of daily living, QMG: quantitative myasthenia gravis, n: number, N: total number, NR: not reported, PBO: placebo, Refract.: refractory

Table D2.10. Key Secondary Efficacy Outcomes II

Study Name /			Pacalina			Presp	ecified worst-ra	ank ANC	OVA score		
Trial Identifier	Arms		N	MG- ADL	Difference (95% Cl)	QMG	Difference (95% Cl)	MGC	Difference (95% Cl)	MG- QOL15	Difference (95% Cl)
					Efgartigimod						
Phase III ADAPT ²¹	Overall						NR				
Phase II Howard 2019 ²⁴	Overall						NR				
					Eculizumab						
						W	/eek 26				
REGAIN Phase III ¹⁶	Overall (Refractory AchR Ab+)	ECU	62	56.6 (4.5)	-11.7 (-24.3, 0.96)	54.7 (4.5)	-16.0 (-28.5, -3.4)	57.3 (4.5)	-10.5 (-23.1, 2.1)	55.5 (4.6)	-14.3 (-27.0, - 1.6)
		Placebo	63	68.3 (4.5)	-	70.7 (4.5)	-	67.7 (4.5)	-	69.7 (4.5)	-
REGAIN OLE Muppidi 2019 ¹⁷	Overall (Refractory AchR Ab+)						NR				
Phase II Howard 2013 ²²	Overall (Refractory)						NR				
Howard 2021	Overall (Refractory AchR Ab+)						NR				
					Rituximab						
Brauner 2020 ⁶⁹	gMG						NR				
				Ν	Aaintenance IVI	G					
Phase II NCT02473952 ²⁷	Overall (AChR Ab+)						NR				
Phase II NCT02473965 ²⁶	Overall (AChR Ab+)						NR				

95% CI: 95% confidence interval, AChR Ab+: acetylcholine receptor antibody positive, ANCOVA: analysis of covariance, ECU: eculizumab, gMG: generalized myasthenia gravis, IVIG: intravenous immunoglobulin, MG-ADL: myasthenia gravis - activities of daily living, MGC: ,myasthenia gravis composite, MG-QoL15/r: myasthenia gravis - quality of life / revised, N: total number, NR: not reported, QMG: quantitative myasthenia gravis

©Institute for Clinical and Economic Review, 2021 Final Report – Myasthenia Gravis

Table D2.11. Key Secondary Efficacy Outcomes III

Study Name / Trial Identifier		Arms	Base line	MGFA	Post-Interve	ntion Status (F	PIS)	l b	Vlean change f aseline Neuro Fatigue total se	rom -QOL core	Propo of Pat ir Remis	ortion tients n ssion
Trial identifier			N	Improved, n (%)	Patients achieving MM, n(%)	Unchanged n (%)	Worse, n (%)	n	mean (95% CI)	p- value	No. at risk	%
				Ef	gartigimod							
Phase III ADAPT ²¹	AC	hR Ab+					NR					
Phase II Howard 2019 ²⁴	C (AC	verall hR Ab+)					NR					
				E	culizumab							
						Week 4						
		ECU	62	30 (54.5)	10 (18.2)	25 (45.5)	0 (0)	NR	NR	NR	NR	NR
	Overall	Placebo	63	15 (24.6)	5 (8.2)	41 (67.2)	5 (8.2)	NR	NR	NR	NR	NR
REGAIN	(Refractory					Week 26			·			
Phase III-9-09-0	AchR Ab+)	ECU	62	34 (60.7)	14 (25.0)	21 (37.5)	1 (1.8)	56	-16.3 (-20.8 to -11.8)	0.0081	NR	NR
		Placebo	63	25 (41.7)	8 (13.3)	30 (50)	5 (8.3)	60	-7.7 (-12.1 to -3.3)	-	NR	NR
			-			Week 4						
		ECU/ECU	NR	NR	NR	NR	NR	52	-17.8 (-22.5 to -13.0)	NR	NR	NR
REGAIN OLE Muppidi	Overall (Refractory	PBO/ECU	NR	NR	NR	NR	NR	60	-17.4(-22.0 to -12.9)	-	NR	NR
2019 ^{10,17,18}	AchR Ab+)					Week 26						
		ECU/ECU	56	36 (75.0)	22 (45.8)	12 (25.0)	0 (0)	NR	NR	NR	NR	NR
		PBO/ECU	60	40 (71.4)	27 (48.2)	15 (26.8)	1 (1.8)	NR	NR	NR	NR	NR

			Week 52												
		ECU/ECU	56	41 (85.4)	22 (45.8)	6 (12.5)	1 (2.1)	48	-17.5 (-22.5 to -12.5)	NR	NR	NR			
		PBO/ECU	60	44 (81.5)	31 (57.4)	10 (18.5)	0 (0)	54	-15.7 (-20.5 to -10.9)	-	NR	NR			
						Week 130									
		ECU/ECU	35	28 (80.0)	18 (51.4)	5 (14.3)	2 (5.7)	NR	NR	NR	NR	NR			
		PBO/ECU	36	33 (94.3)	22 (62.9)	2 (5.7)	0 (0)	NR	NR	NR	NR	NR			
Phase II Howard 2013 ²²	Overall (Refractory)					NR									
Howard 2021	Overall (Refractory AchR Ab+)					NR									
				F	Rituximab										
					Mo	nth 20	1	1			T				
-	RTX	New-onset gMG	24	NR	NR	NR	NR	NR	NR	NR	3	88.8			
	Treatment	Refractory gMG	34	NR	NR	NR	NR	NR	NR	NR	11	60.7			
	New-onset	RTX	24	NR	NR	NR	NR	NR	NR	NR	NA	89			
Brauner 2020 ⁶⁹	Disease	Control	26	NR	NR	NR	NR	NR	NR	NR	NA	66			
Bradiler 2020				1	Mo	nth 40	1	T			1	1			
	RTX	New-onset gMG	NR	NR	NR	NR	NR	NR	NR	NR	0	NA			
	Treatment	Refractory gMG	NR	NR	NR	NR	NR	NR	NR	NR	3	78.9			
	New-onset	RTX	NR	NR	NR	NR	NR	NR	NR	NR	NA	NA			
	Disease	Control	NR	NR	NR	NR	NR	NR	NR	NR	NA	73			
				Mair	ntenance IVIG	i									
Phase II NCT02473952 ²⁷	C (AC	Overall ChR Ab+)					NR								
Phase II NCT02473965 ²⁶	C (AC	Overall ChR Ab+)					NR								

©Institute for Clinical and Economic Review, 2021 Final Report – Myasthenia Gravis %: percent, 95%CI: 95% confidence interval, AChR Ab+: acetylcholine receptor antibody positive, ECU: eculizumab, gMG: generalized myasthenia gravis, IVIG: intravenous immunoglobulin, MGFA: myasthenia gravis foundation of america, MM: minimal manifestations, n: number, No.: number, NA: not applicable, Neuro-QoL: neurological quality of life scale, NR: not reported, PIS: post intervention status, RTX; rituximab

Table D2.12. Safety Outcomes I

Study Name / Trial Identifier	Arms	Time point	N	AE*	SAE†	Treatm ent- related AE	Discont. Treatment due to AEs	Death	Infection AE	≥ 1 Infusion- related reaction event	Hospital Admis.	MG Exacer bation	MG Crisis
								n	ı (%)				
						Efga	rtigimod						
Phase III	EFGA RT		84	65 (77.0)	4 (5.0)	26 (31.0)	3 (3.6)	0 (0)	39 (46.0)	3 (4.0)	NR	NR	NR
ADAPT ²¹	РВО	Week 26	83	70 (84.0)	7 (8.0)	22 (26.5)	3 (3.6)	0 (0)	31 (37.0)	8 (10.0)	NR	NR	NR
Phase II Howard 2019 ²⁴	EFGA RT		12	10 (83.3)	0 (0)	NR	0 (0)	0 (0)	NR	NR	NR	NR	NR
	РВО	Day 78	12	10 (83.3)	0 (0)	NR	0 (0)	0 (0)	NR	NR	NR	NR	NR
	Total		24	20 (83.3)	0 (0)	NR	0 (0)	0 (0)	NR	NR	NR	NR	NR
						Ecu	lizumab						
	ECU		62	NR	9 (15)	NR	4 (6)	0 (0)	NR	NR	9 (15)	6 (10)	1 (1.6)
REGAIN ¹⁶	РВО	Week 26	63	NR	18 (29)	NR	0 (0)	0 (0)	NR	NR	18 (29)	15 (24)	0 (0)
-	Total		125	NR	27 (22)	NR	4 (3)	0 (0)	NR	NR	27 (22)	21 (17)	1 (0.1)
REGAIN OLE Muppidi 2019 ¹⁷	Total	Week 208	117	113 (96.6)	52 (44.4)	NR	6 (5.1)	3 (2.6)	22 (18.8)	NR	NR	29 (24.8)	3 (2.6)
Phase II Howard 2013 ²²	ECU	Week 37 (Includes	13	13 (100)	1 (7.7)	7 (53.8)	NR	0 (0)	NR	NR	NR	NR	NR

	РВО	Washout Period)	13	11 (84.6)	1 (7.7)	6 (46.2)	NR	0 (0)	NR	NR	NR	NR	NR
	PRED		90	87 (96.7)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Nowak 2020 ¹⁹	AZA	End of	39	38 (97.4)	NR	NR	NR	NR	NR	NR	NR	NR	NR
NOWAR 2020	MMF	OLE	30	29 (96.7)	NR	NR	NR	NR	NR	NR	NR	NR	NR
	Total		117	114 (97.4)	NR	NR	7 (6.0)	3 (2.6)	NR	NR	NR	NR	NR
						Rite	uximab						
Phase II BeatMG ⁶⁸	RTX	Wook E2	25	25 (100)	9 (36.0)	19 (76.0)	2 (8.0)	0 (0)	NR	NR	NR	NR	NR
	РВО	Week 52	27	26 (96.3)	14 (51.9)	22 (81.5)	3 (11.1)	0 (0)	NR	NR	NR	NR	NR
	RTX	First 24	24	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Brauner 2020 ⁶⁹	Contr ol	months	26	NR	NR	NR	12 (46.0)	NR	NR	NR	NR	NR	NR
						Mainte	nance IVIG						
Phase II	IGIV- C	M/	30	22 (73.3)	5 (16.7)	NR	2 (6.7)	1 (3.3)	NR	NR	NR	NR	NR
Phase II NCT02473952 ²⁷	РВО	vveek 24	32	21 (65.6)	4 (12.5)	NR	2 (6.3)	0 (0)	NR	NR	NR	NR	NR
Phase II NCT02473965 ²⁶	IGIV- C	Maak 20	30	21 (70.0)	4 (13.3)	NR	6 (20.0)	1 (3.33)	NR	NR	NR	NR	NR
	РВО	vveek 39	30	24 (80.0)	6 (20.0)	NR	4 (13.3)	2 (6.7)	NR	NR	NR	NR	NR

%: percent, AE: adverse event, Admis.: Admission, AZA: azathioprine, Discont.: discontinuation, Efgart.: efgartigimod, ECU: eculizumab, IGIV-C: immune globulin intravenous -c, IVIG: intravenous immunoglobulin, MMF: mycophenolate mofetil, n: number, N: total number, NR: not reported, PBO: placebo, Pred.: prednisone, RTX; rituximab, SAE: serious adverse event

Note: ADAPT safety outcomes include both AChR+ and AChR- patients

* AE: includes AEs indicated as AE, any AE, or treatment-emergent AE

+ SAE: includes SAEs indicated as SAE, any SAE, or treatment-emergent SAE

Table D2.13. Safety Outcomes II

							Con	nmonly repo	rted AEs				
Study Name / Trial Identifier	Arms	Time- point	N	Head- ache	Nasophary ngitis	Nausea	Diarr- hea	Upper Resp. Tract Infection	UTI	Arthral gia	Fatigue	HZ	Cough
								n (%)					
					Ef	gartigimod	I						
Phase III	EFGA RT	Wook 26	84	24 (29.0)	10 (12.0)	7 (8.0)	6 (7.0)	9 (11.0)	8 (10.0)	NR	NR	NR	NR
ADAPT ²¹	РВО	Week 20	83	23 (28.0)	15 (18.0)	9 (11.0)	9 (11.0)	4 (5.0)	4 (5.0)	NR	NR	NR	NR
Dhace II	EFGA RT		12	4 (33.3)	1 (8.3)	1 (8.3)	1 (8.3)	0 (0)	NR	0 (0)	NR	1 (8.3)	NR
Phase II Howard 2019 ²⁴	РВО	Day 78	12	3 (25.0)	0 (0)	1 (8.3)	1 (8.3)	1 (8.3)	NR	2 (16.7)	NR	0 (0)	NR
	Total		24	7 (29.2)	1 (8.3)	2 (8.3)	2 (8.3)	1 (8.3)	NR	2 (8.3)	NR	1 (4.2)	NR
					E	culizumab							
	ECU		62	10 (16)	9 (15)	8 (13)	8 (13)	10 (16)	0	NR	NR	NR	NR
REGAIN ¹⁶	РВО	Week 26	63	12 (19)	10 (16)	9 (14)	8 (13)	12 (19)	1 (2)*	NR	NR	NR	NR
	Total		125	22 (18)	19 (15)	17 (14)	16 (13)	22 (18)	1 (1)*	NR	NR	NR	NR
REGAIN OLE Muppidi 2019 ¹⁷	Total	Week 208	117	44 (37.6)	37 (31.6)	21 (17.9)	27 (23.1)	27 (23.1)	17 (14.5)	22 (18.8)	17 (14.5)	NR	17 (14.5)
	ECU	Week 37	13	3 (23.1)	3 (23.1)	4 (30.8)	NR	NR	NR	NR	NR	NR	NR
Phase II Howard 2013 ²²	РВО	(Includes Washout Period)	13	3 (23.1)	2 (15.4)	2 (15.4)	NR	NR	NR	NR	NR	NR	NR

	PRED		90	34 (37.8)	34 (37.8)	16 (17.8)	17 (18.9)	21 (23.3)	9 (10.0)	18 (20)	NR	NR	13 (4.4)	
Nowek 2020 ¹⁹	AZA	End of	39	17 (43.6)	8 (20.5)	9 (23.1)	14 (35.9)	15 (38.5)	4 (10.3)	10 (25.6)	NR	NR	8 (20.5)	
NOWAK 2020	MMF	OLE	30	9 (30)	9 (30)	6 (20.0)	7 (23.3)	6 (20.0)	6 (20.0)	5 (16.7)	NR	NR	5 (16.7)	
	Total		117	47 (40.2)	42 (35.9)	22 (18.8)	29 (24.8)	28 (23.9)	19 (16.2)	23 (19.7)	NR	NR	22 (18.8)	
	Rituximab													
	RTX		25	8 (32)	NR	2 (8)	3 (12)	9 (36)	2 (8)	6 (24)	3 (12)	NR	0	
Phase II BeatMG ⁶⁸	РВО	Week 52	27	7 (25.9)	NR	6 (22.2)	2 (7.4)	5 (18.5)	3 (11.1)	10 (37)	8 (29.6)	NR	3 (11.1)	
	RTX	First 24	24	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
Brauner 2020 ⁶⁹	Contr ol	months	26	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
					Main	itenance IN	/IG							
Phase II	IGIV- C	Week 24	30	9 (30.0)	3 (10.0)	3 (10.0)	3 (10.0)	0 (0)	NR	2 (6.7)	2 (6.7)	NR	3 (10.0)	
NC102473952-7	РВО		32	4 (12.5)	4 (12.5)	1 (3.1)	2 (6.3)	3 (9.4)	NR	0 (0)	0 (0)	NR	0 (0)	
Phase II	IGIV- C	Week 39	30	10 (33.3)	2 (6.7)	5 (16.7)	1 (3.3)	6 (20.0)	1 (3.3)	4 (13.3)	2 (6.7)	NR	3 (10.0)	
INCIU24/3905-0	РВО		30	3 (10.0)	5 (16.7)	1 (3.3)	3 (10)	3 (10.0)	3 (10.0)	6 (20.0)	2 (6.7)	NR	2 (6.7)	

%: percent, AZA: azathioprine, Efgart.: efgartigimod, ECU: eculizumab, HZ: herpes zoster, IGIV-C: immune globulin intravenous -c, IVIG: intravenous immunoglobulin, MMF: mycophenolate mofetil, n: number, N: total number, NR: not reported, PBO: placebo, Pred.: prednisone, RTX; rituximab, UTI: urinary tract infection

* Classified as serious bacterial urinary tract infection

Table D2.14. Safety Outcomes III

				Rescue t	herapy used during trea	atment peri	od
Study Name / Trial Identifier	Arms	Timepoint	N	High-dose Corticosteroids	Plasmapheresis or plasma exchange	IVIG	Other
					n (%)	1	L
			Efgartigin	nod			
Phase III	EFGART	Week 26	84	NR	NR	NR	NR
ADAPT ²¹	РВО	Week 20	83	NR	NR	NR	NR
	EFGART		12	NR	NR	NR	NR
Phase II Howard 2019 ²⁴	РВО	Day 78	12	NR	NR	NR	NR
noward 2015	Total		24	NR	NR	NR	NR
			Eculizum	ab			
	ECU		62	0	3 (5)	4 (6)	1 (2)
REGAIN ¹⁶	РВО	Week 26	63	5 (8)	4 (6)	6 (10)	2 (3)
	Total		125	5 (4)	7 (6)	10 (8)	3 (2)
REGAIN OLE Muppidi 2019 ¹⁷	Total	Week 208	117	NR	NR	NR	NR
Phase II	ECU	Week 37 (Includes	13	NR	NR	NR	NR
Howard 2013 ²²	РВО	Washout Period)	13	NR	NR	NR	NR
	PRED		90	NR	NR	NR	NR
No	AZA		39	NR	NR	NR	NR
	MMF	End of OLE	30	NR	NR	NR	NR
	Total		117	NR	NR	NR	NR

			Rituximab				
Phase II	RTX	Wook 52	25	NR	NR	NR	NR
BeatMG ⁶⁸	РВО	Week 52	27	NR	NR	NR	NR
Brouper 2020 ⁶⁹	RTX First 24	First 24	24	0.4 (1.5)			
Brauner 2020	Control	months	26	1.3 (2.9)			
			Maintenance I	VIG			
Phase II	IGIV-C	Week 24	30	NR	NR	NR	NR
NCT02473952 ²⁷	РВО	Week 24	32	NR	NR	NR	NR
Phase II	IGIV-C		30	NR	NR	NR	NR
NCT02473965 ²⁶	РВО	Week 39	30	NR	NR	NR	NR

%: percent, AZA: azathioprine, Efgart.: efgartigimod, ECU: eculizumab, IGIV-C: immune globulin intravenous -c,

IVIG: intravenous immunoglobulin, MMF: mycophenolate mofetil, n: number, N: total number, NR: not reported,

PBO: placebo, Pred.: prednisone, RTX; rituximab

D3. Ongoing Studies

Table D3.1. Ongoing Studies

Title / Trial Sponsor	Study Design	Treatment Arms	Patient Population	Primary Outcomes	Estimated Completion Date
			Efgartigimod		
ADAPT+ <u>NCT03770403</u> Sponsor: argenx	Long-Term, Single- Arm, Open-Label, Multicenter Phase 3 follow-on trial	1. Efgartigimod (IV)	Patients who have completed at least 1 cycle of treatment and at least 1 year of trial ARGX-113 (N=151)	[Time Frame: Up to 3 years] Safety and Tolerability as measured by the incidence of treatment emergent (serious) adverse events in the AChR- positive population	June 2023
Phase III AdaptSC <u>NCT04735432</u> Sponsor: argenx	Phase III OL, Parallel- Group, Randomized Trial	 Efgartigimod SC Efgartigimod IV 	Patients with a diagnosis of generalized MG (N=76)	[Time Frame: Up to 3 years] Percent change from baseline in total Immunoglobulin (IgG) levels at day 29	October 2021
Phase III AdaptSC+ <u>NCT04818671</u> Sponsor: argenx	Phase III Long-Term, Single-Arm, Open- Label, Multicenter Trial	1. Efgartigimod SC	Patients with a diagnosis of generalized MG (N=201)	[Time Frame: Up to 2 years] Incidence and severity of AEs, SAEs, and AEs of special interest	April 2023
NCT04833894 Sponsor: argenx	Open-labeled uncontrolled trial to evaluated pharmacokinetics, pharmacodynamics, and safety	1. Efgartigimod IV	Pediatric patients 2-18 with generalized MG (N=12)	[Time Frame: Up to 26 weeks] Efgartigimod concentrations for clearance and volume of Distribution, total Immunoglobulin G, AchR-Ab.	March 2023

			Eculizumab		
Phase III Pediatric NCT03759366 Sponsor: Alexion	OL Single-Arm Multicenter	1. Eculizumab IV (300, 600, 900, 1200 mg based on weight)	Patients aged 6-18 with refractory generalized MG (N=12)	[Time Frame: week 26 (primary evaluation) and week 208 (ext. period)] Change in the QMG total score over time regardless of rescue treatment	July 2025
			Rituximab		
Phase III <u>NCT02950155</u> Sponsor: Fredrik Piehl, Karolinska Institute	Phase III, Double- Blind, Placebo- Controlled, Multicenter RCT	 Rituximab – single infusion of 500mg Placebo (sodium chloride solution) 	Patients with oculobulbar, bulbar, or generalized MG (N=47)	[Time Frame: Week 16] Percentage of patients with a QMG score ≤ 4 and daily prednisolone dose of ≤ 10mg	June 2021
		Ma	aintenance IVIG		
Phase II NCT04728425 Sponsor: University Health Network, Toronto	Phase II RCT	1. IVIG + SCIG 2. SCIG alone	Patients with moderate to severe myasthenia gravis class II-IV (QMG >10 or gMG impairment index score >11 (N=30)	[Time Frame: 6 months] Myasthenia Gravis Impairment Index Efficacy Outcome	June 2022

Source: <u>www.ClinicalTrials.gov</u> (NOTE: studies listed on site include both clinical trials and observational studies)

D4. Previous Systematic Reviews and Technology Assessments

We identified two health technology assessments conducted by the Canadian Agency for Drugs and Technologies in Health (CADTH) on eculizumab and rituximab and one network meta-analysis (NMA) that included eculizumab. All reports are briefly summarized below.

CADTH Clinical Review Report of Eculizumab (2020)⁵³

CADTH investigators performed a systematic review of the benefits and harms of eculizumab for the treatment of adults with refractory AChR-Ab+ generalized MG. The review found one RCT: the Phase III REGAIN trial.¹⁶ This review found that a maintenance dose of 1,200mg IV twice weekly of eculizumab led to improvement in activities of daily living; this treatment effect was deemed uncertain due to the statistical methods used in the analysis. Similarly, CADTH investigators cited relatively small sample sizes and limited follow-up of rare and serious AEs as limitation of the drug's long-term benefits and harms.

CADTH investigators received and critically appraised a sponsor-submitted (Alexion) SLR whose objective was to identify relevant scientific evidence of comparators to eculizumab for maintenance therapy of AChR-Ab+ refractory MG. The SLR included the following comparators: rituximab, IVIG, PLEX, and cyclophosphamide. Twelve relevant studies were included in the assessment. There was an inconsistent definition of refractory MG among the studies. Likewise, there was heterogeneity among the studies' population, methodology, dosage, outcomes, and timing of outcomes which limits the feasibility of estimating the relative efficacy of eculizumab versus comparators via indirect comparison/NMA.

CADTH Health Technology Review of Rituximab (2018 and 2021)^{73,74}

CADTH has conducted a review of rituximab for the treatment of MG in 2018, with an update in 2021.⁶⁷ An evaluation of non-randomized studies suggests that rituximab may be associated with improvements in clinical status, quality of life, and use of concomitant medications. The evidence base for the use of rituximab was deemed to be low-quality due to the lack of randomization/ control groups, small sample sizes, and lack of explicit exclusion criteria. This report did not identify the BeatMG Rituximab Phase II RCT trial in its review of the scientific literature. Side effects of rituximab use were found to be common but not serious. No studies were found that evaluated the cost-effectiveness of rituximab.

Wang, L. et al. (2019). "Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: A network meta-analysis"⁷⁵

Investigators conducted a NMA to compare and rank seven immunotherapies for the treatment of MG. The immunotherapies included cyclosporine A, eculizumab, tacrolimus, belimumab,

methotrexate, azathioprine, and MMF. This study did not include efgartigimod, rituximab, or maintenance IVIG. The total patient population was 808 MG patients across 14 RCTs with a median sample size of 39 patients. The primary outcome of the NMA was the reduction of QMG score; secondary outcomes included glucocorticoid reduction and hazard ratios from the counts of AEs. Both eculizumab and cyclosporine A reached statistical significance versus placebo in the primary outcome when controlling for intervention periods. Eculizumab was ranked as most tolerable therapy and causing the least counts of AEs. Investigators concluded that eculizumab represented the most effective and tolerable therapeutic alternative to be recommended for refractory MG.

E. Long-Term Cost-Effectiveness: Supplemental Information

E1. Detailed Methods

We developed a de novo decision analytic semi-Markov model with time-dependent transitions for this evaluation, informed by key clinical trials and prior relevant economic models. Costs and outcomes were discounted at 3% per year. The model focused on an intention-to-treat analysis with two different cohorts of patients: those with refractory AChR-antibody positive generalized MG (gMG) (defined by MGFA clinical class II to IV) and those with gMG for whom conventional immunosuppressive therapies are insufficiently effective. The model cycle length was one month, based on the rapid effect of eculizumab and efgartigimod from clinical trials and the desire to evaluate differing retreatment frequencies with efgartigimod in scenario analyses.

The base-case analysis compared eculizumab plus conventional therapy to conventional therapy alone in patients with refractory AChR-antibody positive gMG and efgartigimod plus conventional therapy to conventional therapy alone in the broader population of patients with gMG evaluated in the clinical trial of efgartigimod. A detailed description of the model structures used in the base-case analyses is provided in Section 4.1 of this report.

Scenario analyses were conducted to evaluate a comparison of efgartigimod plus conventional therapy to conventional therapy alone in patients with refractory AChR-antibody positive gMG, using a subpopulation of patients from the trial evaluating efgartigimod that met the inclusion criteria for the clinical trial evaluating eculizumab and results from the NMA described in Section 3 of this report. In addition, a direct comparison of efgartigimod and eculizumab was made and the incremental cost-effectiveness estimated. These analyses utilized the same model described in Section 4.1 of this report.

Scenario analyses were also conducted to evaluate IVIG plus conventional therapy, or separately, rituximab plus conventional therapy in patients with gMG using a 4-state Markov model. No modifications were made to the model to evaluate these therapies, with the exception that the clinical response for rituximab occurred in the fourth model cycle instead of the first to better reflect the delay observed in clinical response to rituximab.¹⁶

The same model and methods were used to evaluate the impact of an 8-week redosing cycle for efgartigimod on incremental cost-effectiveness, with the exception that some simulated patients were allowed to lose the effect of efgartigimod in the 4-week period that they were not receiving the treatment. The proportion of patients moving to the unimproved Markov state was derived

from data collected 8 weeks after the first dose. All patients returned to the improved Markov state upon being re-dosed with efgartigimod.

For the scenario evaluating eculizumab or efgartigimod (separately), followed by IVIG or rituximab as second line treatment in patients with gMG (efgartigimod) or refractory AChR-antibody positive gMG (eculizumab), a modified model was used to include these second line treatments, and is shown in Figure E1.1. For this analysis, a 6-state Markov model was used. Simulated patients entered the model through the Markov state, "Unimproved MG on initial line of treatment," and received either eculizumab or efgartigimod. Patients with at least a 3-point improvement in QMG transitioned to the "Improved MG on initial line of treatment" Markov state and remained in that state, if alive, for the duration of the time horizon. Those who did not receive a 3-point improvement in QMG transitioned to the "Unimproved MG on secondary treatment" state and received treatment with either 1) IVIG or 2) rituximab (evaluated in separate models). Depending on whether these treatments were effective, patients transitioned to either the "Improved MG on secondary treatment" Markov state (if treatment was effective) or to the "Unimproved MG, treatment discontinued" state (if treatment is insufficiently effective) and remained in those states for the remainder of the time horizon, if alive. Simulated patients could enter the "Death" state in any cycle of the model. Simulated patients could experience "MG-related hospitalizations" and "MG-related emergency room visits" in any living state of the model, with the probability of experiencing these events in any cycle being higher for patients in any "Unimproved MG" state.

Figure E1.1. Model Schematic: Six-State Model Depicting Treatment for Myasthenia Gravis with Initial Treatment, Followed by Secondary Treatment for Patients Deriving Insufficient Benefit from Initial Treatment



Table E1.1. Impact Inventory

	Included in This Analysis			Notes on
	Type of Impact			guantified),
Sector	(Add additional domains, as relevant)	Health Care	Societal	Likely
	relevanty	Sector	Societai	Magnitude &
Formal Health (Sara Sastar			Impact (if not)
Formal Health C	Langovity offects	v	Not Available	
Automoc	Longevity effects	X	Not Available	
Outcomes	offocts	^	NOT AVAILABLE	
		v	Not Available	
Madical Casta	ALS Daid by third party payors	×	Not Available	
weet and costs	Paid by triffu-party payers		Not Available	
	Future related medical sector		Not Available	
	Future related medical costs	×	Not Available	
	Future unrelated medical costs		NOT AVAILABLE	
Informal Health	Care Sector			
Health-	Patient time costs	NA	Not Available	
Related Costs	Unpaid caregiver-time costs	NA	Not Available	
	Iransportation costs	NA	Not Available	
Non-Health Car	e Sector			1
Productivity	Labor market earnings lost	NA	Not Available	
	Cost of unpaid lost	NA	Not Available	
	productivity due to illness			
	Cost of uncompensated	NA	Not Available	
	household production			
Consumption	Future consumption unrelated	NA		
	to health			
Social services	Cost of social services as part	NA		
	of intervention			
Legal/Criminal	Number of crimes related to	NA		
Justice	intervention			
	Cost of crimes related to	NA		
	intervention			
Education	Impact of intervention on	NA		
	educational achievement of			
	population			
Housing	Cost of home improvements,	NA		
	remediation			
Environment	Production of toxic waste	NA		
	pollution by intervention			
Other	Other impacts (if relevant)	NA		

NA: not applicable

Adapted from Sanders et al⁷⁶

Target Population

The population of interest for this economic evaluation was the prevalent cohort of individuals in the United States with gMG, defined as MGFA clinical classification II to IV. Base-case analyses focused on patients with either refractory AChR-antibody positive gMG, when evaluating eculizumab, and a broader population of patients with gMG, including both refractory and non-refractory patients, for patients receiving efgartigimod. The baseline population characteristics and sources for patients with refractory AChR-antibody positive gMG and broader gMG are shown in Table E1.2. Since data stratified by gender and age was available only for the study evaluating efgartigimod, this study's data was used exclusively in the model when estimating patient mortality.

	Eculizumab (n=62), Refractory AChR-antibody positive gMG	Efgartigimod (n=84), All enrolled patients
Mean Age (SD), Years	47.15 (15.7)	45.9 (14.4)
Female, %	66.0	75.0
MGFA class, %		
Class II	29.0	40.5
Class III	59.7	56.0
Class IV	11.3	3.6
AChR-Ab Status, %		
Positive	100	77.4
Negative	0	22.6
MuSK-Ab Status		
Positive	N/A	N/A
Negative		
Source	Howard 2017 ¹⁶	argenx 2021, Howard 2021 ^{23,30}

Table E1.2. Base-Case Model Cohort Characteristics

N/A: not available

*AchR-Ab positive subgroup from ADAPT trial

Treatment Strategies

Treatment strategies included in the base case were eculizumab plus conventional therapy compared with conventional therapy alone, represented by the placebo control group from the corresponding clinical trial, and efgartigimod plus conventional therapy compared with conventional therapy alone, represented by the placebo control group from the corresponding clinical trial.

Additional treatment strategies were considered in scenario analyses, described in Section 4.1 of the main report.

E2. Model Assumptions and Inputs

The key model inputs for base-case analyses are provided in Section 4.2 of this report. For scenario analyses, the effectiveness of IVIG and rituximab were estimated from long-term clinical trials evaluating these drugs plus conventional therapy compared with conventional therapy alone.^{25,40} All additional model assumptions, definitions, and inputs used are shown in Tables E2.1 and E2.2.

Model Inputs

Clinical Inputs

Table E2.1. Additional Model Assumptions

Assumption	Rationale
Efgartigimod administration will cost the same as	Pricing is not available for efgartigimod
that of eculizumab (Base Case)	administration as it is not yet approved by the
	FDA. Pricing for administering efgartigimod is
	likely to be similar to that of eculizumab.
IVIG's effect in the first cycle is the same as	The effectiveness of IVIG at 4 weeks has not been
observed at 24 weeks	reported. Since IVIG is nearly immediately
	effective, we assumed that the effectiveness at 4
	weeks was similar to what was reported in the clinical trial. ⁴⁰
Rituximab's effect is observed in the 4 th cycle	Evidence suggests that there is a delay in the
after the first treatment (Scenario Analysis 3)	onset of action of rituximab, with peak
	effectiveness observed at approximately month
	4.5. ⁵ As the monthly impact of rituximab on
	QMG scores is not known, we have assumed that
	onset and peak action all occur in the 4 th model
	cycle after rituximab administration.
Patients not responding to secondary treatment	We have chosen to evaluate only one additional
options will have that treatment discontinued	treatment after eculizumab or efgartigimod. This
and will remain in an unimproved MG state	assumption will affect a relatively small
(Scenario Analysis 4)	proportion of simulated patients (i.e., those in
	whom therapy with eculizumab or efgartigimod
	and IVIG or rituximab is ineffective) and is
	expected to have minimal impact on incremental
Detiente obere en el tertere terretori illere estre in in	COST effectiveness.
Patients who respond to treatment will remain in	Inere is insufficient evidence available to
an improved MG state (All Models)	there wis initially effective eventually derive
	insufficient bonefit from the same therapy
	Multiple clinical trials have demonstrated cimilar
	response rates once peak treatment
	affectiveness is obtained
	effectiveness is obtained.

Table E2.2. Additional Model Inputs

Parameter	Input	Source
Proportion of patients achieving 3 point or more reduction in		Bootstrapped value derived
QMG with efgartigimod plus CT in patients with refractory	0.75	from Howard 2021 and meta-
AChR-antibody positive gMG (Scenario Analyses 1 and 2)		analysis results ²¹
Proportion of patients achieving 3 point or more reduction in	0.62	Bootstrapped value derived
QMG with IVIG (Scenario Analysis 3)	0.62	from NCT02473952 ⁴⁰
Proportion of patients achieving 3 point or more reduction in	0.49	Bootstrapped value derived
QMG with CT (IVIG comparator)	0.48	from NCT02473952 ⁴⁰
Proportion of patients achieving 3 point or more reduction in	0.50	Bootstrapped value derived
QMG with rituximab plus CT	0.56	from NCT02110706 ²⁵
Proportion of patients achieving 3 point or more reduction in	0.20	Bootstrapped value derived
QMG with rituximab (efgartigimod comparator)	0.36	from NCT02110706 ²⁵
Mean change in QMG among responders to eculizumab plus	6.05	Bootstrapped value derived
CT at week 4	-6.95	from Howard 2017 ¹⁶
Mean change in QMG among non-responders to eculizumab	0.77	Bootstrapped value derived
plus CT at week 4	0.77	from Howard 2017 ¹⁶
Mean change in QMG among responders to eculizumab plus	7.25	Bootstrapped value derived
CT at week 8 and beyond	-7.25	from Howard 2017 ¹⁶
Mean change in QMG among non-responders to eculizumab	0.54	Bootstrapped value derived
plus CT at week 8 and beyond	0.51	from Howard 2017 ¹⁶
Mean change in QMG among responders to CT (eculizumab	6.52	Bootstrapped value derived
comparator)	-6.53	from Howard 2017 ¹⁶
Mean change in QMG among non-responders to CT		Bootstrapped value derived
(eculizumab comparator)	1.4	from Howard 2017 ¹⁶
		Bootstrapped value derived
Mean change in QMG among responders to efgartigimod plus	0.04	from data provided in
СТ	-8.94	confidence by argenx and
		meta-analysis results ³⁰
		Bootstrapped value derived
Mean change in QMG among non-responders to efgartigimod	0.21	from data provided in
plus CT	0.31	confidence by argenx and
		meta-analysis results ³⁰
		Bootstrapped value derived
Mean change in QMG among responders to CT (efgartigimod	6.04	from data provided in
comparator)	-6.94	confidence by argenx and
		meta-analysis results ³⁰
		Bootstrapped value derived
Mean change in QMG among non-responders to CT	1.05	from data provided in
(efgartigimod comparator)	1.85	confidence by argenx and
		meta-analysis results ³⁰
Mean shange in OMC among responders to offertigized plus		Bootstrapped value derived
The notion to with refrectory AChP antibody positive sMC	0.16	from data provided in
(Sconario Analysos 1 and 2)	-9.16	confidence by argenx and
(Scenario Analyses 1 and 2)		meta-analysis results ³⁰
Mean change in OMG among non-recoonders to ofgertigized		Bootstrapped value derived
nus CT in patients with refractory AChP antihody positive	0.26	from data provided in
aMG (Scenario Analyses 1 and 2)	0.20	confidence by argenx and
Sivio (Scenario Analyses I and 2)		meta-analysis results ³⁰

Mean change in QMG among responders to efgartigimod plus CT in patients with AChR-antibody positive gMG (Scenario Analysis 3)	-8.96	Bootstrapped value derived from Howard 2021 ²¹
Mean change in QMG among non-responders to efgartigimod plus CT in patients with AChR-antibody positive gMG (Scenario Analyses 3)	0.43	Bootstrapped value derived from Howard 2021 ²¹
Mean change in QMG among responders to CT in patients with AChR-antibody positive gMG (Scenario Analysis 3)	-5.05	Bootstrapped value derived from Howard 2021 ²¹
Mean change in QMG among non-responders to CT in patients with AChR-antibody positive gMG (Scenario Analyses 3)	0.46	Bootstrapped value derived from Howard 2021 ²¹
Mean change in QMG among responders to IVIG (Scenario Analysis 4)	-7.82	Bootstrapped value derived from NCT02473952 ⁴⁰
Mean change in QMG among non-responders to IVIG (Scenario Analysis 4)	0.62	Bootstrapped value derived from NCT02473952 ⁴⁰
Mean change in QMG among responders to CT (IVIG comparator) (Scenario Analysis 4)	-7.99	Bootstrapped value derived from NCT02473952 ⁴⁰
Mean change in QMG among non-responders to CT (IVIG comparator) (Scenario Analysis 4)	2.18	Bootstrapped value derived from NCT02473952 ⁴⁰
Mean change in QMG among responders to rituximab (Scenario Analysis 5)	-7.83	Bootstrapped value derived from NCT02110706 ²⁵
Mean change in QMG among responders to rituximab (Scenario Analysis 5)	1.07	Bootstrapped value derived from NCT02110706 ²⁵
Mean change in QMG among responders to CT (rituximab comparator) (Scenario Analysis 5)	-5.88	Bootstrapped value derived from NCT02110706 ²⁵
Mean change in QMG among responders to CT (rituximab comparator) (Scenario Analysis 5)	0.65	Bootstrapped value derived from NCT02110706 ²⁵
Mean change in QMG among responders to efgartigimod plus CT at week 8 (Scenario Analysis 6)	-7.83	Bootstrapped value derived from data provided in confidence by argenx and meta-analysis results ³⁰
Mean change in QMG among non-responders to efgartigimod plus CT at week 8 (Scenario Analysis 6)	1.08	Bootstrapped value derived from data provided in confidence by argenx and meta-analysis results ³⁰
Utility among responders to efgartigimod plus CT in patients with refractory AChR-antibody positive gMG (Scenario Analyses 1 and 2)	0.75	Bootstrapped value derived from data provided in confidence by argenx and meta-analysis results ³⁰
Utility among non-responders to efgartigimod plus CT in patients with refractory AChR-antibody positive gMG (Scenario Analyses 1 and 2)	0.46	Bootstrapped value derived from data provided in confidence by argenx and meta-analysis results ³⁰
Utility among responders to efgartigimod plus CT in patients with AChR-antibody positive gMG (Scenario Analysis 3)	0.74	Bootstrapped value derived from Howard 2021 ²¹
Utility among non-responders to efgartigimod plus CT in patients with AChR-antibody positive gMG (Scenario Analyses 3)	0.45	Bootstrapped value derived from Howard 2021 ²¹
Utility among responders to CT in patients with AChR- antibody positive gMG (Scenario Analysis 3)	0.62	Bootstrapped value derived from Howard 2021 ²¹

Utility among non-responders to CT in patients with AChR- antihody positive gMG (Scenario Analyses 3)	0.45	Bootstrapped value derived from Howard 2021 ²¹
Utility among responders to IVIG (Scenario Analysis 4)	0.71	Bootstrapped value derived from NCT02473952 ⁴⁰
Utility among non-responders to IVIG (Scenario Analysis 4)	0.45	Bootstrapped value derived from NCT02473952 ⁴⁰
Utility among responders to CT (IVIG comparator) (Scenario Analysis 4)	0.71	Bootstrapped value derived from NCT02473952 ⁴⁰
Utility among non-responders to CT (IVIG comparator) (Scenario Analysis 4)	0.40	Bootstrapped value derived from NCT02473952 ⁴⁰
Utility among responders to rituximab (Scenario Analysis 5)	0.71	Bootstrapped value derived from NCT02110706 ²⁵
Utility among responders to rituximab (Scenario Analysis 5)	0.43	Bootstrapped value derived from NCT02110706 ²⁵
Utility among responders to CT (rituximab comparator) (Scenario Analysis 5)	0.65	Bootstrapped value derived from NCT02110706 ²⁵
Utility among responders to CT (rituximab comparator) (Scenario Analysis 5)	0.45	Bootstrapped value derived from NCT02110706 ²⁵
Utility among responders to efgartigimod plus CT at week 8 (Scenario Analysis 6)	0.71	Bootstrapped value derived from data provided in confidence by argenx and meta-analysis results ³⁰
Utility among non-responders to efgartigimod plus CT at week 8 (Scenario Analysis 6)	0.43	Bootstrapped value derived from data provided in confidence by argenx and meta-analysis results ³⁰
IVIG cost for induction dose	\$11,100**	Federal Supply Schedule 2021 ³⁶
IVIG cost for maintenance dose	\$5,600**	Federal Supply Schedule 2021 ³⁶
Rituximab cost per 4-week regimen	\$14,400***	Federal Supply Schedule 2021 ³⁶
Eculizumab administration, each	\$230	https://hcpcs.codes/j- codes/J1300/ ⁷⁷
Efgartigimod administration, each	\$230	Assumed
IVIG administration, each	\$74	CMS.gov physician fee schedule lookup ⁷⁸
Rituximab administration	\$58	https://hcpcs.codes/j- codes/J9312/ ⁷⁷

CT: conventional therapy

*Midpoint between annual cost of eculizumab and IVIG

**Note that IVIG was dosed at 3-week intervals. Therefore, per cycle costs were adjusted to account for additional doses in each 4-week cycle.

***Rituximab is dosed once weekly for 4 weeks, administered twice per year.

Clinical Probabilities/Response to Treatment

Clinical probabilities for the base case are described in the Section 4.2 of the report. As with the base case, clinical probabilities for the scenario analyses were estimated from clinical trial data. The proportion of patients achieving a minimum 3-point improvement in QMG was derived from clinical trials by bootstrapping mean change in QMG at appropriate time points using the mean, standard deviation, and assuming a normal distribution. The bootstrapping method also allowed for changes

in QMG score to be estimated for individuals. The primary clinical trial evaluating IVIG assessed outcomes at 24 weeks.⁴⁰ Due to the rapid action of IVIG, we assumed that a similar response would be observed within 4 weeks as was observed at 24 weeks. The primary clinical trial evaluating rituximab assessed outcomes at 52 weeks. In addition, rituximab has a delayed onset of action, with peak effect occurring at 4.5 weeks in single dose clinical trials.²⁵ We therefore assumed that rituximab's onset of action would occur and peak in the model cycle representing weeks 16-20.

Through the course of this evaluation, we received academic-in-confidence data from efgartigimod's manufacturer on some (but not all) of the bootstrapped measures used in the model. We decided to use the bootstrapped measures within the base-case model to achieve consistency across all treatment evaluations and reportability of the bootstrapped estimates. Finally, to test the sensitivity of the use of bootstrapped estimates in the efgartigimod base case, we replaced bootstrapped estimates with those supplied as academic in confidence from the manufacturer, where possible, and found that the incremental cost-effectiveness changed by less than 10%.

<u>Mortality</u>

Mortality was included in the model as described in the Key Model Assumptions and Inputs of this report. As evidence suggesting that mortality is different among patients with differing severity of MG is lacking and treatments have not been evaluated for their impact on mortality, treatments in the model were assumed to not have an impact on mortality.

<u>Utilities</u>

Health state utilities were derived from a deidentified data source provided by Dr. Barnett.^{†33,34} Health state utilities were derived from baseline QMG scores and changes to baseline QMG scores reported in clinical trials. Changes to baseline QMG scores were used to estimate state-specific QMG scores and corresponding utility in those in improved and unimproved Markov states, using a bootstrapping methodology described in the Key Model Assumptions and Inputs Section of the report.

Argenx provided utilities collected during the ADAPT trial as data in confidence (data not shown).³⁰ We used these data to inform a scenario analysis (Scenario 8). The utility inputs provided by argenx were used without modification, with one exception. Since we assumed that non-responders would have their treatments discontinued (and incur no benefit of or cost for treatment), the non-responder utility values for efgartigimod and the comparator were averaged and applied to both

[†] Carolina Barnett-Tapia, MD, PhD is an Assistant Professor of Medicine in Neurology at the University of Toronto, and conducts research on patient-centered outcomes in neuromuscular disorders, including myasthenia gravis.

non-responder groups. Including these data-in-confidence utilities versus the base case utilities had a minimal impact on the results (Table 4.8).

<u>Adverse Events</u>

AEs were considered for inclusion in the model only if they occurred at a probability of at least 5% or would be expected to result in a substantial increased cost to treat or decrease in utility, and were significantly higher than placebo, or if the AE would be expected to result in a substantial increased cost to treat or decrease in utility. Due to the potential risk of meningitis (specifically, Neisseria meningitidis serogroups A, C, Y, and W-135), a meningococcal vaccine is required prior to receiving eculizumab. The cost of this vaccine was included for patients receiving eculizumab. The only other AEs that occurred with a statistically higher frequency in treatment than in placebo included headache with IVIG (33% vs. 10% with placebo) and first infusion reaction with rituximab (27% vs. 19% with placebo). However, costs of treatment of and disutility associated with these conditions was determined to be minimal and would not measurably impact these treatments' cost-effectiveness.

Economic Inputs

Drug Acquisition Costs

Drug acquisition costs were estimated using the Federal Supply Schedule, available through the Veterans Administration Drug Pricing Database.³⁶ Since efgartigimod is not yet approved, a placeholder price was generated using the midpoint of the annual costs of IVIG and eculizumab.³⁷ Drug acquisition costs are shown in Table E2.3.

Table E2.3. D	rug Cost Inputs
---------------	-----------------

Interventions	Administration	Unit	FSS per Unit *	Net Price per Unit	Annual Drug Cost**
Eculizumab	900 mg weekly for 4 weeks, then 1200 mg maintenance every 2 weeks	10mg/mL, 30 mL vial	\$6,031	\$6,031	\$653,106
Efgartigimod	Weekly IV infusions (10 mg/kg), every week for 4 weeks, administered every 4 weeks	n/a	n/a	n/a	\$418,432***
Efgartigimod (Scenario 6)	Weekly IV infusions (10 mg/kg), every week for 4 weeks, administered every 8 weeks	n/a	n/a	n/a	\$418,432***
IVIG (for a 90 kg person)	180 g loading dose; 90 g maintenance every 3 weeks	5g/vial	\$428	\$428	\$183,759
Rituximab and biosimilars (for a person with BSA=1.9)	713 mg weekly for 4 consecutive weeks; re-dose every 6 months	10mg/mL, 10 mL vial	\$702 [‡]	\$702 [‡]	\$40,006

*FSS as of June 29, 2021

**The annual drug cost includes induction and maintenance doses.

***The midpoint between the annual cost of IVIG and eculizumab was used to estimate the cost of efgartigimod.
 *Mean cost for Rituxan and biosimilars.

Administration and Monitoring Costs

The costs for administering eculizumab, efgartigimod, IVIG, and rituximab were included in the model. Administration costs were obtained from CMS.gov.⁷⁸ Where these codes were not available, they were obtained from HCPCS.codes.⁷⁷ Administration costs used in the model are shown in Table E2.4.

Table E2.4. Dose, Frequency of Administration, and Annual Monitoring and Administration
Utilization

Intervention	Route	Frequency of Administration	Administration Cost per Dose	Administration Cost per Year
Eculizumab	IV	Induction weekly for 4 weeks, then every 2 weeks	\$230	\$6470
Efgartigimod	IV	Weekly infusions for 4 weeks, dosed every 4 weeks (base-case) or dosed every 8 weeks (scenario 6)	\$230*	\$12,017*
IVIG	IV	Every 3 weeks	\$74	\$1280
Rituximab and biosimilars	IV	Weekly for 4 consecutive weeks, every 6 months	\$94	\$753

*The cost per dose for efgartigimod administration was assumed to be the same as for eculizumab

Health Care Utilization Costs

The costs of hospitalizations and emergency visits were included in the model. These costs were described in the Key Model Inputs Table 4.3 in the report.

Productivity Costs and Caregiver Burden

The systematic review that we conducted identified no suitable studies that could provide inputs for productivity costs or caregiver burden. A modified societal perspective considering productivity and caregiver costs was not conducted.

E3. Results

The total discounted lifetime costs, QALYs, and mean QMG score over the two-year time horizon are shown in Table E3.1 for all scenario analyses interventions and comparators. Undiscounted base-case results are presented in Table E3.2. Incremental cost-effectiveness ratios for all scenarios are shown in the main report, in the section titled Scenario Analyses.

Treatment	Drug Cost	Drug Cost Total Cost		Life	evLYGs	Time in Improved	
				TCars		State (years)	
Efgartigimod plus CT in							
refractory AChR Ab+	\$613,800	\$710,900	1.30	1.93	1.30	1.46	
(Scenarios 1 and 2)							
Efgartigimod plus CT in	\$580.400	\$678,300	1.26	1.93	1 26	1.38	
AChR Ab+ (Scenario 3)	<i>4300,100</i>				1.20		
CT (efgartigimod		\$95,500	0.98	1.93	0.98		
comparator) in AChR	\$0					0.71	
Ab+ (Scenario 3)							
IVIG plus CT (Scenario 4)	\$171,600	\$258,700	1.17	1.93	1.17	1.20	
CT (IVIG comparator)	ŚŊ	\$90,700	1.06	1 03	1.06	0.93	
(Scenario 4)	ŞU	\$50,700	1.00	1.55	1.00	0.55	
Rituximab (Scenario 5)	\$48,300	\$139,200	1.10	1.93	1.10	0.97	
CT (rituximab				1.93	0.98	0.62	
comparator) (Scenario	\$0	\$97,500	0.98				
5)							
Efgartigimod plus CT,							
dosed every 8 weeks	\$604,700	\$697,000	1.23	1.93	1.23	1.27	
(Scenario 6)							
Eculizumab/IVIG	6924 F00	¢010.400	1.24	1.93	1.24	1 50	
(Scenario 7)	\$834,500	\$919,400				1.39	
Eculizumab/Rituximab	6700 000	6975 000	1 21	1 02	1 21	1 10	
(Scenario 7)	\$788,800	\$875,900	1.21	1.95	1.21	1.40	
Efgartigimod/IVIG	¢640.600	6722 F00	1 25	1.02	1.25	1 72	
(Scenario 7)	\$640,600	\$752,500	1.55	1.95	1.55	1./5	
Efgartigimod/Rituximab	¢609.200	\$700.000	1 22	1.02	1 22	1 66	
(Scenario 7)	3008,300	\$700,900	1.55	1.95	1.55	1.00	
Efgartigimod plus CT,							
using argenx-provided	\$595,100	\$692,700	1.54	1.93	1.54	1.41	
utilities (Scenario 8)							
CT (efgartigimod							
comparator), using		¢04.000	1 20	1.02	1 20	0.74	
argenx-provided utilities	Ş0	ου ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο	1.30	1.93	1.30	0.74	
(Scenario 8)							

Table E3.1. Discounted Results for All Scenario Analyses

CT: conventional therapy, evLYG: equal value of life years gained, IVIG: intravenous immunoglobulin, QALY: quality-adjusted life year

Treatment	Drug Cost	Total Cost	QALYs	Life Years	evLYGs	Mean QMG	Time in Improved State
Eculizumab plus CT	\$780,900	\$878,200	1.16	1.99	1.16	12.77	1.12
CT (eculizumab	\$0	\$ <u>98</u> 200	1 01	1 99	1 01	14 94	0 71
comparator)	γu	<i>\$50,200</i>	1.01	1.55	1.01	14.54	0.71
Efgartigimod plus CT	\$611,900	\$712,200	1.31	1.99	1.31	10.13	1.41
CT (efgartigimod comparator)	\$0	\$97,500	1.01	1.99	1.01	14.94	0.74
Efgartigimod plus CT in							
refractory AChR Ab+	\$631,100	\$730,900	1.33	1.99	1.33	9.74	1.46
(Scenarios 1 and 2)							
Efgartigimod plus CT in AChR Ab+ (Scenario 3)	\$596,700	\$697,400	1.30	1.99	1.30	10.33	1.38
CT (efgartigimod							
comparator) in AChR	\$0	\$102,500	0.98	1.99	0.98	15.42	0.52
Ab+ (Scenario 3)							
IVIG plus CT (Scenario	\$176.200	\$265.700	1.20	1.99	1.20	11.90	1.20
4)	+=/ 0/=00	<i>+_00)/00</i>					•
CT (IVIG comparator)	\$0	\$93,300	1.09	1.99	1.09	12.99	0.94
(Scenario 4)	Ć 40 F 00	¢142.000	1 1 2	1.00	1 1 2	10.00	0.07
CT (rituximab (Scenario 5)	\$49,500	\$143,000	1.13	1.99	1.13	10.88	0.97
comparator) (Scenario	ŚO	\$100,300	1.01	1.99	1.01	14.94	0.62
5)	ΨŪ						
Efgartigimod plus CT,							
dosed every 8 weeks	\$620,800	\$715,700	1.27	1.99	1.27	10.88	1.27
(Scenario 6)							
Eculizumab/IVIG	\$956 600	\$9/13 900	1 27	1 99	1 27	10 73	1 59
(Scenario 7)	3830,000	JJ43,900	1.27	1.55	1.27	10.75	1.55
Eculizumab/Rituximab	\$809.600	\$899.000	1.24	1.99	1.24	11.28	1.48
(Scenario 7)	+/	+/					
Efgartigimod/IVIG (Scenario 7)	\$658,600	\$753,100	1.39	1.99	1.39	8.86	1.73
Efgartigimod/Rituxima	6625 400	6700 COO	1.37	1.99	1.37	9.21	
b (Scenario 7)	\$625,400	\$720,600					1.65
Efgartigimod plus CT,				1.99	1.59	10.13	1.41
using argenx-provided	\$611,900	\$712,200	1.59				
utilities (Scenario 8)							
CT (efgartigimod							
comparator), using	\$0	\$0 \$97,500	1.34	1.99	1.34	14.94	0.74
argenx-provided							

Table E3.2. Undiscounted Results for All Base-Case and Scenario Analyses

CT: conventional therapy, evLYG: equal value of life years gained, IVIG: intravenous immunoglobulin, QALY: quality-adjusted life year, QMG: quantitative myasthenia gravis score

E4. Sensitivity Analyses

Results of the sensitivity analyses are presented in the main report section titled Sensitivity Analyses. The full cost-effectiveness acceptability curves for eculizumab and efgartigimod are shown in Figures E4.1 and E4.2 where "Placebo" is reflective of Conventional Therapy, the main comparator for eculizumab and efgartigimod.



Figure E4.1. Cost-Effectiveness Acceptability Curve for Eculizumab vs. Placebo

Figure E4.2. Cost-Effectiveness Acceptability Curve for Efgartigimod vs. Placebo (based on placeholder pricing)



E5. Scenario Analyses

Scenario analyses were presented in the Section E3 results of this Supplement.

Threshold Analyses

The annualized prices required to achieve thresholds of \$50,000 to \$200,000 per QALY gained are shown in Table 4.9 for the base-case analyses. Threshold analyses for efgartigimod, with efficacy based on either 4-week (i.e., assuming dosing occurs every 4 weeks; base-case) or 4- and 8-week ADAPT assessments (i.e., assuming dosing occurs every 8 weeks; scenario 6) is shown in Table E5.1.

The placeholder base-case annual net price (FSS) for efgartigimod was \$418,400, and the annual administration cost was \$12,000 if administered once weekly for four weeks every four weeks (base case) and \$6,000 if administered once weekly for four weeks every 8 weeks (scenario 6). The annual threshold price was dependent on the administration costs, with lower thresholds being impacted to a greater extent by high estimated annual administration costs. For example, at a threshold of \$50,000 per QALY gained, the base-case annual administration costs included in the model (\$12,000) were higher than the supported annual cost of efgartigimod (\$8,200; total cost \$20,200). However, since actual administration costs are not yet known, a total annual threshold price for efgartigimod, including annual administration cost, is provided in the table.

Table E5.1. QALY-Based Threshold Analysis Results for Efgartigimod Dosed Once Weekly for FourWeeks Every Four Weeks (Base-Case) and Once Weekly for Four Weeks Every 8 Weeks (Scenario6)

	Annual Price to Achieve \$50,000 per QALY		Annual Price to Achieve \$100,000 per QALY		Annual Price to Achieve \$150,000 per QALY		Annual Price to Achieve \$200,000 per QALY	
	Without	With	Without	With	Without	With	Without	With
	Costs	Costs	Costs	Costs	Costs	Costs	Costs	Costs
Efgartigimod, 4- week (weekly dosing)	\$8,200	\$20,200	\$18,300	\$30,300	\$28,400	\$40,400	\$38,600	\$50,500
Efgartigimod, 4- and 8-week (4 weeks on, 4 weeks off dosing)	\$10,300	\$16,300	\$18,800	\$24,800	\$27,300	\$33,300	\$35,900	\$41,900

Admin: administration, QALY: quality-adjusted life year

E6. Heterogeneity and Subgroups

There are a number of factors that may affect treatment response in patients with MG. The presence of certain antibodies, such as MuSK, may predict a poorer outcome. Additionally, gender,

race, age of onset, history of smoking, and concomitant autoimmune disease may be predictive of disease course, severity, and impact patient reported outcomes.⁷⁹⁻⁸¹ As a result, treatment efficacy may vary in clinical trials, depending on the demographics of the enrolled population. Unfortunately, little is known about the impact of these potential prognostic factors on treatment effectiveness. However, each of the clinical trials evaluated in this review included relatively small numbers of participants, with a large variation in patient age, antibody status, and prior treatment. This variability and lack of analysis of comparable subgroups, complicated the comparison of trial results.

E7. Model Validation

Model validation followed standard practices in the field. We tested all mathematical functions in the model to ensure they were consistent with the report (and supplemental Appendix materials). We also conducted sensitivity analyses with null input values to ensure the model was producing findings consistent with expectations. Further, independent modelers tested the mathematical functions in the model as well as the specific inputs and corresponding outputs.

Model validation was also conducted in terms of comparisons to other model findings. We searched the literature to identify models that were similar to our analysis, with comparable populations, settings, perspective, and treatments.

Prior Economic Models

In order to develop a comprehensive model and identify potential model inputs, we reviewed all identified published models for assessing treatments for MG. Chicaiza-Becerra evaluated the costeffectiveness of open or thoracoscopic thymectomy compared to medical treatment in managing MG without thymomas from the Columbian health system perspective.⁸² The Markov model included four states, not complete remission, complete remission, myasthenic crises, and death. The model evaluated a cohort of 22-year-old patients with a time-horizon of 55 years and used a one-year cycle length. There were several assumptions stated, including that myasthenic crisis occurred only in patients who were not in complete remission and that patients could not return to "without complete remission" after remission was achieved. The included thymectomy AEs were surgical wound infection, mediastinitis, mediastinal hematoma and presence of pericardial exudate. The authors noted that a major limitation of the analysis was there was that the effectiveness estimates for the treatments were obtained from case series and not randomized, comparative trials. Additionally, data used to populate the model's transition probabilities were from small trials. Economic inputs were derived from the Columbian official tariff rates manual. This study provided important considerations to the conceptualization of our Markov model.

Heatwole evaluated the costs of IVIG and PLEX for patients with MG crisis using a simple decision tree model.⁸³ The decision tree evaluated the hospitalization costs of these treatments and their
complications. As this model was evaluating short-term treatments and not long-term chronic treatment, the modeling methods did not apply well for assessing the cost-effectiveness of the treatments being evaluated in this report.

A review by the Canadian Agency for Drugs and Technologies in Health (CADTH) described an unpublished cost-effectiveness model submitted by Alexion Pharma Canada Corporation evaluating the cost effectiveness of eculizumab plus standard of care compared to standard of care alone.⁸⁴ Although the Markov model structure, inputs, and sources were not shown, a description of the model states was provided. Model states included an initial refractory gMG health state, health states defined by change in MG-ADL after six months of treatment, short-term exacerbation or myasthenic crisis states, and death. The cycle length was six months and the time horizon was 52.5 years. Most model probabilities were derived from the REGAIN study.¹⁶ Utility was estimated from MG-ADL using a post-hoc analysis of the REGAIN trial data. Drug costs were obtained from Canadian price lists. Administration costs were either covered by the sponsor or, in the case of home-based administration, were estimated using average hourly nursing wages. The resulting incremental cost-effectiveness ratio was \$1.2 million (CAD) per QALY gained. Sensitivity analyses and a number of scenario analyses were conducted. Critical appraisal by CADTH identified important key limitations, including 1) not having rituximab as a comparator; 2) inclusion of a progressive MG course of illness over time, which is inconsistent with evidence; 3) higher than expected mortality in patients experiencing myasthenic crisis; 4) a disproportionate disutility for patients experiencing myasthenic crisis; and 5) discontinuation of eculizumab was not consistent with clinical practice. Upon reanalysis, addressing as many of the criticisms as were possible with the model design, the incremental cost-effectiveness of eculizumab was estimated at \$1.5 million (CAD) per QALY gained. This report provided important considerations for the development of the model in this report.

F. Potential Budget Impact: Supplemental Information

F1. Methods

We used results from the same model employed for the cost-effectiveness analyses to estimate total potential budget impact. Potential budget impact was defined as the total differential cost of using each new therapy rather than relevant existing therapy for the treated population, calculated as differential health care costs (including drug costs) minus any offsets in these costs from averted health care events. All costs were undiscounted and estimated over one- and five-year time horizons. The five-year timeframe was of primary interest, given the potential for cost offsets to accrue over time and to allow a more realistic impact on the number of patients treated with the new therapy.

This potential budget impact analysis included the estimated number of individuals in the US who would be eligible for treatment. To this end, we used inputs for the projected average US population size from 2021-2025 (339,640,651 individuals) and MG prevalence in the setting of MGFA clinical classification II-IV (20,000 MG cases per 100,000 US individuals, 69% of which with classification II-IV disease), yielding 46,870 gMG patients.^{85,86} Based on methods reported within a CADTH Common Drug Review report of eculizumab in gMG, we assumed that 100% of these gMG patients would be diagnosed.⁸⁴ We went on to assume that 100% of patients would be eligible for treatment with efgartigimod. For the purposes of this analysis, 20% of these 46,870 patients initiated new efgartigimod treatment in each of the five years, resulting in 9,374 additional patients treated each year.

Comparators in the budget impact model included eculizumab and conventional therapy. Conventional therapy consisted of thymectomy when appropriate, acetylcholinesterase inhibitors, corticosteroids and/or non-steroidal immunosuppressive therapy. Starting market share for eculizumab in the model was based off of analyst projections for eculizumab revenue and total MG pharmaceutical spend through 2025.⁸⁷⁻⁸⁹ These analyses suggested an initial modeled market share of 2.27% by patient volume for eculizumab, with the remaining 97.73% of initial market share by patient volume attributed to conventional therapies. In the efgartigimod scenario, efgartigimod added to conventional therapy market uptake was drawn proportionally from eculizumab and conventional therapies. Additionally, we used an estimate of net price (FSS-derived price for eculizumab and IVIG, from which a placeholder price for efgartigimod was calculated), and the three threshold prices (at \$50,000, \$100,000, and \$150,000 per QALY) in our estimates of efgartigimod's potential budget impact. ICER's methods for estimating potential budget impact are described in detail elsewhere and have recently been updated.^{90,91} The intent of our revised approach to budgetary impact is to document the percentage of patients that could be treated at selected prices without crossing a budget impact threshold that is aligned with overall growth in the US economy.

Using this approach to estimate potential budget impact, we then compared our estimates to an updated budget impact threshold that represents a potential trigger for policy mechanisms to improve affordability, such as changes to pricing, payment, or patient eligibility. As described in <u>ICER's methods presentation</u>, this threshold is based on an underlying assumption that health care costs should not grow much faster than growth in the overall national economy. From this foundational assumption, our potential budget impact threshold is derived using an estimate of growth in US gross domestic product (GDP) +1%, the average number of new drug approvals by the FDA over the most recent five-year period for which data were available, and the contribution of spending on retail and facility-based drugs to total health care spending over the most recent five-year period for which data were spending over the most recent five-year period for which data were spending over the most recent five-year period for which data were spending over the most recent five-year period for which data were spending over the most recent five-year period for which data were spending over the most recent five-year period for which data were spending over the most recent five-year period for which data were available.

For 2021-2022, the five-year annualized potential budget impact <u>threshold</u> that should trigger policy actions to manage access and affordability is calculated to total approximately \$734 million per year for new drugs.

F2. Results

Table F1.1 illustrates the per-patient budget impact results in more detail, for efgartigimod placeholder price (\$418,000* per year), and the benchmark prices to reach \$150,000, \$100,000, and \$50,000 per QALY (\$28,400, \$18,300, and \$8,200, per year, respectively) added to conventional therapy compared to eculizumab therapy and conventional therapy.

Table F1.1. Average /	Annual Per-Patient	: Budget Impact	Calculations O	ver a Five-year	Time Horizon

	Average Annual Per-Patient Budget Impact for Each Calculated Price Point			
	Placeholder Price*	\$150,000/QALY	\$100,000/QALY	\$50,000/QALY
Efgartigimod and CT vs. eculizumab and CT	\$297,000	\$21,800	\$14,500	\$7,300

CT: conventional therapy, FSS: Federal Supply Service, QALY: quality-adjusted life year

*This is an unvalidated placeholder price that is assumed to lie at the midpoint between calculated IVIG price and calculated eculizumab price; this methodology is partially sourced from argenx Q2 and Q3 earnings calls.^{37,43}

Figure F1.1 illustrates the cumulative per-patient budget impact calculations for efgartigimod added to conventional therapy compared to eculizumab and conventional therapy based on the net price

used within the cost-effectiveness analysis. We suggest caution in interpreting the potential budget impact of efgartigimod due to the placeholder annual net price assumed. We observed the general trend of slightly decreasing year over year per treated patient potential budget impacts due to treatment discontinuation over time.





* Placeholder price was assumed. Interpret findings with caution.

G. Public Comments

This section includes summaries of the public comments prepared for the New England CEPAC Public Meeting on September 24th. These summaries were prepared by those who delivered the public comments at the meeting and are presented in order of delivery. One speaker did not submit a summary of their public comment.

A video recording of all comments can be found <u>here</u>. Conflict of interest disclosures are included for each speaker who is not employed by a pharmaceutical manufacturer.

Glenn Phillips, PhD Senior Director, Health Economics and Outcomes Research, argenx

Argenx would like to thank ICER for reviewing treatments for myasthenia gravis (MG) bringing light to the burden of this condition for people diagnosed with MG and their caregivers. The burden of this condition is not well characterized and we have learned much about its significant impact through interactions with patients and caregivers. We are thankful to the MG community for their input, helping us better understand the burden of MG.

As in most rare diseases, limited literature hampers the accurate characterization of the burden of MG and limits comprehensive value assessment of MG treatments. Value frameworks, such as the one used by ICER, are important to estimating the value that treatments bring to patients and the healthcare system, but they must be applied carefully. Given current limitations, it is premature for ICER to conclude that efgartigimod is not cost effective. It is our hope that ICER will consider updating this review when data is available to better characterize the value of efgartigimod.

The review of treatments for MG is limited by a lack of literature on the burden of MG and treatment options to address MG. People with MG report significant impact on quality of life and ability to work often leading to significant financial struggles. Women are generally affected at younger ages impacting not only their careers, but also potentially delaying or preventing child bearing. Additionally, patients may suffer potentially fatal respiratory complications requiring hospitalizations and extended recovery times. Most MG treatments are not approved by the FDA and have limited published data; manufacturers of novel treatments for MG are fighting against ghosts and caught in an "unmet need trap" wherein the cost effectiveness is rated incrementally to low cost comparators with limited proven efficacy.

Willingness to pay for treatments for rare diseases is underestimated in the ICER value framework. The prices recommended in economic reviews for rare disease treatments are rarely consistent with rates reimbursed in the real world. In MG specifically, two current off-label treatments are reimbursed at rates that ICER suggests are not cost effective, and a currently available on-label treatment is reimbursed for a small subset of MG patients at a much higher rate. This suggests a greater willingness to pay for these treatments than ICER allows for in their review. Much has been written about appropriate cost per QALY thresholds; an earnest review and consideration of appropriate thresholds is warranted given the wide disparity between ICER's suggested prices and amounts actually.

Prices suggested by ICER are unrealistic to continued drug development in rare diseases. Development of a new medication for a rare disease is an expensive undertaking with total cost well over \$500 million and often more than \$700 million. Companies that develop treatments for rare diseases want to help these patients; however, to continue to develop rare disease treatments it must be profitable. ICER's suggested prices for most rare diseases would disincentivize pursuing drug development. This begs the question – what is the cost effectiveness of a drug not developed?

The full value offered by novel treatments is often not reflected in ICER's reviews. Efgartigimod's individualized dosing approach used in the ADAPT trials was implemented at the behest of patients and will offer a naturally value-based approach to treatment. Patients will only receive treatment needed to control MG; and payers will only pay for necessary treatment. Additionally, most value frameworks ignore the value of patient services offered by manufacturers. Patients with conditions like MG, with limited approved treatment options, have generally not had the opportunity to benefit from patient services offered by companies with FDA approved treatments. Argenx will offer many services including reimbursement support, remote patient monitoring, information on site of care and community support options, and case management services. Recognizing the value of these services would better reflect the total offering associated with efgartigimod.

Argenx is deeply committed to the MG patient community. Beyond our clinical trial program, we have invested in MyRealWorld MG, a large, international real world data collection effort enrolling patients from 9 countries, to better understand and characterize the burden of this disease on patients and their loved ones. We encourage ICER to consider these points and not prematurely conclude that efgartigimod is not cost effective. Given that efgartigimod is not yet available and the limitations in available data on the burden of MG, comparative data to relevant treatments, , and the real impact of individualized dosing, the findings of the current review are speculative and should be framed as such.

Tammy Boyd Chief Policy Officer and Counsel, Black Women's Health Imperative *Conflict of interest: BWHI receives <2% of its funding from Alexion through the Rare Disease Diversity Coalition.*

BWHI appreciates ICER's efforts to more fully incorporate the lived experience of Black women and girls in its reviews. ICER must be proactive in ensuring reviews do not have the unintended effect of perpetuating or even widening disparities in access to care and health outcomes.

Development of, and access to, new MG treatments is a priority because Black women and girls with MG can face near-insurmountable burdens in the workplace and at home. The voting panel should carefully consider our concerns with the Evidence Report and its shortcomings in capturing the lied experience of Black women and girls as it assesses the long-term value of MG treatments.

ICER's extremely high cost per QALY for new MG treatments looks like a judgment that these treatments have minimal impact on quality of life and day-to-day function for MG patients. Yet, patients on the new treatments describe the difference in their ability to function as night-and-day.

BWHI emphasized substantial race and sex differences in disease severity, age at disease onset, symptom burden, and response to older treatment options as critical to any value assessment. ICER mentioned addressing these in "other benefits and contextual consideration" but did not account for them in their model inputs. Black women and girls with MG have just a 20-40% chance that older treatments will work well enough to work or raise a family, and early age onset can make it impossible to complete high school, much less fulfill aspirations of a college degree and career. Bottom line - poorly controlled MG in young Black women can consign them to a lifelong struggle for economic viability, social inclusion, and health when the deck is already stacked against them.

ICER did not account for work productivity or caregiver burden in its utility values due to lack of research linking treatment improvements to improved productivity. Without adequate precision, the question is --what is an acceptable magnitude of error.

Excluding critical factors *is itself a determination* that the gain in productivity for patients responding to these treatments is zero. BWHI provided literature with data on substantial disease burden and productivity impact of refractory generalized MG. It is implausible to imagine symptom control would not result in productivity gains, given:

 Black patients are younger and, due to age and impacts of systemic racism on economic opportunities, are more likely to be limited to employment opportunities with less flexibility and greater physical demands. Uncontrolled MG-related fatigue and muscle weakness can make it impossible to maintain employment in these jobs.

- Women of childbearing age often face menstruation cycle-related exacerbations, almost certainly impacting productivity and distinguishing the disease in women from men, underscoring the disproportionate burden on Black women, *and is not considered in ICER's review.*
- We appreciate ICER acknowledging MG's impact on delayed childbearing potential, particularly in Black women. For many, having and raising children is a defining goal. We doubt any research will accurately quantify the utility value associated with being a mother, but determining whether treatments are worth the money without incorporating this utility <u>devalues goals that are unique to women</u>.

While ICER acknowledged Covid-19's impact, it is a real-world factor with an unforeseeable trajectory, making access to new treatments a matter of life and death. This is extremely important given both MG and the pandemic exact disproportionate burdens on the Black community. MG patients have more severe COVID disease, and infection can exacerbate MG symptoms. Also:

- In communities with high COVID-19 hospitalizations, MG patients not responding to treatment and suffering exacerbations and crises could find it impossible to receive the care needed, given insufficient hospital capacity.
- Older treatments appear to impact vaccine efficacy. ICER acknowledges when patients on immunosuppressive medications are vaccinated, they may not develop an antibody response, or their response may be weakened. We agree booster vaccines are a positive step, but they would be of little value unless patients are able to access treatments that effectively control symptoms without impacting vaccine efficacy.

BWHI remains concerned that ICER's review does not incorporate real-world information on how these treatments are used and their impact on patients. While there is little published data, ICER should contact MG experts regarding reduced use of steroids, decreased frequency of exacerbations and myasthenic crises, and durable impact on symptoms. For Black women and girls, it appears MG clinicians are hesitant to prescribe high-dose steroids and immunosuppressive medications that are ICER's comparators in young women due to concerns with the consequences of long-term use.

Kevin B. Kimble, Esq

Executive Director Southern Christian Leadership Global Policy Initiative

Kevin Kimble collaborated with BWHI in the composition of his public comments. He disclosed no financial conflicts of interest.

SCL-GPI is committed to addressing inequities to ensure that all people of color and other marginalized communities can achieve the American Dream. Health inequities continue to be a barrier to this goal. My remarks (1) acknowledge goals SCL-GPI and ICER share and (2) express concern about the role ICER seeks in our health care system. This is in light of serious questions about ICER's process: specifically, whether ICER accounts appropriately for the real-life experiences of patients and health inequities in its analysis of cost-effectiveness or value. These questions continue in this review of myasthenia gravis (MG) therapies. I hope ICER will do the work necessary, in the MG review and future value assessments, to account correctly for the lived experience of patients of color.

MG is a rare disease with a significant impact on the Black community. It is essential to ensure the industry develops MG therapies and patients have access. Black women, who experience the substantially different burden of MG than the average MG patient assumed by ICER, often face more significant challenges to their ability to function in everyday life, at work, and home. Black women with MG have merely a 20-40% chance that traditional treatments will be sufficiently effective to improve their ability to work or raise a family. The earlier age of onset, as young as teenage years for Black MG patients, as opposed to the age assumed by ICER (44), make the burden to complete school or work much more significant.

ICER's role in our health system has been growing, with payors using ICER's reviews to guide decisions that determine the contours of patient access to therapies. While we share the goals to improve health outcomes through affordable, valuable care, questions about whether ICER's "value" analyses fail to consider, systemically or sufficiently, the real-world lived experiences of patients of color concern SCL-GPI. Questions about whether ICER considers appropriately the differences between white and non-white patients – which may lead to actions that perpetuate or exacerbate health inequities, in light of the role ICER plays in the access-related decisions of payors, continue in the MG review.

To assess value properly, ICER must account for the substantial differences in race, disease severity, age at disease onset, symptom burden, and response to older treatment options. It is crucial to understand, and account for, how MG affects the lives of Black patients. Because Black patients, due to the earlier onset and the impact of systemic racism on economic opportunities, are more likely to be limited to employment opportunities with less flexibility and greater physical demands (especially challenging with uncontrolled MG).

ICER's failure to account for work productivity or caregiver burden in its utility values, due to the absence of its traditional preferred data linking MG innovations to improved productivity, concerns SCL-GPI. While we understand ICER's traditional methodologies, the practical impact of excluding these factors from consideration is equivalent to not counting this significant impact on patient lives – or undervaluing the effect on certain patients.

What should ICER do when its traditional methods are challenged? Consult MG experts to learn how MG innovations impact the lives of patients. Impacts such as the reduced use of steroids, decreased frequency of exacerbations, and myasthenic crises are important to Black patients. This is because MG clinicians seem to hesitate to prescribe high-dose steroids and immunosuppressive medications that are comparators in clinical trials in young women due to concerns regarding their long-term impact on health. Also, one MG therapy under review, Eculizumab, has been on the market since 2017. ICER could survey patients and clinicians regarding how this therapy is used in the real world rather than assuming it is used the same as in clinical trials.

The decisions ICER makes can help eliminate -- or continue to perpetuate – health inequities. It will not be easy to achieve our goal -- to ensure ICER incorporates, systemically and sufficiently, the lived experiences of patients of color in value assessments that payors use to define the contours of access. Systemic change takes time, commitment, creativity, and understanding. We ask that any review of disease states with health inequities be published by ICER only after it incorporates the impact on the lives of patients of color into its core analysis.

H. Conflict of Interest Disclosures

Tables H1 through H3 contain conflict of interest (COI) disclosures for all participants at the September 24th Public Meeting of the New England CEPAC.

Table H1. ICER Staf	f and Consultants	and COI Disclosures
---------------------	-------------------	---------------------

ICER Staff and Consultants*		
Foluso Agboola, MBBS, MPH, Vice President of Research, ICER	Maggie O'Grady, Program Manager, ICER	
Jon Campbell, PhD, MS, Senior Vice President for Health Economics, ICER	Steven D. Pearson, MD, MSc, President, ICER	
Monica Frederick, Senior Program and Event Coordinator, ICER	David M. Rind, MD, MSc, Chief Medical Officer, ICER	
Avery McKenna, Senior Research Assistant, Evidence Synthesis, ICER	Jeffrey A. Tice, MD Professor of Medicine, University of California, San Francisco	
Ashton Moradi, PharmD, MS, Health Economist, ICER	Daniel R. Touchette, PharmD, MA University of Illinois at Chicago College of Pharmacy	
Dmitriy Nikitin, MSPH, Research Lead, Evidence Synthesis, ICER		

*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Participating Members of New England CEPAC*		
Austin Frakt, PhD, Director, Partnered Evidence- Based Policy Resource Center, VA Boston Healthcare System; Professor, Boston University School of Public Health	Tara Lavelle, PhD, Assistant Professor, Center for the Evaluation of Value and Risk in Health at Tufts Medical Center	
Marthe Gold, MD, MPH, Logan Professor	Greg Low, RPh, PhD, Program Director, MGPO	
Emerita, CUNY School of Medicine	Pharmacy Quality and Utilization Program	
Megan Golden, JD, Co-Director, Mission:Cure	Aaron Mitchell, MD, MPH, Assistant Attending, Memorial Sloan Kettering Cancer Center	
Rebecca Kirch, JD, Executive Vice President, Health Care Quality and Value for the National Patient Advocate Foundation (NPAF)	Brian O'Sullivan, MD, Professor of Pediatrics, Geisel School of Medicine, Dartmouth College	
Stephen Kogut, PhD, MBA, RPh, Professor of Pharmacy Practice, University of Rhode Island College of Pharmacy	Jason H. Wasfy, MD, MPhil (Chair), Director, Quality and Outcomes Research, Massachusetts General Hospital Heart Center; Medical Director, Massachusetts General Physicians Organization	
Donald Kreis, JD, Consumer Advocate, New Hampshire Office of the Consumer Advocate		

Table H2. New England CEPAC Panel Member Participants and COI Disclosures

*No relevant conflicts of interest to disclose, defined as more than \$10,000 in healthcare company stock or more than \$5,000 in honoraria or consultancies during the previous year from health care manufacturers or insurers.

Table H3. Policy Roundtable Participants and COI Disclosures

Policy Roundtable Participant	Conflict of Interest
Adrejia Boutté, JD, Patient Expert	No financial conflicts to disclose.
Marcia Lorimer, MSN, CPNP, Board Chair Emerita, Myasthenia Gravis Foundation of America	The MGFA receives >25% of its funding from health care companies, including Alexion and argenx.
Kimberly Grant, PharmD, Clinical Pharmacist, IPD Analytics	Dr. Grant is a full-time employee of IPD Analytics.
Pushpa Narayanaswami, MD, Vice-Chair, Clinical Operations, Beth Israel Deaconess Medical Center; Associate Professor of Neurology, Harvard Medical School	Dr. Narayanaswami has received funding in excess of \$5,000 from Alexion, argenx, and UCB, and has received research support from Momenta/Janssen, Alexion, and UCB.
Glenn A. Phillips , PhD , Senior Director, Health Economics and Outcomes Research, argenx	Dr. Phillips is a full-time employee of argenx.
A. Gordon Smith, MD , Professor and Chair of Neurology, Virginia Commonwealth University	Dr. Smith has received funding in excess of \$5,000 from Alexion, argenx, Eidos, and Lexicon.
Emily Tsiao , PharmD , Clinical Pharmacist, Premera Blue Cross	Dr. Tsiao is a full-time employee of Premera Blue Cross.